Welcome to STN International! Enter x:x

LOGINID:sssptau125rxt

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 20	EVENTLINE will be removed from STN
NEWS 28	Mar 24	PATDPAFULL now available on STN
NEWS 29	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 30	Apr 11	Display formats in DGENE enhanced
NEWS 31	Apr 14	MEDLINE Reload
NEWS 32	Apr 17	Polymer searching in REGISTRY enhanced
NEWS 33	Apr 21	Indexing from 1947 to 1956 being added to records in CA/CAPLUS
NEWS 34	Apr 21	New current-awareness alert (SDI) frequency in WPIDS/WPINDEX/WPIX
NEWS 35	Apr 28	RDISCLOSURE now available on STN
NEWS 36	May 05	Pharmacokinetic information and systematic chemical names added to PHAR
NEWS 37	May 15	MEDLINE file segment of TOXCENTER reloaded
NEWS 38	May 15	Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 39	May 16	CHEMREACT will be removed from STN
NEWS 40	May 19	Simultaneous left and right truncation added to WSCA
NEWS 41	May 19	RAPRA enhanced with new search field, simultaneous left and right truncation

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT

```
                MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
                AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS INTER     General Internet Information
 NEWS LOGIN     Welcome Banner and News Items
 NEWS PHONE     Direct Dial and Telecommunication Network Access to STN
 NEWS WWW       CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   26 MAY 2003  HIGHEST RN 520505-31-1
DICTIONARY FILE UPDATES:  26 MAY 2003  HIGHEST RN 520505-31-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Crossover limits have been increased.  See HELP CROSSOVER for details.

Experimental and calculated property data are now available.  See HELP
PROPERTIES for more information.  See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> e strvudine
E1            2     STRV/BI
E2            1     STRVS/BI
E3            0 --> STRVUDINE/BI
E4            5     STRW/BI
E5            3     STRX/BI
E6           44     STRY/BI
E7            1     STRYACRYL/BI
E8           17     STRYCH/BI
E9           18     STRYCHAN/BI
E10           7     STRYCHANE/BI
E11           2     STRYCHANOL/BI
E12           7     STRYCHANONE/BI
```

```
=> s strvudine
L1            0 STRVUDINE

=> s d4t
L2            0 D4T

=> e d4t
E1            2     D4SN/BI
E2            2     D4ST/BI
E3            0 --> D4T/BI
E4            1     D4TA5/BI
E5            1     D4TI/BI
E6            1     D4TI2ZR/BI
E7            1     D4TM1/BI
E8            1     D4TMP/BI
E9            1     D4UCLA1/BI
E10           2     D4UCLA2/BI
E11           1     D4UWM1/BI
E12           1     D4UWM2/BI

=> s stavudine
L3            5 STAVUDINE

=> d l3 1-5

L3   ANSWER 1 OF 5  REGISTRY  COPYRIGHT 2003 ACS
RN   501939-31-7  REGISTRY
CN   Thymidine, 2',3'-didehydro-3'-deoxy-, compd. with N,N-dimethylacetamide
     (4:3) (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   Stavudine DMA solvate (1:0.75)
FS   STEREOSEARCH
MF   C10 H12 N2 O4 . 3/4 C4 H9 N O
SR   CA
LC   STN Files:   CA, CAPLUS

     CM   1

     CRN  3056-17-5
     CMF  C10 H12 N2 O4

Absolute stereochemistry.
```




```
     CM   2

     CRN  127-19-5
     CMF  C4 H9 N O
```



2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L3 ANSWER 2 OF 5 REGISTRY COPYRIGHT 2003 ACS
RN 118910-37-5 REGISTRY
CN Thymidine 5'-(trihydrogen diphosphate), 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **Stavudine diphosphate**
FS STEREOSEARCH
MF C10 H14 N2 O10 P2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

16 REFERENCES IN FILE CA (1957 TO DATE)
1 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
16 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L3 ANSWER 3 OF 5 REGISTRY COPYRIGHT 2003 ACS
RN 27646-59-9 REGISTRY
CN 5'-Thymidylic acid, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Thymine, 1-(2,3-dideoxy-.beta.-D-glycero-pent-2-enofuranosyl)-, 5'-(dihydrogen phosphate) (8CI)
OTHER NAMES:
CN d4TMP
CN **Stavudine monophosphate**
FS STEREOSEARCH
MF C10 H13 N2 O7 P
CI COM
LC STN Files: BIOSIS, CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

26 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
27 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L3 ANSWER 4 OF 5 REGISTRY COPYRIGHT 2003 ACS
RN 26194-89-8 REGISTRY
CN Thymidine 5'-(tetrahydrogen triphosphate), 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Thymine, 1-(2,3-dideoxy-.beta.-D-glycero-pent-2-enofuranosyl)-, 5'-(tetrahydrogen triphosphate) (8CI)
OTHER NAMES:
CN 2',3'-Didehydro-3'-deoxythymidine 5'-triphosphate
CN **Stavudine triphosphate**
FS STEREOSEARCH
DR 146369-73-5
MF C10 H15 N2 O13 P3
CI COM
LC STN Files: ADISNEWS, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CHEMCATS, DDFU, DRUGU, EMBASE, MEDLINE, TOXCENTER, USPATFULL
(*File contains numerically searchable property data)

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

54 REFERENCES IN FILE CA (1957 TO DATE)
54 REFERENCES IN FILE CAPLUS (1957 TO DATE)

L3 ANSWER 5 OF 5 REGISTRY COPYRIGHT 2003 ACS
RN 3056-17-5 REGISTRY
CN Thymidine, 2',3'-didehydro-3'-deoxy- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 2'-Thymidinene, 3'-deoxy- (8CI)
CN Thymine, 1-(2,3-dideoxy-.beta.-D-glycero-pent-2-enofuranosyl)- (7CI, 8CI)

OTHER NAMES:
CN 2',3'-Didehydro-3'-deoxythymidine
CN 3'-Deoxy-2',3'-didehydrothymidine
CN BMY 27857
CN D 4T
CN D 4T (nucleoside)
CN Sanilvudine
CN **Stavudine**
CN Zerit
FS STEREOSEARCH
DR 132425-31-1
MF C10 H12 N2 O4
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMINFORMRX, CIN, CSCHEM, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK*, PHAR, PROMT, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1253 REFERENCES IN FILE CA (1957 TO DATE)
34 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1260 REFERENCES IN FILE CAPLUS (1957 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> s paraoxon
L4 42 PARAOXON

=> d l4 38-42

L4 ANSWER 38 OF 42 REGISTRY COPYRIGHT 2003 ACS
RN 2255-19-8 REGISTRY
CN Phosphoric acid, dibutyl 4-nitrophenyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phosphoric acid, dibutyl p-nitrophenyl ester (6CI, 7CI, 8CI)
OTHER NAMES:
CN Ba 2667
CN BAY 11686
CN **Butyl paraoxon**
CN **Di-n-butyl paraoxon**
FS 3D CONCORD
MF C14 H22 N O6 P

LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, CHEMINFORMRX, NIOSHTIC, RTECS*, TOXCENTER
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

18 REFERENCES IN FILE CA (1957 TO DATE)
18 REFERENCES IN FILE CAPLUS (1957 TO DATE)
10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L4 ANSWER 39 OF 42 REGISTRY COPYRIGHT 2003 ACS
RN 1153-30-6 REGISTRY
CN Phosphoric acid, 4-nitrophenyl dipropyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phosphoric acid, p-nitrophenyl dipropyl ester (6CI, 7CI, 8CI)
OTHER NAMES:
CN BAY 55640
CN **Paraoxon propyl**
CN **Propyl paraoxon**
CN Propyl-E 600
FS 3D CONCORD
MF C12 H18 N O6 P
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAOLD, CAPLUS, NIOSHTIC, RTECS*, TOXCENTER
(*File contains numerically searchable property data)



514/132

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

20 REFERENCES IN FILE CA (1957 TO DATE)
20 REFERENCES IN FILE CAPLUS (1957 TO DATE)
9 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L4 ANSWER 40 OF 42 REGISTRY COPYRIGHT 2003 ACS
RN 950-35-6 REGISTRY
CN Phosphoric acid, dimethyl 4-nitrophenyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phosphoric acid, dimethyl p-nitrophenyl ester (6CI, 7CI, 8CI)
OTHER NAMES:
CN BAY 11678
CN Desmethylnitrophos
CN Dimethyl 4-nitrophenyl phosphate
CN Dimethyl p-nitrophenyl phosphate

CN **Dimethyl paraoxon**
CN Methyl-E 600
CN **Methylparaoxon**
CN Methylparathion oxon
CN p-Nitrophenyl dimethyl phosphate
CN **Paraoxon methyl**
FS 3D CONCORD
MF C8 H10 N O6 P
LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMINFORMRX, CHEMLIST, CSCHEM, CSNB, EMBASE, IPA, MEDLINE, MSDS-OHS, NIOSHTIC, RTECS*, SPECINFO, TOXCENTER, ULIDAT, USPATFULL
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

319 REFERENCES IN FILE CA (1957 TO DATE)
319 REFERENCES IN FILE CAPLUS (1957 TO DATE)
36 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L4 ANSWER 41 OF 42 REGISTRY COPYRIGHT 2003 ACS
RN 311-45-5 REGISTRY
CN Phosphoric acid, diethyl 4-nitrophenyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Phosphoric acid, diethyl p-nitrophenyl ester (6CI, 8CI)
OTHER NAMES:
CN 4-Nitrophenyl diethyl phosphate
CN Chinorto
CN Diethyl 4-nitrophenyl phosphate
CN Diethyl p-nitrophenyl phosphate
CN E 600
CN E 600 (pesticide)
CN Ester 25
CN **Ethyl paraoxon**
CN Eticol
CN Fosfakol
CN HC 2072
CN Mintacol
CN Miotisal
CN Miotisal A
CN Oxyparathion
CN p-Nitrophenyl diethyl phosphate
CN Paraoxan
CN **Paraoxon**
CN **Paraoxon-ethyl**
CN Phosphachole
CN Phosphacol
CN Phosphakol
CN Ts 219
FS 3D CONCORD

MF C10 H14 N O6 P
CI COM
LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DETHERM*, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NIOSHTIC, PIRA, PROMT, RTECS*, SPECINFO, TOXCENTER, ULIDAT, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2060 REFERENCES IN FILE CA (1957 TO DATE)
18 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
2061 REFERENCES IN FILE CAPLUS (1957 TO DATE)
211 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L4 ANSWER 42 OF 42 REGISTRY COPYRIGHT 2003 ACS
RN 311-44-4 REGISTRY
CN Phosphoric acid, bis(2-chloroethyl) 4-nitrophenyl ester (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Ethanol, 2-chloro-, p-nitrophenyl phosphate (2:1)
CN Phosphoric acid, bis(2-chloroethyl) p-nitrophenyl ester (7CI, 8CI)
OTHER NAMES:
CN 110H60
CN **2-Chloroethyl paraoxon**
CN Nitrophenylhalon
CN PE 304
FS 3D CONCORD
DR 14714-91-1
MF C10 H12 Cl2 N O6 P
LC STN Files: BIOSIS, CA, CAOLD, CAPLUS, RTECS*, TOXCENTER
(*File contains numerically searchable property data)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

9 REFERENCES IN FILE CA (1957 TO DATE)
9 REFERENCES IN FILE CAPLUS (1957 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
=> s phyostigmine
L5            0 PHYOSTIGMINE

=> s phyostigmine
L6            0 PHYOSTIGMINE

=> s physostigmine
L7           54 PHYSOSTIGMINE

=> d l7 45-54

L7   ANSWER 45 OF 54  REGISTRY  COPYRIGHT 2003 ACS
RN   6091-09-4  REGISTRY
CN   Physostigmine, sulfite (2:1) (8CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C15 H21 N3 O2 . 1/2 H2 O3 S

     CM   1

     CRN  7782-99-2
     CMF  H2 O3 S
```



```
     CM   2

     CRN  57-47-6
     CMF  C15 H21 N3 O2

Absolute stereochemistry.  Rotation (-).
```



514/414

```
L7   ANSWER 46 OF 54  REGISTRY  COPYRIGHT 2003 ACS
RN   6091-08-3  REGISTRY
CN   Physostigmine, tartrate (2:1) (8CI)  (CA INDEX NAME)
FS   STEREOSEARCH
MF   C15 H21 N3 O2 . 1/2 C4 H6 O6

     CM   1
```

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



CM 2

CRN 57-47-6
CMF C15 H21 N3 O2

Absolute stereochemistry. Rotation (-).



L7 ANSWER 47 OF 54 REGISTRY COPYRIGHT 2003 ACS
RN 6091-07-2 REGISTRY
CN **Physostigmine, compd. with boric acid (H3BO3) (1:1) (8CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Boric acid, compd. with physostigmine (1:1)**
FS STEREOSEARCH
MF C15 H21 N3 O2 . B H3 O3

CM 1

CRN 10043-35-3
CMF B H3 O3



CM 2

CRN 57-47-6
CMF C15 H21 N3 O2

Absolute stereochemistry. Rotation (-).



L7 ANSWER 48 OF 54 REGISTRY COPYRIGHT 2003 ACS
RN 6091-06-1 REGISTRY
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-, monobenzoate (salt) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzoic acid, compd. with (3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl methylcarbamate (1:1)
CN **Physostigmine, monobenzoate (8CI)**
OTHER NAMES:
CN **Physostigmine benzoate**
FS STEREOSEARCH
MF C15 H21 N3 O2 . C7 H6 O2
LC STN Files: BEILSTEIN*
(*File contains numerically searchable property data)

CM 1

CRN 65-85-0
CMF C7 H6 O2



CM 2

CRN 57-47-6
CMF C15 H21 N3 O2

Absolute stereochemistry. Rotation (-).



L7 ANSWER 49 OF 54 REGISTRY COPYRIGHT 2003 ACS
RN 5990-00-1 REGISTRY
CN **Physostigmine, p-(benzyloxy)benzenesulfonate (7CI, 8CI)** (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Benzenesulfonic acid, p-(benzyloxy)-, compd. with physostigmine (1:1)**
FS STEREOSEARCH
MF C15 H21 N3 O2 . C13 H12 O4 S
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, TOXCENTER
(*File contains numerically searchable property data)

CM 1

CRN 5950-16-3
CMF C13 H12 O4 S



CM 2

CRN 57-47-6
CMF C15 H21 N3 O2

Absolute stereochemistry. Rotation (-).



2 REFERENCES IN FILE CA (1957 TO DATE)
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)
1 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 50 OF 54 REGISTRY COPYRIGHT 2003 ACS
RN 1399-96-8 REGISTRY
CN **Isophysostigmine, sulfate (8CI)** (CA INDEX NAME)
MF C15 H21 N3 O2 . 1/2 H2 O4 S

CM 1

CRN 7664-93-9
CMF H2 O4 S



CM 2

CRN 1399-95-7
CMF C15 H21 N3 O2
CCI MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L7 ANSWER 51 OF 54 REGISTRY COPYRIGHT 2003 ACS
RN 1399-95-7 REGISTRY
CN **Isophysostigmine (8CI)** (CA INDEX NAME)
MF C15 H21 N3 O2
CI COM, MAN
LC STN Files: NAPRALERT

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

L7 ANSWER 52 OF 54 REGISTRY COPYRIGHT 2003 ACS
RN 64-47-1 REGISTRY
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)-, sulfate (2:1) (salt) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Physostigmine, sulfate (2:1) (8CI)**
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-, sulfate (2:1) (salt)
OTHER NAMES:
CN Eserine sulfate
CN Eserine sulphate
CN **Physostigmine hemisulfate**
CN **Physostigmine sulfate**
CN **Physostigmine sulphate**
FS STEREOSEARCH
DR 11036-67-2, 11041-29-5
MF C15 H21 N3 O2 . 1/2 H2 O4 S
CI COM
LC STN Files: AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CHEMCATS, CHEMLIST, CSCHEM, EMBASE, HODOC*, HSDB*, IPA, MRCK*, MSDS-OHS, NIOSHTIC, RTECS*, TOXCENTER, USAN,

USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

CM 1

CRN 7664-93-9
CMF H2 O4 S



CM 2

CRN 57-47-6
CMF C15 H21 N3 O2

Absolute stereochemistry. Rotation (-).



364 REFERENCES IN FILE CA (1957 TO DATE)
364 REFERENCES IN FILE CAPLUS (1957 TO DATE)
3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 53 OF 54 REGISTRY COPYRIGHT 2003 ACS
RN 57-64-7 REGISTRY
CN Benzoic acid, 2-hydroxy-, compd. with (3aS,8aR)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl methylcarbamate (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzoic acid, 2-hydroxy-, compd. with (3aS-cis)-1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b]indol-5-yl methylcarbamate (1:1)
CN **Physostigmine salicylate (6CI)**
CN **Physostigmine, monosalicylate (8CI)**
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)-, mono(2-hydroxybenzoate) (salt) (9CI)
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-, mono(2-hydroxybenzoate) (salt)
CN **Salicylic acid, compd. with physostigmine (1:1) (8CI)**
OTHER NAMES:
CN **(-)-Physostigmine salicylate**

CN Eserine salicylate
CN Isopto Eserine
FS STEREOSEARCH
DR 11033-04-8, 11036-66-1
MF C15 H21 N3 O2 . C7 H6 O3
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST, CSCHEM, DDFU, DETHERM*, DRUGU, EMBASE, HSDB*, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, RTECS*, TOXCENTER, USAN, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

CM 1

CRN 69-72-7
CMF C7 H6 O3



CM 2

CRN 57-47-6
CMF C15 H21 N3 O2

Absolute stereochemistry. Rotation (-).



675 REFERENCES IN FILE CA (1957 TO DATE)
675 REFERENCES IN FILE CAPLUS (1957 TO DATE)
59 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L7 ANSWER 54 OF 54 REGISTRY COPYRIGHT 2003 ACS
RN 57-47-6 REGISTRY
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS,8aR)- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN **Physostigmine (8CI)**
CN Pyrrolo[2,3-b]indol-5-ol, 1,2,3,3a,8,8a-hexahydro-1,3a,8-trimethyl-, methylcarbamate (ester), (3aS-cis)-
OTHER NAMES:

CN (-)-Eserine
CN **(-)-Physostigmine**
CN Cogmine
CN Eserine
CN Esromiotin
CN MCV 4484
CN NIH 10421
CN Physostol
FS STEREOSEARCH
DR 511-49-9, 50975-37-6
MF C15 H21 N3 O2
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, GMELIN*, HODOC*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, MSDS-OHS, NAPRALERT, NIOSHTIC, PHAR, PIRA, PROMT, RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

3507 REFERENCES IN FILE CA (1957 TO DATE)
34 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
3509 REFERENCES IN FILE CAPLUS (1957 TO DATE)
23 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> d his

(FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003)

FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003
E STRVUDINE
L1 0 S STRVUDINE
L2 0 S D4T
E D4T
L3 5 S STAVUDINE
L4 42 S PARAOXON
L5 0 S PHYOSTIGMINE
L6 0 S PHYOSTIGMINE
L7 54 S PHYSOSTIGMINE

```
=> file caplus
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                        68.74      68.95

FILE 'CAPLUS' ENTERED AT 16:36:06 ON 27 MAY 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 27 May 2003  VOL 138 ISS 22
FILE LAST UPDATED: 26 May 2003  (20030526/ED)

  This file contains CAS Registry Numbers for easy and accurate
  substance identification.


=> d his

     (FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003)

     FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003
                E STRVUDINE
L1              0 S STRVUDINE
L2              0 S D4T
                E D4T
L3              5 S STAVUDINE
L4             42 S PARAOXON
L5              0 S PHYOSTIGMINE
L6              0 S PHYOSTIGMINE
L7             54 S PHYSOSTIGMINE

     FILE 'CAPLUS' ENTERED AT 16:36:06 ON 27 MAY 2003

=> s l3
L8          1300 L3

=> s l4
L9          2913 L4

=> s l7
L10         4718 L7

=> e hiv
E1             1     HIUTI/BI
E2             1     HIUVECS/BI
E3         49410 --> HIV/BI
E4             1     HIV0/BI
E5             4     HIV01/BI
E6             1     HIV02/BI
```

```
E7       13089     HIV1/BI
E8           1     HIV111B/BI
E9           1     HIV183/BI
E10          1     HIV1BRU/BI
E11          1     HIV1D117III/BI
E12          1     HIV1E/BI

=> s e3 or e7
         49410 HIV/BI
         13089 HIV1/BI
L11      50075 HIV/BI OR HIV1/BI

=> e herpes
E1           9     HERPERVIRUS/BI
E2           1     HERPERVIRUSES/BI
E3       21343 --> HERPES/BI
E4           3     HERPES1/BI
E5           1     HERPES6/BI
E6           2     HERPESELECT/BI
E7           2     HERPESEVIRUS/BI
E8           1     HERPESIRUS/BI
E9           1     HERPESIVIRUS/BI
E10          1     HERPESIVRUSES/BI
E11          4     HERPESLIKE/BI
E12          1     HERPESSAIMIRI/BI

=> s e3
L12      21343 HERPES/BI

=> s hhv or hsv or hcmv or cmv
          1071 HHV
          9489 HSV
          2298 HCMV
          5317 CMV
L13      17244 HHV OR HSV OR HCMV OR CMV

=> s l12 or l13
L14      29657 L12 OR L13

=> s phosphate ester
        481122 PHOSPHATE
        518186 ESTER
L15       7547 PHOSPHATE ESTER
                 (PHOSPHATE(W)ESTER)

=> d his

     (FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003)

     FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003
                 E STRVUDINE
L1             0 S STRVUDINE
L2             0 S D4T
                 E D4T
L3             5 S STAVUDINE
L4            42 S PARAOXON
L5             0 S PHYOSTIGMINE
L6             0 S PHYOSTIGMINE
L7            54 S PHYSOSTIGMINE

     FILE 'CAPLUS' ENTERED AT 16:36:06 ON 27 MAY 2003
L8          1300 S L3
```

```
L9          2913 S L4
L10         4718 S L7
                 E HIV
L11        50075 S E3 OR E7
                 E HERPES
L12        21343 S E3
L13        17244 S HHV OR HSV OR HCMV OR CMV
L14        29657 S L12 OR L13
L15         7547 S PHOSPHATE ESTER

=> s l8 and l15
L16            2 L8 AND L15

=> d l15 1-2

L15  ANSWER 1 OF 7547  CAPLUS  COPYRIGHT 2003 ACS
AN   2003:398106  CAPLUS
TI   Absorption Rate Limit Considerations for Oral Phosphate Prodrugs
AU   Heimbach, Tycho; Oh, Doo-Man; Li, Lilian Y.; Forsberg, Markus; Savolainen,
     Jouko; Leppaenen, Jukka; Matsunaga, Yasushi; Flynn, Gordon; Fleisher,
     David
CS   The University of Michigan, College of Pharmacy, 428 Church Street, Ann
     Arbor, MI, 48109, USA
SO   Pharmaceutical Research (2003), 20(6), 848-856
     CODEN: PHREEB; ISSN: 0724-8741
PB   Kluwer Academic/Plenum Publishers
DT   Journal
LA   English

L15  ANSWER 2 OF 7547  CAPLUS  COPYRIGHT 2003 ACS
AN   2003:397235  CAPLUS
TI   The XT-Tube Extractor: A Hollow Fiber-Based Supported Liquid Membrane
     Extractor for Bioanalytical Sample Preparation
AU   Jonsson, Ove B.; Nordloef, Ulrika; Nilsson, Ulrika L.
CS   Department of Analytical Chemistry, Stockholm University, Stockholm, Swed.
SO   Analytical Chemistry ACS ASAP
     CODEN: ANCHAM; ISSN: 0003-2700
PB   American Chemical Society
DT   Journal
LA   English


=> e ester
E1            1     ESTEQUATS/BI
E2            2     ESTEQUIOMETRIA/BI
E3       518186 --> ESTER/BI
E4            1     ESTER1/BI
E5            1     ESTER2/BI
E6            1     ESTER20/BI
E7            1     ESTER2HCL/BI
E8            1     ESTER3/BI
E9            2     ESTER4/BI
E10           1     ESTER50/BI
E11           2     ESTER8/BI
E12           1     ESTER9/BI

=> s e3
L17      518186 ESTER/BI

=> s ;17 and l8
ENTER LOGIC EXPRESSION, QUERY NAME, OR (END):s
L18     2414368 S
```

```
17 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l17 and l8
L19         54 L17 AND L8

=> d l19 20-54

L19  ANSWER 20 OF 54  CAPLUS  COPYRIGHT 2003 ACS
AN   2000:742057  CAPLUS
DN   133:309791
TI   Synthesis, activity and formulations of pharmaceutical compounds for
     treatment of oxidative stress and/or endothelial dysfunction
IN   Del Soldato, Piero
PA   Nicox S.A., Fr.
SO   PCT Int. Appl., 140 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 2000061541      A2   20001019       WO 2000-EP3239   20000411
     WO 2000061541      A3   20010927
         W:  AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID,
             IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX,
             NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     IT 1311923         B1   20020320       IT 1999-MI752    19990413
     BR 2000009703      A    20020108       BR 2000-9703     20000411
     EP 1169298         A2   20020109       EP 2000-926870   20000411
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     JP 2002541236      T2   20021203       JP 2000-610818   20000411
     NO 2001004928      A    20011213       NO 2001-4928     20011010
PRAI IT 1999-MI752      A    19990413
     WO 2000-EP3239     W    20000411
OS   MARPAT 133:309791

L19  ANSWER 21 OF 54  CAPLUS  COPYRIGHT 2003 ACS
AN   2000:742053  CAPLUS
DN   133:310142
TI   Synthesis, activity and formulations of pharmaceutical compounds for
     treatment of oxidative stress and/or endothelial dysfunction
IN   Del Soldato, Piero
PA   Nicox S.A., Fr.
SO   PCT Int. Appl., 159 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 2000061537      A2   20001019       WO 2000-EP3234   20000411
     WO 2000061537      A3   20010927
```

W: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, DM, EE, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

IT	1311924	B1	20020320	IT 1999-MI753	19990413
BR	2000009702	A	20020108	BR 2000-9702	20000411
EP	1169294	A2	20020109	EP 2000-925203	20000411
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP	2002541233	T2	20021203	JP 2000-610814	20000411
NO	2001004927	A	20011213	NO 2001-4927	20011010
PRAI IT	1999-MI753	A	19990413		
	WO 2000-EP3234	W	20000411		

OS MARPAT 133:310142

L19 ANSWER 22 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 2000:725436 CAPLUS
DN 133:301171
TI Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
IN Chen, Feng-jing; Patel, Manesh V.
PA Lipocine, Inc., USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2000059475	A1	20001012	WO 2000-US7342	20000316

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US	6383471	B1	20020507	US 1999-287043	19990406
EP	1165048	A1	20020102	EP 2000-916547	20000316
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI US	1999-287043	A	19990406		
	WO 2000-US7342	W	20000316		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 23 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 2000:619245 CAPLUS
DN 133:329124
TI A QSAR study investigating the effect of l-alanine **ester** variation on the anti-HIV activity of some phosphoramidate derivatives of d4T
AU Knaggs, M. H.; McGuigan, C.; Harris, S. A.; Heshmati, P.; Cahard, D.; Gilbert, I. H.; Balzarini, J.
CS Welsh School of Pharmacy, Cardiff University, Cardiff, CF10 3XF, UK
SO Bioorganic & Medicinal Chemistry Letters (2000), 10(18), 2075-2078
CODEN: BMCLE8; ISSN: 0960-894X

PB Elsevier Science Ltd.
DT Journal
LA English
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 24 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 2000:259989 CAPLUS
DN 132:293599
TI preparation of calanolide analogs for treating and preventing tuberculosis
IN Xu, Ze-Qi; Lin, Yuh-Meei; Flavin, Michael
PA Sarawak Medichem Pharmaceuticals, Inc., USA
SO PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000021514	A2	20000420	WO 1999-US23689	19991014
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2346813	AA	20000420	CA 1999-2346813	19991014
	US 6268393	B1	20010731	US 1999-417672	19991014
	EP 1143952	A2	20011017	EP 1999-960118	19991014
	EP 1143952	A3	20020911		
	EP 1143952	B1	20030226		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	AT 233089	E	20030315	AT 1999-960118	19991014
	US 2001027209	A1	20011004	US 2000-735067	20001211
PRAI	US 1998-104409P	P	19981015		
	US 1999-417672	A1	19991014		
	WO 1999-US23689	W	19991014		

OS MARPAT 132:293599

L19 ANSWER 25 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1999:644567 CAPLUS
DN 132:135
TI Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine
AU Saboulard, Didier; Naesens, Lieve; Cahard, Dominique; Salgado, Antonio; Pathirana, Ranjith; Velazquez, Sonsoles; Mcguigan, Christopher; De Clercq, Erik; Balzarini, Jan
CS Rega Institute for Medical Research, Katholieke Universiteit Leuven, Louvain, Belg.
SO Molecular Pharmacology (1999), 56(4), 693-704
CODEN: MOPMA3; ISSN: 0026-895X
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 26 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1999:139847 CAPLUS
DN 130:209924
TI Preparation of amino acid-containing nucleoside esters as inhibitors of retroviral reverse transcriptase and hepatitis B virus DNA polymerase
IN Zhou, Xiao-Xiong; Johansson, Nils-Gunnar; Wahling, Horst
PA Medivir AB, Swed.
SO PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 6

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9909031	A1	19990225	WO 1998-SE1467	19980414
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	AU 9887548	A1	19990308	AU 1998-87548	19980814
	AU 728892	B2	20010118		
	EP 988304	A1	20000329	EP 1998-939041	19980814
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
	NZ 502837	A	20010126	NZ 1998-502837	19980814
	AT 200900	E	20010515	AT 1998-939041	19980814
	EP 1123935	A2	20010816	EP 2001-103370	19980814
	EP 1123935	A3	20010905		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, FI, RO				
	JP 2001515079	T2	20010918	JP 2000-509711	19980814
	NZ 508502	A	20020426	NZ 1998-508502	19980814
	ZA 9901148	A	19990812	ZA 1999-1148	19990212
	CA 2318975	AA	19990819	CA 1999-2318975	19990212
	WO 9941268	A1	19990819	WO 1999-SE189	19990212
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1058687	A1	20001213	EP 1999-932499	19990212
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	NZ 506033	A	20020201	NZ 1999-506033	19990212
	JP 2002503670	T2	20020205	JP 2000-531460	19990212
	US 6458772	B1	20021001	US 1999-249317	19990212
	CA 2318978	AA	19990819	CA 1999-2318978	19990215
	WO 9941275	A1	19990819	WO 1999-SE194	19990215
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

	AU 9932820	A1	19990830	AU 1999-32820	19990215
	AU 754733	B2	20021121		
	EP 1054891	A1	20001129	EP 1999-932500	19990215
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002503673	T2	20020205	JP 2000-531466	19990215
	CA 2325523	AA	19991014	CA 1999-2325523	19990330
	WO 9951613	A1	19991014	WO 1999-SE528	19990330
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1121366	A1	20010808	EP 1999-921327	19990330
	R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002510698	T2	20020409	JP 2000-542334	19990330
	AU 9932819	A1	19990830	AU 1999-32819	19990830
	AU 732408	B2	20010426		
	US 2002128301	A1	20020912	US 2001-927254	20010810
PRAI	SE 1997-2957	A	19970815		
	SE 1997-4147	A	19971112		
	SE 1998-452	A	19980213		
	SE 1998-469	A	19980216		
	SE 1998-1216	A	19980403		
	WO 1998-SE1467	W	19980414		
	ZA 1998-7267	A	19980813		
	EP 1998-939041	A3	19980814		
	NZ 1998-502837	A1	19980814		
	SE 1998-3438	A	19981007		
	US 1999-249317	A	19990212		
	WO 1999-SE189	W	19990212		
	WO 1999-SE194	W	19990215		
	WO 1999-SE528	W	19990330		
	WO 1999-SE1403	A2	19990818		

OS MARPAT 130:209924
RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 27 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1998:816112 CAPLUS
DN 130:47466
TI Inhibitors of human immunodeficiency virus integration that bind the tyrosine-29 pocket of the matrix protein and inhibit karyopherin .alpha. binding
IN Pan, Senliang; Bukrinsky, Michael; Haffar, Omar K.
PA The Picower Institute for Medical Research, USA
SO U.S., 12 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5849793	A	19981215	US 1997-911883	19970815
	CA 2300876	AA	19990225	CA 1998-2300876	19980814
	WO 9909005	A1	19990225	WO 1998-US16923	19980814
	W: AU, CA, IL, JP, NZ				

RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

	AU 9890201	A1	19990308	AU 1998-90201	19980814
	EP 1015422	A1	20000705	EP 1998-942068	19980814
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001515063	T2	20010918	JP 2000-509689	19980814
PRAI	US 1997-911883	A	19970815		
	WO 1998-US16923	W	19980814		

OS MARPAT 130:47466
RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 28 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1998:807805 CAPLUS
DN 130:177179
TI Synthesis, anti-human immunodeficiency virus activity and esterase lability of some novel carboxylic **ester**-modified phosphoramidate derivatives of stavudine (d4T)
AU McGuigan, C.; Sutton, P. W.; Cahard, D.; Turner, K.; O'Leary, G.; Wang, Y.; Gumbleton, M.; De Clercq, E.; Balzarini, J.
CS Welsh School Pharmacy, Cardiff University, Cardiff, CF1 3XF, UK
SO Antiviral Chemistry & Chemotherapy (1998), 9(6), 473-479
CODEN: ACCHEH; ISSN: 0956-3202
PB International Medical Press
DT Journal
LA English
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 29 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1998:742529 CAPLUS
DN 130:38650
TI Preparation of polysaccharides sulfates binding anti-HIV nucleosides or protease inhibitors and anti-AIDS drugs
IN Uryu, Toshiyuki; Kaneko, Utaro
PA Ajinomoto Co., Inc., Japan
SO Jpn. Kokai Tokkyo Koho, 11 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 10306102	A2	19981117	JP 1997-130310	19970501
PRAI JP 1997-130310		19970501		

L19 ANSWER 30 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1998:330565 CAPLUS
DN 129:41360
TI Tri-N-Boc-tetraazamacrocycle-nucleoside conjugates: synthesis and anti-HIV activities
AU Dessolin, J.; Vlieghe, P.; Bouygues, M.; Medou, M.; Quelever, G.; Camplo, M.; Chermann, J. C.; Kraus, J. L.
CS Laboratoire de Chimie Biomoleculaire, Faculte des Sciences de Luminy, Universite de la Mediterranee, Marseille, 13288, Fr.
SO Nucleosides & Nucleotides (1998), 17(5), 957-968
CODEN: NUNUD5; ISSN: 0732-8311
PB Marcel Dekker, Inc.
DT Journal
LA English
RE.CNT 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 31 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1998:226576 CAPLUS
DN 128:316891
TI Direct transport of 2',3'-didehydro-3'-deoxythymidine (D4T) and its **ester** derivatives to the cerebrospinal fluid via the nasal mucous membrane in rats
AU Yajima, Toshiyuki; Juni, Kazuhiko; Saneyoshi, Mineo; Hasegawa, Tetsuya; Kawaguchi, Takeo
CS Faculty of Pharmaceutical Sciences, Josai University, Saitama, 35002, Japan
SO Biological & Pharmaceutical Bulletin (1998), 21(3), 272-277
CODEN: BPBLEO; ISSN: 0918-6158
PB Pharmaceutical Society of Japan
DT Journal
LA English
RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 32 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1998:205372 CAPLUS
DN 128:289775
TI Synthesis and anti-HIV activity of some novel chain-extended phosphoramidate derivatives of d4T (stavudine): esterase hydrolysis as a rapid predictive test for antiviral potency
AU McGuigan, C.; Tsang, H.-W.; Sutton, P. W.; De Clercq, E.; Balzarini, J.
CS Welsh School Pharmacy, University Wales Cardiff, Cardiff, CF1 3XF, UK
SO Antiviral Chemistry & Chemotherapy (1998), 9(2), 109-115
CODEN: ACCHEH; ISSN: 0956-3202
PB International Medical Press
DT Journal
LA English

L19 ANSWER 33 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1998:98348 CAPLUS
DN 128:176175
TI Compositions comprising an inducing agent and an antiviral agent for the treatment of blood, viral and cellular disorders
IN Perrine, Susan P.; Faller, Douglas V.; White, Brian F.
PA Perrine, Susan P., USA; Faller, Douglas V.; White, Brian F.
SO PCT Int. Appl., 136 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9804290	A2	19980205	WO 1997-US12818	19970728
	WO 9804290	A3	19980813		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5939456	A	19990817	US 1996-687670	19960726
	AU 9738891	A1	19980220	AU 1997-38891	19970728
	EP 969869	A2	20000112	EP 1997-936153	19970728
	R: BE, CH, DE, FR, GB, GR, IT, LI				

	JP 2001527517	T2	20011225	JP 1998-508931	19970728
	US 2001009922	A1	20010726	US 2001-756489	20010108
PRAI	US 1996-687670	A	19960726		
	US 1996-687671	A	19960726		
	WO 1997-US12818	W	19970728		

OS MARPAT 128:176175

L19 ANSWER 34 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1998:42288 CAPLUS
DN 128:119660
TI Pharmaceuticals containing VX478, zidovudine and FTC and/or 3TC for HIV virus treatment
IN St. Clair, Martha Heider; Barry, David Walter
PA Glaxo Group Ltd., UK
SO PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9749411	A1	19971231	WO 1997-EP3247	19970623
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2258956	AA	19971231	CA 1997-2258956	19970623
	AU 9732627	A1	19980114	AU 1997-32627	19970623
	AU 727983	B2	20010104		
	BR 9709939	A	19990810	BR 1997-9939	19970623
	EP 938321	A1	19990901	EP 1997-928263	19970623
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	CN 1228026	A	19990908	CN 1997-197357	19970623
	NZ 333099	A	20000623	NZ 1997-333099	19970623
	JP 2000515852	T2	20001128	JP 1998-502320	19970623
	TW 469132	B	20011221	TW 1997-86111193	19970805
	US 6544961	B1	20030408	US 1998-202660	19981218
	NO 9806034	A	19990223	NO 1998-6034	19981222
	KR 2000022226	A	20000425	KR 1998-710646	19981224
PRAI	US 1996-20543P	P	19960625		
	US 1996-21027P	P	19960702		
	GB 1996-14022	A	19960704		
	WO 1997-EP3247	W	19970623		

L19 ANSWER 35 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1997:521950 CAPLUS
DN 127:171589
TI Managing the chemotherapy of patients who are HIV positive using a graphical representation of sensitivity of the pol gene products to inhibitors
IN De Bethune, Marie-Pierre; Hertogs, Kurt; Pauwels, Rudi
PA Virco N.V., Belg.; De Bethune, Marie-Pierre; Hertogs, Kurt; Pauwels, Rudi
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9727480	A1	19970731	WO 1997-IB71	19970124
	W: AU, BA, BG, BR, CA, CN, CZ, HU, IL, IS, JP, KR, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TR, UA, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9713168	A1	19970820	AU 1997-13168	19970124
	AU 717755	B2	20000330		
	EP 877937	A1	19981118	EP 1997-900712	19970124
	EP 877937	B1	20020522		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	CN 1209875	A	19990303	CN 1997-191904	19970124
	BR 9707204	A	19991228	BR 1997-7204	19970124
	RU 2174014	C2	20010927	RU 1998-116294	19970124
	IL 125442	A1	20020310	IL 1997-125442	19970124
	AT 217971	E	20020615	AT 1997-900712	19970124
	ES 2177922	T3	20021216	ES 1997-900712	19970124
	ZA 9700669	A	19980625	ZA 1997-669	19971227
	NO 9803300	A	19980925	NO 1998-3300	19980716
	US 6221578	B1	20010424	US 1998-117217	19980724
	US 2002042679	A1	20020411	US 2000-735487	20001214
	US 6528251	B2	20030304		
PRAI	EP 1996-200175	A	19960126		
	WO 1997-IB71	W	19970124		
	US 1998-117217	A3	19980724		

L19 ANSWER 36 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1997:262832 CAPLUS
DN 126:343796
TI The design and synthesis of nucleoside triphosphate isosteres as potential inhibitors of HIV reverse transcriptase
AU Weaver, Richard; Gilbert, Ian H.
CS Welsh School Pharmacy, Univ. Wales, Cardiff, CF1 3XF, UK
SO Tetrahedron (1997), 53(15), 5537-5562
CODEN: TETRAB; ISSN: 0040-4020
PB Elsevier
DT Journal
LA English

L19 ANSWER 37 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1996:594429 CAPLUS
DN 125:264892
TI Nasal absorption of 2',3'-didehydro-3'-deoxythymidine (D4T) and its esters in rats
AU Yajima, Toshiyuki; Hasegawa, Tetsuya; Juni, Kazuhiko; Saneyoshi, Mineo; Kawaguchi, Takeo
CS Faculty of Pharmaceutical Sciences, Josai Univ., Sakado, 350-02, Japan
SO Biological & Pharmaceutical Bulletin (1996), 19(9), 1234-1237
CODEN: BPBLEO; ISSN: 0918-6158
PB Pharmaceutical Society of Japan
DT Journal
LA English

L19 ANSWER 38 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1996:524251 CAPLUS
DN 125:196243
TI Process for bulk-scale preparation of 2',3'-didehydro-3'-dideoxythymidine
IN Skonezny, Paul M.; Eisenreich, Emerich; Stark, Derron R.; Boyhan, Brenda T.; Baker, Stephen R.
PA Bristol-Myers Squibb Co., USA
SO U.S., 7 pp., Cont.-in-part of U.S. Ser. No. 152,155, abandoned.

CODEN: USXXAM
DT Patent
LA English
FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5539099	A	19960723	US 1994-309636	19940923
	TW 399060	B	20000721	TW 1994-83109894	19941026
	EP 653435	A1	19950517	EP 1994-402483	19941103
	EP 653435	B1	19970205		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	AT 148707	E	19970215	AT 1994-402483	19941103
	ES 2098884	T3	19970501	ES 1994-402483	19941103
	IL 111570	A1	20010724	IL 1994-111570	19941109
	FI 9405322	A	19950516	FI 1994-5322	19941111
	AU 9478803	A1	19950601	AU 1994-78803	19941114
	AU 686249	B2	19980205		
	HU 69171	A2	19950828	HU 1994-3256	19941114
	CA 2135853	AA	19950516	CA 1994-2135853	19941115
	JP 07196682	A2	19950801	JP 1994-315431	19941115
	CN 1107856	A	19950906	CN 1994-120105	19941115
	CN 1043646	B	19990616		
	CN 1215057	A	19990428	CN 1998-116706	19980725
	CN 1069648	B	20010815		
PRAI	US 1993-152155	B2	19931115		
	US 1993-152778	B2	19931115		
	US 1994-309636	A	19940923		

L19 ANSWER 39 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1996:430706 CAPLUS
DN 125:157743
TI Novel nucleoside phosphoramidates as inhibitors of HIV: studies on the stereochemical requirements of the phosphoramidate amino acid
AU McGuigan, C.; Salgado, A.; Yarnold, C.; Harries, T. Y.; De Clercq, E.; Balzarini, J.
CS Welsh Sch. Pharm., Univ. Wales Cardiff, Cardiff, CF1 3XF, UK
SO Antiviral Chemistry & Chemotherapy (1996), 7(4), 184-188
CODEN: ACCHEH; ISSN: 0956-3202
PB Blackwell
DT Journal
LA English

L19 ANSWER 40 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1996:380127 CAPLUS
DN 125:115042
TI Asymmetric Synthesis of Nucleosides via Molybdenum-Catalyzed Alkynol Cycloisomerization Coupled with Stereoselective Glycosylations of Deoxyfuranose Glycals and 3-Amidofuranose Glycals
AU McDonald, Frank E.; Gleason, Mark M.
CS Department of Chemistry, Northwestern University, Evanston, IL, 60208-3113, USA
SO Journal of the American Chemical Society (1996), 118(28), 6648-6659
CODEN: JACSAT; ISSN: 0002-7863
PB American Chemical Society
DT Journal
LA English
OS CASREACT 125:115042

L19 ANSWER 41 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1995:812971 CAPLUS
DN 123:228218
TI Combination of quinoxalines and nucleosides for treating viral infection

and preparation of the quinoxalines.
IN Meichsner, Christoph; Riess, Guenther; Kleim, Joerg Peter; Roesner, Manfred; Paessens, Arno; Blunck, Martin
PA Hoechst A.-G., Germany; Aventis Pharma Deutschland GmbH
SO Eur. Pat. Appl., 69 pp.
CODEN: EPXXDW
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 657166	A1	19950614	EP 1994-119146	19941205
EP 657166	B1	20030409		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
DE 4342024	A1	19950614	DE 1993-4342024	19931209
AT 236642	E	20030415	AT 1994-119146	19941205
CN 1108935	A	19950927	CN 1994-119877	19941207
CA 2137605	AA	19950610	CA 1994-2137605	19941208
AU 9480421	A1	19950615	AU 1994-80421	19941208
AU 697486	B2	19981008		
ZA 9409785	A	19950712	ZA 1994-9785	19941208
JP 07196511	A2	19950801	JP 1994-330455	19941208
HU 70037	A2	19950928	HU 1994-3518	19941208
HU 221498	B	20021028		
PRAI DE 1993-4342024	A	19931209		

OS CASREACT 123:228218; MARPAT 123:228218

L19 ANSWER 42 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1995:703896 CAPLUS
DN 124:9257
TI Efficient transformation of thymidine into 2',3'-didehydro-2',3'-dideoxythymidine (D4T) involving opening of a 2,3'-anhydro derivative by phenylselenol
AU Becouarn, Stefan; Czernecki, Stanislas; Valery, Jean-Marc
CS Laboratoire Chimie Glucides, Universite Pierre Marie Curie, Paris, 75005, Fr.
SO Nucleosides & Nucleotides (1995), 14(6), 1227-32
CODEN: NUNUD5; ISSN: 0732-8311
PB Dekker
DT Journal
LA English
OS CASREACT 124:9257

L19 ANSWER 43 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1995:662363 CAPLUS
DN 123:56508
TI Preparation of (arylhydroxymethyl)phosphonate esters of nucleoside analogs and related compounds as drugs.
IN Uhlmann, Eugen; Meier, Chris
PA Hoechst A.-G., Germany
SO Ger. Offen., 25 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI DE 4321946	A1	19950112	DE 1993-4321946	19930701
CA 2165971	AA	19950112	CA 1994-2165971	19940629
WO 9501363	A1	19950112	WO 1994-EP2121	19940629
W: AU, CA, FI, JP, NO, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

	AU 9470735	A1	19950124	AU 1994-70735	19940629
	AU 698928	B2	19981112		
	EP 707591	A1	19960424	EP 1994-919670	19940629
	EP 707591	B1	20010926		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08512039	T2	19961217	JP 1994-503269	19940629
	AT 206130	E	20011015	AT 1994-919670	19940629
	ES 2165391	T3	20020316	ES 1994-919670	19940629
	NO 9505352	A	19960214	NO 1995-5352	19951229
	FI 9506341	A	19960219	FI 1995-6341	19951229
	US 6028182	A	20000222	US 1996-578686	19960102
PRAI	DE 1993-4321946	A	19930701		
	WO 1994-EP2121	W	19940629		
OS	MARPAT 123:56508				

L19 ANSWER 44 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1995:511464 CAPLUS
DN 122:265932
TI Preparation of nucleoside analog fatty esters as antiviral compounds
IN Boerretzen, Bernt; Dalen, Are; Myhren, Finn; Stokke, Kjell Torgeir
PA Norsk Hydro A/S, Norway
SO PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9422887	A1	19941013	WO 1994-NO71	19940405
	W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	CA 2158853	AA	19941013	CA 1994-2158853	19940405
	AU 9465141	A1	19941024	AU 1994-65141	19940405
	AU 685104	B2	19980115		
	EP 693077	A1	19960124	EP 1994-912709	19940405
	EP 693077	B1	19980923		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 08508477	T2	19960910	JP 1994-521952	19940405
	JP 3049258	B2	20000605		
	HU 73659	A2	19960930	HU 1995-2896	19940405
	AT 171457	E	19981015	AT 1994-912709	19940405
	ES 2124883	T3	19990216	ES 1994-912709	19940405
	RU 2139884	C1	19991020	RU 1995-119386	19940405
	PL 177263	B1	19991029	PL 1994-310970	19940405
	CZ 287755	B6	20010117	CZ 1995-2593	19940405
	SK 281231	B6	20010118	SK 1995-1233	19940405
	NO 9503768	A	19951110	NO 1995-3768	19950922
	FI 9504727	A	19951004	FI 1995-4727	19951004
	US 6153594	A	20001128	US 1995-532754	19951129
	HK 1003437	A1	20000707	HK 1998-102521	19980324
	US 6335322	B1	20020101	US 1999-435641	19991109
PRAI	GB 1993-7043	A	19930405		
	WO 1994-NO71	W	19940405		
	GB 1995-15279	A	19950725		
	US 1995-532754	A2	19951129		
	US 1998-983483	A3	19980526		
OS	CASREACT 122:265932; MARPAT 122:265932				

L19 ANSWER 45 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1995:213452 CAPLUS
DN 122:133729
TI A phosphoramidite-based synthesis of phosphoramidate amino acid diesters of antiviral nucleosides
AU Abraham, Timothy W.; Wagner, Carston R.
CS College Pharmacy, Univ. Minnesota, Minneapolis, MN, 55455, USA
SO Nucleosides & Nucleotides (1994), 13(9), 1891-903
CODEN: NUNUD5; ISSN: 0732-8311
PB Dekker
DT Journal
LA English
OS CASREACT 122:133729

L19 ANSWER 46 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1994:173200 CAPLUS
DN 120:173200
TI Prodrugs of 2',3'-didehydro-3'-deoxythymidine
AU Hasegawa, Tetsuya; Seki, Toshinobu; Juni, Kazuhiko; Saneyoshi, Mineo; Kawaguchi, Takeo
CS Fac. Pharm. Sci., Josai Univ., Saitama, 350-02, Japan
SO Journal of Pharmaceutical Sciences (1993), 82(12), 1232-6
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English

L19 ANSWER 47 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1994:116622 CAPLUS
DN 120:116622
TI Prodrugs of 2',3'-Didehydro-3'-deoxythymidine (D4T): Synthesis, Antiviral Activity, and Rapid Pharmacokinetic Evaluation
AU Tortolani, David R.; Russell, John W.; Whiterock, Valerie J.; Hitchcock, Michael J. M.; Ghazzouli, Ismail; Martin, John C.; Mansuri, Muzammil M.; Starrett, John E., Jr.
CS Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Wallingford, CT, 06492-7660., USA
SO Journal of Pharmaceutical Sciences (1994), 83(3), 339-43
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English

L19 ANSWER 48 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1993:480205 CAPLUS
DN 119:80205
TI Targeted drug delivery via mixed phosphate derivatives
IN Bodor, Nicholas S.
PA University of Florida, USA
SO PCT Int. Appl., 248 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9217185	A1	19921015	WO 1992-US2239	19920327
	W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US				
	RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
	CA 2108041	AA	19920930	CA 1992-2108041	19920327
	AU 9216748	A1	19921102	AU 1992-16748	19920327
	AU 668506	B2	19960509		
	EP 577725	A1	19940112	EP 1992-909373	19920327

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE
JP 06510020 T2 19941110 JP 1992-508920 19920327
PRAI US 1991-677304 19910329
WO 1992-US2239 19920327
OS MARPAT 119:80205

L19 ANSWER 49 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1992:511992 CAPLUS
DN 117:111992
TI Phosphonate derivatives of certain nucleosides
IN Halazy, Serge; Casara, Patrick; Neises, Bernhard; Jund, Karin
PA Merrell Dow Pharmaceuticals, Inc., USA
SO Eur. Pat. Appl., 19 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 477454	A1	19920401	EP 1990-402695	19900928
R: FR				
EP 479640	A2	19920408	EP 1991-402517	19910923
EP 479640	A3	19930127		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 04316589	A2	19921106	JP 1991-274878	19910927
PRAI EP 1990-402695		19900928		

OS MARPAT 117:111992

L19 ANSWER 50 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1991:435571 CAPLUS
DN 115:35571
TI Percutaneous penetration of 2',3'-didehydro-3'-deoxythymidine (D4T) and its **ester** prodrugs through rat skin
AU Kawaguchi, Takeo; Hasegawa, Tetsuya; Endoh, Hirotaka; Seki, Toshinobu; Juni, Kazuhiko; Saneyoshi, Mineo
CS Life Sci. Res. Cent., Josai Univ., Saitama, Japan
SO Drug Delivery System (1991), 6(1), 57-60
CODEN: DDSYEI; ISSN: 0913-5006
DT Journal
LA Japanese

L19 ANSWER 51 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1991:164714 CAPLUS
DN 114:164714
TI Preparation of fatty acid derivatives of nucleosides or acylic nucleosides as antiviral agents
IN Horrobin, David Frederick; Stewart, John Charles Marshall; Winther, Michael David
PA Efamol Holdings PLC, UK
SO Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI EP 393920	A2	19901024	EP 1990-303904	19900411
EP 393920	A3	19910703		
EP 393920	B1	19970709		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5216142	A	19930601	US 1990-521075	19900410
EP 693498	A1	19960124	EP 1995-114526	19900411

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE

	AT 155142	E	19970715	AT 1990-303904	19900411
	ES 2108686	T3	19980101	ES 1990-303904	19900411
	CA 2014662	AA	19901017	CA 1990-2014662	19900417
	CA 2014662	C	20020917		
	AU 9053290	A1	19901018	AU 1990-53290	19900417
	AU 637362	B2	19930527		
	JP 02304084	A2	19901217	JP 1990-99445	19900417
	JP 2952505	B2	19990927		
	ZA 9002868	A	19910227	ZA 1990-2868	19900417
	US 5276020	A	19940104	US 1992-990190	19921214
PRAI	GB 1989-8646	A	19890417		
	GB 1989-21266	A	19890920		
	US 1990-521075	A3	19900410		
	EP 1990-303904	A3	19900411		

L19 ANSWER 52 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1990:503397 CAPLUS
DN 113:103397
TI Porphyrin and phthalocyanine antiviral compositions
IN Schinazi, Raymond F.; Dixon, Dabney White; Marzilli, Luigi G.
PA Georgia State University Foundation, Inc., USA
SO PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8911277	A2	19891130	WO 1989-US2256	19890523
	WO 8911277	A3	19891228		
	W: AU, DK, FI, JP, KR, NO				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	US 5192788	A	19930309	US 1988-197764	19880523
	US 5109016	A	19920428	US 1989-355499	19890522
	AU 8938306	A1	19891212	AU 1989-38306	19890523
	US 5281616	A	19940125	US 1992-873415	19920424
PRAI	US 1988-197764		19880523		
	US 1989-355499		19890522		
	US 1989-355499		19890522		
	US 1989-355499		19890522		
	US 1989-355499		19890522		
	US 1989-355499		19890522		
	WO 1989-US2256		19890523		

L19 ANSWER 53 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1989:115257 CAPLUS
DN 110:115257
TI A dihydropyridine carrier system for sustained delivery of 2',3'-dideoxynucleosides to the brain
AU Palomino, Eduardo; Kessel, David; Horwitz, Jerome P.
CS Sch. Medicine, Wayne State Univ., Detroit, MI, 48201, USA
SO Journal of Medicinal Chemistry (1989), 32(3), 622-5
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 110:115257

L19 ANSWER 54 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1970:79401 CAPLUS
DN 72:79401
TI Synthesis of some nucleotides derived from 3'-deoxythymidine

AU Russell, Alan F.; Moffatt, J. G.
CS Inst. of Mol. Biol., Palo Alto, CA, USA
SO Biochemistry (1969), 8(12), 4889-96
CODEN: BICHAW; ISSN: 0006-2960
DT Journal
LA English

=> d l19 50 53 54 46 47 all

L19 ANSWER 50 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1991:435571 CAPLUS
DN 115:35571
TI Percutaneous penetration of 2',3'-didehydro-3'-deoxythymidine (D4T) and its **ester** prodrugs through rat skin
AU Kawaguchi, Takeo; Hasegawa, Tetsuya; Endoh, Hirotaka; Seki, Toshinobu; Juni, Kazuhiko; Saneyoshi, Mineo
CS Life Sci. Res. Cent., Josai Univ., Saitama, Japan
SO Drug Delivery System (1991), 6(1), 57-60
CODEN: DDSYEI; ISSN: 0913-5006
DT Journal
LA Japanese
CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 1
AB In an attempt to develop a transdermal therapeutic system for the virucidal agents 2',3'-didehydro-3'-deoxythymidine (D4T) and its lipophilic prodrugs, percutaneous penetration of the drugs was examd. through the rat skin. The ability of penetration enhancers (azone and l-menthol) to increase the transdermal delivery of the drugs was evaluated in excised rat skin. Azone and l-menthol showed an enhancing effect on the penetration of D4T and its 5'-acetate at a concn. of 3% in water. The penetration of the 5'-octanoate was very small even in the presence of the enhancers. A D4T suspension contg. 3% l-menthol was applied on the abdominal skin and blood plasma concns. were measured. D4T was detected in plasma 12 after the application and stable plasma concns. (1-3 .mu.M) were maintained for 8 h.
ST didehydrodeoxythymidine prodrug transdermal formulation pharmacokinetics; skin didehydrodeoxythymidine prodrug penetration pharmacokinetics
IT Skin, metabolism
(didehydrodeoxythymidine and **ester** prodrugs penetration of, from transdermal formulations)
IT Drug bioavailability
(of didehydrodeoxythymidine and **ester** prodrugs, from transdermal formulations)
IT Biological transport
(absorption, of didehydrodeoxythymidine and **ester** prodrugs, from transdermal formulations)
IT Pharmaceutical dosage forms
(transdermal, prodrugs, of didehydrodeoxythymidine and **ester**, pharmacokinetics of)
IT 2216-51-5 59227-89-3, Azone
RL: BIOL (Biological study)
(as formulation component for didehydrodeoxythymidine and prodrugs, pharmacokinetics in relation to)
IT **3056-17-5**, 2',3'-Didehydro-3'-deoxythymidine 77421-68-2
134767-53-6
RL: BIOL (Biological study)
(transdermal formulation of, pharmacokinetics of, azone and menthol in)

L19 ANSWER 53 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1989:115257 CAPLUS
DN 110:115257

TI A dihydropyridine carrier system for sustained delivery of 2',3'-dideoxynucleosides to the brain

AU Palomino, Eduardo; Kessel, David; Horwitz, Jerome P.
CS Sch. Medicine, Wayne State Univ., Detroit, MI, 48201, USA

SO Journal of Medicinal Chemistry (1989), 32(3), 622-5
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
CC 33-9 (Carbohydrates)
Section cross-reference(s): 1
OS CASREACT 110:115257

GI



I II III IV

AB The present study evaluates the utility of the dihydropyridine .dblharw. pyridinium salt redox system for the specific delivery and sustained release of a model 2',3'-dideoxynucleotide to the brain of mice as the initial effort in a search for agents that may prove effective in reversing the complicating nuerol. disorders of AIDS. The unsatd. nucleoside 2',3'-didehydro-2',3'-dideoxythymidine (I), which is effective in protecting ATH8 cells against the cytopathogenicity of HIV-1, was converted to the corresponding N-methyl-1,4-dihydronicotinate deriv., II, in 3 steps. The 5'-O-nicotinate **ester**, III, obtained by reaction of I with nicotinoyl chloride, was converted in quant. yield to the N-methylpyridinium salt IV on treatment with MeI in acetone. Redn. of the latter with Na2S2O4 gave II in 50% yield. Pseudo-first-order rate consts. for the oxidn. of II to III were obsd.in plasma and in homogenates of mouse liver and brain. None of the chem. delivery system II could be detected in the brain of female BDF/1 mice at 1 h postinjection. The peak level of IV in the brain occurred at 3 h with a half-life of 25 h. Both I and N-methylnicotinic acid were readily identified by HPLC in brain homogenate derived from mice injected (25 mg/kg) with II. TLC showed a low level penetration of mouse brain by I (0.44 .mu.g/g wet tissue)

following injection of the corresponding labeled [methyl-3H]-2',3'-unsatd. nucleoside (25 mg/kg). The data indicate that II crosses the blood-brain barrier to be oxidized by cerebral tissue to the ionic structure IV which is locked therein. The sustained local release of a 2',3'-dideoxynucleoside, such as I, from a chem. delivery system (II) represents a potentially useful approach to the treatment of AIDS dementia complex.

ST dihydropyridine carrier system dideoxynucleoside brain; nucleoside dideoxy carrier system brain; thymidine dideoxydidehydro carrier system brain; AIDS dideoxynucleoside carrier system brain

IT Immunodeficiency
(acquired immune deficiency syndrome, treatment of, dihydropyridine carrier system for sustained delivery of dideoxynucleosides to brain for)

IT Nucleosides, biological studies
RL: BIOL (Biological study)
(dideoxy, dihydropyridine carrier system for sustained delivery of, to brain, in AIDS treatment)

IT 10400-19-8, Nicotinoyl chloride
RL: RCT (Reactant); RACT (Reactant or reagent)
(esterification of, with didehydrodideoxythymidine)

IT **3056-17-5**
RL: RCT (Reactant); RACT (Reactant or reagent)
(esterification of, with nicotinoyl chloride)

IT 118869-93-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and quaternization of, with Me iodide)

IT 118869-94-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and redn. of)

IT 7775-14-6P, Sodium dithionite
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

IT 118869-95-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, for sustained delivery of dideoxynucleoside to the brain, for AIDS treatment)

L19 ANSWER 54 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1970:79401 CAPLUS
DN 72:79401
TI Synthesis of some nucleotides derived from 3'-deoxythymidine
AU Russell, Alan F.; Moffatt, J. G.
CS Inst. of Mol. Biol., Palo Alto, CA, USA
SO Biochemistry (1969), 8(12), 4889-96
CODEN: BICHAW; ISSN: 0006-2960
DT Journal
LA English
CC 33 (Carbohydrates)

AB Phosphorylation of 3'-deoxy-3'-iodothymidine gives the corresponding3'-deoxy-3'-iodothymidine 5'-phosphate in high yield. Activation of the phosphate group can be achieved by formation of the phosphoromorpholidate under anhydrous conditions, and subsequent condensation with tributylammonium pyrophosphate in anhydrous dimethyl sulfoxide gives 3'-deoxy-3'-iodothymidine 5'-triphosphate in modest yield. The latter reaction is complicated by simultaneous dehydrohalogenation giving the related 2',3'-unsatd. nucleoside 5'-triphosphate and by extensive intramol. displacement of iodide ion by phosphate giving a3',5'-cyclic phosphate with the 2-deoxy-.beta.-D-threo-pentofuranosyl configuration. The same spectrum of products is obtained using 3'-deoxy-3'-iodothymidine 5'-phosphoroimid-azolate prepd. from the parent

nucleoside and triimidazolephos-phine oxide. The various products are characterized by enzymic and spectroscopic techniques, and redn. of either the iodotriphosphate or the unsatd. triphosphate with H and Pd gives 3'-deoxythymidine 5'-triphosphate. Phosphorylation of 1-(2-deoxy-.beta.-D-threo-pentofuranosyl)thymine with diphenyl phosphorochloridate gives the cryst. 5'-diphenyl phosphate **ester** that can be converted with base into the same 3',5'-cyclic phosphate obtained as a by-product during prepn. of the triphosphates above. A pair of 3',5'-cyclic phosphate triester diastereoisomeric about their phosphorus atoms are intermediates in this cyclization reaction.

ST nucleotides prepn; deoxythymidines iodo; thymidines phosphorylation; phosphorylation thymidines

IT Nucleotides, preparation
RL: PREP (Preparation)
(3'-deoxythymidine derivs.)

IT 4H-Furo[3,2-d]-1,3,2-dioxaphosphorin, nucleoside derivs.
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

IT 611-60-9P 15981-92-7P 16053-52-4P 26194-88-7P 27641-12-9P
27641-15-2P 27641-16-3P 27646-57-7P 27646-58-8P **27646-59-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

L19 ANSWER 46 OF 54 CAPLUS COPYRIGHT 2003 ACS
AN 1994:173200 CAPLUS
DN 120:173200
TI Prodrugs of 2',3'-didehydro-3'-deoxythymidine
AU Hasegawa, Tetsuya; Seki, Toshinobu; Juni, Kazuhiko; Saneyoshi, Mineo; Kawaguchi, Takeo
CS Fac. Pharm. Sci., Josai Univ., Saitama, 350-02, Japan
SO Journal of Pharmaceutical Sciences (1993), 82(12), 1232-6
CODEN: JPMSAE; ISSN: 0022-3549
DT Journal
LA English
CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 1, 33
GI



I

AB Six **ester** prodrugs of 2',3'-didehydro-3'-deoxythymidine (I) were prepd., and their physicochem. properties evaluated. Marked differences were obsd. All of the prodrugs were chem. stable within the pH range 2-7. Hydrolysis of these esters was obsd. in all cases for 4 rat enzyme systems (plasma, liver, duodenum, and kidney), with I being regenerated. I or the prodrug was administered orally to rats, and the plasma concns. of I and a corresponding prodrug were measured. The half-life of I after i.v.

administration was 35.9 min. The half-life calcd. from the terminal phase and the max. concn. in plasma following oral administration of I were 35.9 min and 48.4 .mu.M, resp. After oral prodrug administration (with water or olive oil as a solvent), though none of the prodrugs was detected in plasma except for 5'-hemisuccinyl deriv. of I and 5'-hemiglutaryl deriv. of I with olive oil as a solvent, retention time of plasma I concn. was extended and the elevated I concn. in plasma decreased.

ST prodrug didehydrodeoxythymidine prepn; dehydrodeoxythymidine prodrug prepn; hydrolysis didehydrodeoxythymidine prodrug

IT Blood plasma
Kidney
Liver
(didehydrodeoxythymidine prodrugs hydrolysis in)

IT Hydrolysis
Partition
Solubility
(of didehydrodeoxythymidine prodrugs)

IT Drug bioavailability
(of ehydrodeoxythymidine, from prodrugs)

IT Intestine
(duodenum, didehydrodeoxythymidine prodrugs hydrolysis in)

IT 77421-68-2P 122567-97-9P 126209-27-6P 134767-53-6P 152336-78-2P 152336-79-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and hydrolysis and physicochem. properties of, as didehydrodeoxythymidine prodrug)

IT **3056-17-5**, 2',3'-Didehydro-3'-deoxythymidine
RL: BIOL (Biological study)
(prodrugs for, prepn. and hydrolysis and physicochem. properties of)

L19 ANSWER 47 OF 54 CAPLUS COPYRIGHT 2003 ACS

AN 1994:116622 CAPLUS

DN 120:116622

TI Prodrugs of 2',3'-Didehydro-3'-deoxythymidine (D4T): Synthesis, Antiviral Activity, and Rapid Pharmacokinetic Evaluation

AU Tortolani, David R.; Russell, John W.; Whiterock, Valerie J.; Hitchcock, Michael J. M.; Ghazzouli, Ismail; Martin, John C.; Mansuri, Muzammil M.; Starrett, John E., Jr.

CS Pharmaceutical Research Institute, Bristol-Myers Squibb Company, Wallingford, CT, 06492-7660., USA

SO Journal of Pharmaceutical Sciences (1994), 83(3), 339-43
CODEN: JPMSAE; ISSN: 0022-3549

DT Journal

LA English

CC 63-5 (Pharmaceuticals)
Section cross-reference(s): 1, 33

AB A series of 5'-derivs. and modified pyrimidine analogs of 2',3'-didehydro-3'-deoxythymidine (d4T, stavudine) were synthesized to det. their potential as oral prodrugs of d4T. Utilizing a screen developed for the rapid evaluation of a variety of prodrugs in mice, it was detd. that 5'-acetate provided comparable plasma levels of d4T after oral administration of the prodrug to that when d4T was administered alone. The relative oral bioavailability of methoxy acetate and cyclohexyl carbonate derivs. was 79 and 41%, resp. The dihydropyridine **ester** did not provide detectable levels of d4T up to 1 h after oral administration of 6. Thiopyrimidine and aminopyrimidine derivs. also failed to provide measurable levels of d4T after oral administration. 5'-Derivs. showed similar activity to that of d4T against HIV and MuLV, as did 5'-benzoyl-4-thio deriv. However, the corresponding 4-thio 5'-alc. deriv. was inactive.

ST stavudine prodrug prepn antiviral bioavailability

IT Virucides and Virustats

(didehydrodeoxythymidine prodrugs as, prepn. and pharmacokinetics of)
IT Drug bioavailability
(of didehydrodeoxythymidine prodrugs)
IT Virus, animal
(human immunodeficiency, treatment of, by didehydrodeoxythymidine prodrugs)
IT Pharmaceutical dosage forms
(prodrugs, of didehydrodeoxythymidine, prepn. and antiviral activity and pharmacokinetics of)
IT 118869-95-7
RL: BIOL (Biological study)
(antiviral activity and bioavailability of, as stavudine prodrug)
IT **3056-17-5**, Stavudine
RL: RCT (Reactant); RACT (Reactant or reagent)
(antiviral activity and reactions of)
IT 5983-08-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and amination and antiviral activity of, as stavudine prodrug)
IT 77421-68-2P 120826-44-0P 126209-28-7P 152917-61-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and antiviral activity of, as stavudine prodrug)
IT 122567-98-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and deprotection and antiviral activity of, as stavudine prodrug)
IT 126209-30-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and reaction of, with cyclohexanol)
IT 122567-97-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. and thiation of)
IT 530-62-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with stavudine)
IT 108-93-0, Cyclohexanol, reactions
RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with stavudine deriv.)

=> s l9 and l11
L20 3 L9 AND L11

=> d l20 1-3

L20 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 2003:97550 CAPLUS
DN 138:164674
TI Molecular markers for hepatocellular carcinoma and their use in diagnosis and therapy
IN Debuschewitz, Sabine; Jobst, Juergen; Kaiser, Stephan
PA Germany
SO PCT Int. Appl., 98 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

PI WO 2003010336 A2 20030206 WO 2002-EP8305 20020725
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
DE 10136273 A1 20030213 DE 2001-10136273 20010725
PRAI DE 2001-10136273 A 20010725

L20 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 2001:454452 CAPLUS
DN 135:313108
TI In vivo pharmacokinetics and metabolism of anti-human immunodeficiency virus agent d4T-5'-[P-bromophenyl methoxyalaninyl phosphate] (sampidine) in mice
AU Chen, Chun-Lin; Venkatachalam, T. K.; Zhu, Zhao-Hai; Uckun, Fatih M.
CS Drug Discovery Program, Department of Pharmaceutical Sciences, Parker Hughes Institute, St. Paul, MN, 55113, USA
SO Drug Metabolism and Disposition (2001), 29(7), 1035-1041
CODEN: DMDSAI; ISSN: 0090-9556
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L20 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 1996:365474 CAPLUS
DN 125:58113
TI Preparation of arylthio and dithiobisarylamide compounds as antibacterial and antiviral agents
IN Domagala, John Michael; Elslager, Edward Faith; Gogliotti, Rocco Dean
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9604242	A1	19960215	WO 1995-US8802	19950711
W: AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, UA, UZ, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5463122	A	19951031	US 1994-286816	19940805
US 5734081	A	19980331	US 1995-446917	19950601
AU 9530087	A1	19960304	AU 1995-30087	19950711
AU 710806	B2	19990930		
EP 775110	A1	19970528	EP 1995-926276	19950711
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 10504292	T2	19980428	JP 1995-506523	19950711
RU 2156236	C2	20000920	RU 1997-103207	19950711
PL 181425	B1	20010731	PL 1995-318540	19950711
FI 9700417	A	19970131	FI 1997-417	19970131

	NO 9700495	A	19970402	NO 1997-495	19970204
	BG 63301	B1	20010928	BG 1997-101189	19970204
PRAI	US 1994-286816	A	19940805		
	US 1995-446917	A	19950601		
	WO 1995-US8802	W	19950711		

OS MARPAT 125:58113

=> d 120 3 all

L20 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2003 ACS
AN 1996:365474 CAPLUS
DN 125:58113
TI Preparation of arylthio and dithiobisarylamide compounds as antibacterial and antiviral agents
IN Domagala, John Michael; Elslager, Edward Faith; Gogliotti, Rocco Dean
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM C07C323-62
ICS C07C323-63; C07C323-67; C07D207-16; C07D239-42; C07D295-18; A61K031-165; A61K031-105
CC 25-19 (Benzene, Its Derivatives, and Condensed Benzenoid Compounds)
Section cross-reference(s): 10, 63
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9604242	A1	19960215	WO 1995-US8802	19950711
	W: AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, UA, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5463122	A	19951031	US 1994-286816	19940805
	US 5734081	A	19980331	US 1995-446917	19950601
	AU 9530087	A1	19960304	AU 1995-30087	19950711
	AU 710806	B2	19990930		
	EP 775110	A1	19970528	EP 1995-926276	19950711
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 10504292	T2	19980428	JP 1995-506523	19950711
	RU 2156236	C2	20000920	RU 1997-103207	19950711
	PL 181425	B1	20010731	PL 1995-318540	19950711
	FI 9700417	A	19970131	FI 1997-417	19970131
	NO 9700495	A	19970402	NO 1997-495	19970204
	BG 63301	B1	20010928	BG 1997-101189	19970204
PRAI	US 1994-286816	A	19940805		
	US 1995-446917	A	19950601		
	WO 1995-US8802	W	19950711		

OS MARPAT 125:58113
GI For diagram(s), see printed CA Issue.
AB The title compds. [I; A = monocyclic or bicyclic aryl which can contain up to 3 heteroatoms (e.g., O, S, N); R1, R2 = H, halogen, alkyl, alkoxy, cycloalkyl, OH, CN, NO2, etc.; X = (un)substituted amido, CHO, halocarbonyl, alkylcarbonyl, alkoxycarbonyl, etc.; Y = H, SZ; Z = H, halogen, alkyl, alkylcarbonyl, cycloalkyl, etc; n = 1, 2], useful as antibiotics and antiviral agents, are prepd. and I-contg. formulations presented. Thus, 2,2'-dithiobisbenzoyl chloride was reacted with 4-(aminosulfonyl)aniline, producing 2,2'-dithiobis-4'-[sulfamoylbenzanilide], m.p. 311-312.degree., which demonstrated a EC50 of 0.7 .mu.M in a H9/**HIV**-1 cell assay.

ST sulfamoylbenzanilide prepn antiviral agent; antibiotic prepn sulfamoylbenzanilide; arylthio prepn antibacterial agent; **HIV** antiviral agent prepn sulfamoylbenzanilide; AIDS treatment prepn sulfamoylbenzanilide

IT Antibiotics
Bactericides, Disinfectants, and Antiseptics
Virucides and Virustats
(arylthio and dithiobisarylamide compds.)

IT Acquired immune deficiency syndrome
(arylthio and dithiobisarylamide compds. for treatment of)

IT 2752-94-5P 14208-44-7P 19532-46-8P 19532-48-0P 19602-84-7P
19602-86-9P 19602-89-2P 30018-07-6P 37010-19-8P 37038-17-8P
49755-40-0P 49755-48-8P 50383-29-4P 63956-06-9P 89011-97-2P
96835-63-1P 96835-64-2P 121451-38-5P 171744-40-4P 171744-41-5P
171744-42-6P 173590-72-2P 173590-73-3P 173590-74-4P 173590-78-8P
177785-53-4P 177785-54-5P 177785-55-6P 177785-56-7P 177785-57-8P
177785-58-9P 177785-59-0P 177785-60-3P 177785-61-4P 177785-62-5P
177785-63-6P 177785-64-7P 177785-65-8P 177785-66-9P 177785-67-0P
177785-68-1P 177785-69-2P 177785-70-5P 177785-71-6P 177785-72-7P
177785-73-8P 177785-74-9P 177785-75-0P 177785-76-1P 177785-77-2P
177785-78-3P 177785-79-4P 177785-80-7P 177785-81-8P 177785-82-9P
177785-83-0P 177785-84-1P 177785-85-2P 177785-86-3P 177785-87-4P
177785-88-5P 177785-89-6P 177785-90-9P 177785-91-0P 177785-92-1P
177785-93-2P 177785-94-3P 177785-95-4P 177785-96-5P 177785-97-6P
177785-98-7P 177785-99-8P 177786-00-4P 177786-01-5P 177786-02-6P
177786-03-7P 177786-04-8P 177786-05-9P 177786-06-0P 177786-07-1P
177786-08-2P 177786-09-3P 177786-10-6P 177786-11-7P 177786-12-8P
177786-13-9P 177786-14-0P 177786-15-1P 177786-16-2P 177786-17-3P
177786-18-4P 177786-19-5P 177786-20-8P 177786-21-9P 177786-22-0P
177786-23-1P 177786-24-2P 177786-25-3P 177786-26-4P 177786-27-5P
177786-28-6P 177786-29-7P 177786-30-0P 177786-31-1P 177786-32-2P
177786-33-3P 177786-34-4P 177786-35-5P 177786-36-6P 177786-37-7P
177786-38-8P 177786-39-9P 177786-40-2P 177786-41-3P 177786-42-4P
177786-43-5P 177786-44-6P 177786-45-7P 177786-46-8P 177786-47-9P
177786-49-1P 177786-50-4P 177786-51-5P 177786-52-6P 177786-53-7P
177786-54-8P 177786-55-9P 177786-56-0P 177786-57-1P 177786-58-2P
177786-59-3P 177786-60-6P 177786-61-7P 177786-62-8P 177786-63-9P
177786-64-0P 177786-65-1P 177786-66-2P 177786-67-3P 177786-68-4P
177786-69-5P 177786-70-8P 177786-71-9P 177786-72-0P 177786-73-1P
177786-74-2P 177932-76-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of arylthio and dithiobisarylamide compds. as antibacterial and antiviral agents)

IT 56-91-7 63-74-1 68-35-9 75-09-2, reactions 79-42-5 90-04-0
95-53-4, reactions 95-64-7 95-76-1 96-27-5 98-18-0 99-09-2
100-01-6, reactions 104-94-9 107-95-9, .beta.-Alanine 108-24-7
108-98-5, Benzenethiol, reactions 110-18-9 110-91-8, Morpholine, reactions 119-80-2 123-75-1, Pyrrolidine, reactions 138-37-4
144-80-9 147-93-3 328-74-5 371-40-4 393-11-3 443-79-8, DL-Isoleucine 498-94-2, 4-Piperidinecarboxylic acid 540-37-4
554-00-7 578-54-1 591-19-5 591-54-8, 4-Pyrimidinamine 616-91-1
626-01-7 626-43-7 643-28-7 765-30-0, Cyclopropanamine 769-92-6
873-74-5 1197-18-8 1197-55-3 1538-75-6 1791-13-5 1801-99-6
1953-02-2 2038-03-1, 4-Morpholineethanamine 2516-96-3 2592-95-2
2757-23-5 2812-46-6 2835-68-9 3306-62-5 3483-12-3 3862-73-5
4369-80-6 4892-02-8 5082-74-6, 3-Pyrrolidinemethanol 5183-78-8
5305-59-9 5470-49-5 6919-61-5 7298-84-2 7449-74-3 7720-45-8
7750-45-0 7752-82-1 13363-59-2 13616-79-0 14597-58-1
14984-58-8 16588-15-1 16874-08-1 16874-17-2 18239-19-5
18239-23-1 19532-69-5 19532-70-8 19602-82-5 20557-42-0

20859-02-3 27738-89-2 27757-85-3, 2-Thiophenemethanamine 32677-01-3
34297-27-3 39235-27-3 42807-86-3 50479-22-6 51537-21-4
53448-09-2 53668-35-2 69320-89-4 75844-69-8 81223-41-8
92906-21-3 147027-69-8 147027-78-9 147081-44-5 161879-13-6
162089-06-7 171744-39-1 177785-39-6 177785-41-0 177785-42-1
177785-43-2 177785-44-3 177785-45-4 177785-46-5 177785-47-6
177785-48-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of arylthio and dithiobisarylamide compds. as antibacterial and antiviral agents)

IT 13363-60-5P 18239-20-8P 18239-22-0P 18394-74-6P 147027-70-1P
147027-74-5P 177785-38-5P 177785-49-8P 177785-50-1P 177785-51-2P
177785-52-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(prepn. of arylthio and dithiobisarylamide compds. as antibacterial and antiviral agents)

=> s l9 and l14
L21 0 L9 AND L14

=> s l10 and l11
L22 2 L10 AND L11

=> d l22 1-2

L22 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 2001:454452 CAPLUS
DN 135:313108
TI In vivo pharmacokinetics and metabolism of anti-human immunodeficiency virus agent d4T-5'-[P-bromophenyl methoxyalaninyl phosphate] (sampidine) in mice
AU Chen, Chun-Lin; Venkatachalam, T. K.; Zhu, Zhao-Hai; Uckun, Fatih M.
CS Drug Discovery Program, Department of Pharmaceutical Sciences, Parker Hughes Institute, St. Paul, MN, 55113, USA
SO Drug Metabolism and Disposition (2001), 29(7), 1035-1041
CODEN: DMDSAI; ISSN: 0090-9556
PB American Society for Pharmacology and Experimental Therapeutics
DT Journal
LA English
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2003 ACS
AN 1998:293427 CAPLUS
DN 129:8597
TI Embedding and encapsulation of controlled release particles
IN Van Lengerich, Bernhard H.
PA Van Lengerich, Bernhard H., USA
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9818610	A1	19980507	WO 1997-US18984	19971027
W: AU, CA, JP, NO, PL, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9749915	A1	19980522	AU 1997-49915	19971027
AU 744156	B2	20020214		

```
     EP 935523         A1   19990818       EP 1997-912825   19971027
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
     JP 2002511777     T2   20020416       JP 1998-520558   19971027
     NO 9902036        A    19990428       NO 1999-2036     19990428
PRAI US 1996-29038P    P    19961028
     US 1997-52717P    P    19970716
     WO 1997-US18984   W    19971027
RE.CNT  5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d l22 2 all

L22  ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2003 ACS
AN   1998:293427  CAPLUS
DN   129:8597
TI   Embedding and encapsulation of controlled release particles
IN   Van Lengerich, Bernhard H.
PA   Van Lengerich, Bernhard H., USA
SO   PCT Int. Appl., 63 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
IC   ICM  B29C047-04
     ICS  B01J013-04; A01N025-26
CC   63-6 (Pharmaceuticals)
     Section cross-reference(s): 5
FAN.CNT 1
     PATENT NO.        KIND  DATE           APPLICATION NO.  DATE
     ---------------   ----  --------       ---------------  --------
PI   WO 9818610         A1   19980507       WO 1997-US18984  19971027
         W:  AU, CA, JP, NO, PL, US
         RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     AU 9749915         A1   19980522       AU 1997-49915    19971027
     AU 744156          B2   20020214
     EP 935523          A1   19990818       EP 1997-912825   19971027
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
     JP 2002511777      T2   20020416       JP 1998-520558   19971027
     NO 9902036         A    19990428       NO 1999-2036     19990428
PRAI US 1996-29038P     P    19961028
     US 1997-52717P     P    19970716
     WO 1997-US18984    W    19971027
AB   Controlled release, discrete, solid particles which contain an
     encapsulated and/or embedded component such as a heat sensitive or readily
     oxidizable pharmaceutically, biol., or nutritionally active component are
     continuously produced without substantial destruction of the matrix
     material or encapsulant.  A release-rate controlling component is
     incorporated into the matrix to control the rate of release of the
     encapsulant from the particles.  The addnl. component may be a hydrophobic
     component or a high water binding capacity component for extending the
     release time.  The plasticizable matrix material, such as starch, is
     admixed with at least one plasticizer, such as water, and at least one
     release-rate controlling component under low shear mixing conditions to
     plasticize the plasticizable material without substantially destroying the
     at least one plasticizable material and to obtain a substantially
     homogeneous plasticized mass.  The plasticizer content is substantially
     reduced and the temp. of the plasticized mass is substantially reduced
     prior to admixing the plasticized mass with the encapsulant to avoid
     substantial destruction of the encapsulant and to obtain a formable,
     extrudable mixt.  The mixt. is extruded though a die without substantial
```

or essentially no expansion and cut into discrete, relatively dense particles. Release properties may also be controlled by precoating the encapsulant and/or coating the extruded particles with a film-forming component. An example of encapsulation of acetylcysteine is given using starch, polyethylene, glycerol monostearate, and vegetable oil.

ST encapsulation controlled release particle

IT Drug delivery systems
(controlled-release; embedding and encapsulation of controlled release particles)

IT Antitumor agents
Antiviral agents
Encapsulation
(embedding and encapsulation of controlled release particles)

IT Estrogens
Polyoxyalkylenes, biological studies
Tuberculin
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(embedding and encapsulation of controlled release particles)

IT Antibiotics
Antioxidants
Detergents
Emulsifying agents
Extrusion, nonbiological
Fats and Glyceridic oils, biological studies
Fatty acids, biological studies
Flavor
Fungicides
Glass transition
Heat treatment
Herbicides
Hydrocolloids
Insecticides
Lipids, biological studies
Paraffin waxes, biological studies
Peptides, biological studies
Perfumes
Pesticides
Plasticizers
Polyolefins
Polyurethanes, biological studies
Proteins, general, biological studies
Rodenticides
Steroids, biological studies
Surfactants
Waxes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(embedding and encapsulation of controlled release particles)

IT Antibodies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; embedding and encapsulation of controlled release particles)

IT Drug delivery systems
(particles; embedding and encapsulation of controlled release particles)

IT 50-02-2, Dexamethasone 50-04-4, Cortisone acetate 50-06-6, Phenobarbital, biological studies 50-12-4, Mephenytoin 50-14-6, Ergocalciferol 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-27-1, Estriol 50-28-2, Estradiol, biological studies 50-33-9, Phenylbutazone, biological studies 50-36-2, Cocaine 50-41-9, Clomiphene citrate 50-44-2, Mercaptopurine 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-52-2,

Thioridazine 50-53-3, Chlorpromazine, biological studies 50-54-4, Quinidine sulfate 50-55-5, Reserpine 50-58-8, Phendimetrazine tartrate 50-63-5, Chloroquine phosphate 50-78-2, Acetylsalicylic acid 50-81-7, Ascorbic acid, biological studies 50-96-4, Isoetharine hydrochloride 51-05-8, Procaine hydrochloride 51-15-0, Pralidoxime chloride 51-21-8, Fluorouracil 51-30-9, Isoproterenol hydrochloride 51-34-3, Scopolamine 51-43-4, Epinephrine 51-48-9, Levothyroxine, biological studies 51-52-5, Propylthiouracil 51-55-8, Atropine, biological studies 51-57-0, Methamphetamine hydrochloride 51-64-9, Dextroamphetamine 51-83-2, Carbachol 51-84-3, Acetylcholine, biological studies 51-98-9, Norethindrone acetate 52-01-7, Spironolactone 52-24-4, Thiotepa 52-49-3, Trihexyphenidyl hydrochloride 52-53-9, Verapamil 52-67-5, Penicillamine 52-68-6, Trichlorfon 52-86-8, Haloperidol 52-89-1, Cysteine hydrochloride 53-03-2, Prednisone 53-16-7, Estrone, biological studies 53-19-0, Mitotane 53-39-4, Oxandrolone 53-60-1, Promazine hydrochloride 53-86-1, Indomethacin 54-21-7, Sodium salicylate 54-31-9, Furosemide 54-36-4, Metyrapone 54-64-8, Thimerosal 54-85-3, Isoniazid 55-03-8, Levothyroxine sodium 55-06-1, Liothyronine sodium 55-63-0, Nitroglycerin 55-98-1, Busulfan 56-29-1, Hexobarbital 56-47-3, Desoxycorticosterone acetate 56-53-1, Diethylstilbestrol 56-54-2, Quinidine 56-75-7, Chloramphenicol 56-84-8, L-Aspartic acid, biological studies 56-87-1, L-Lysine, biological studies 57-13-6, Urea, biological studies 57-22-7, Vincristine 57-33-0, Pentobarbital sodium 57-41-0, Phenytoin 57-42-1, Meperidine 57-43-2, Amobarbital **57-47-6**, Physostigmine 57-53-4, Meprobamate 57-63-6, Ethinyl estradiol 57-66-9, Probenecid 57-68-1, Sulfamethazine 57-83-0, Progesterone, biological studies 57-92-1, Streptomycin, biological studies 57-96-5, Sulfinpyrazone 58-00-4, Apomorphine 58-08-2, Caffeine, biological studies 58-14-0, Pyrimethamine 58-18-4, Methyltestosterone 58-22-0 58-25-3, Chlordiazepoxide 58-27-5, Menadione 58-32-2, Dipyridamole 58-33-3, Promethazine hydrochloride 58-38-8, Prochlorperazine 58-39-9, Perphenazine 58-40-2, Promazine 58-54-8, Ethacrynic acid 58-55-9, Theophylline, biological studies 58-56-0, Pyridoxine hydrochloride 58-85-5, Biotin 58-89-9, Lindane 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 59-33-6, Pyrilamine maleate 59-43-8, Thiamin, biological studies 59-52-9, Dimercaprol 59-63-2, Isocarboxazid 59-66-5, Acetazolamide 59-67-6, Niacin, biological studies 59-92-7, Levodopa, biological studies 60-13-9, Amphetamine sulfate 60-18-4, Tyrosine, biological studies 60-54-8, Tetracycline 60-56-0, Methimazole 60-80-0, Antipyrine 60-87-7, Promethazine 60-99-1, Levomepromazine 61-00-7, Acepromazine 61-25-6, Papaverine hydrochloride 61-68-7, Mefenamic acid 61-76-7, Phenylephrine hydrochloride 61-90-5, Leucine, biological studies 62-31-7, Dopamine hydrochloride 62-44-2, Phenacetin 62-67-9, Nalorphine 62-90-8, Nandrolone phenpropionate 63-68-3, Methionine, biological studies 63-91-2, Phenylalanine, biological studies 63-92-3, Phenoxybenzamine hydrochloride 63-98-9, Phenacemide 64-31-3, Morphine sulfate 64-72-2, Chlortetracycline hydrochloride 64-77-7, Tolbutamide 64-86-8, Colchicine 65-45-2, Salicylamide 66-76-2, Dicoumarol 67-03-8, Thiamine hydrochloride 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-73-2, Fluocinolone acetonide 67-96-9, Dihydrotachysterol 67-97-0, Cholecalciferol 68-19-9, Cyanocobalamin 68-22-4, Norethindrone 68-35-9, Sulfadiazine 68-41-7, Cycloserine 68-89-3, Metamizole 69-23-8, Fluphenazine 69-44-3, Amodiaquine hydrochloride 69-53-4, Ampicillin 69-72-7, Salicylic acid, biological studies 71-00-1, Histidine, biological studies 71-58-9, Medroxyprogesterone acetate 71-63-6, Digitoxin 71-68-1, Hydromorphone hydrochloride 71-81-8 72-14-0, Sulfathiazole 72-17-3, Sodium lactate 72-18-4, Valine, biological studies 72-19-5, L-Threonine, biological studies 72-33-3, Mestranol 72-63-9, Methandrostenolone 73-22-3, L-Tryptophan,

biological studies 73-48-3, Bendroflumethiazide 76-38-0, Methoxyflurane 76-42-6, Oxycodone 76-43-7, Fluoxymesterone 76-57-3, Codeine 77-09-8 77-19-0, Dicyclomine 77-21-4, Glutethimide 77-26-9, Butalbital 77-27-0, Thiamylal 77-36-1, Chlorthalidone 77-41-8, Methsuximide 78-44-4, Carisoprodol 79-57-2, Oxytetracycline 80-08-0, Dapsone 80-13-7, Halazone 80-53-5, Terpin 81-07-2, Saccharin 81-13-0, Dexpanthenol 81-23-2, Dehydrocholic acid 81-81-2, Warfarin 83-43-2, Methylprednisolone 83-73-8, Iodoquinol 83-88-5, Riboflavin, biological studies 84-02-6, Prochlorperazine maleate 84-17-3, Dienestrol 84-22-0, Tetrahydrozoline 84-80-0, Phytonadione 85-79-0, Dibucaine 86-35-1, Ethotoin 87-00-3, Homatropine 87-08-1, Phenoxymethylpenicillin 87-33-2, ISDN 89-57-6, 5-Aminosalicylic acid 90-33-5, Hymecromone 90-34-6, Primaquine 91-33-8, Benzthiazide 91-81-6, Tripelennamine 92-13-7, Pilocarpine 93-14-1, Guaifenesin 94-09-7, Benzocaine 94-20-2, Chlorpropamide 95-25-0, Chlorzoxazone 97-53-0, Eugenol 97-77-8, Disulfiram 98-96-4, Pyrazinamide 99-66-1, Valproic acid 100-97-0, biological studies 101-26-8, Pyridostigmine bromide 101-31-5, Hyoscyamine 102-76-1, Triacetin 103-16-2, Monobenzone 103-86-6, Hydroxyamphetamine 103-90-2, Acetaminophen 104-28-9, Cinoxate 104-31-4, Benzonatate 107-43-7, Betaine 108-46-3, 1,3-Benzenediol, biological studies 110-85-0, Piperazine, biological studies 110-94-1, Pentanedioic acid 113-18-8, Ethchlorvynol 113-52-0, Imipramine hydrochloride 113-59-7, Chlorprothixene 113-92-8, Chlorpheniramine maleate 114-07-8, Erythromycin 114-80-7, Neostigmine bromide 115-38-8, Mephobarbital 115-77-5, biological studies 120-97-8, Dichlorphenamide 121-25-5, Amprolium 121-54-0
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(embedding and encapsulation of controlled release particles)

IT 121-75-5, Malathion 123-31-9, 1,4-Benzenediol, biological studies 124-90-3, Oxycodone hydrochloride 124-94-7, Triamcinolone 125-28-0, Dihydrocodeine 125-33-7, Primidone 125-71-3, Dextromethorphan 125-72-4, Levorphanol tartrate 126-07-8, Griseofulvin 127-07-1, Hydroxyurea 127-33-3, Demeclocycline 127-48-0, Trimethadione 127-69-5, Sulfisoxazole 127-79-7, Sulfamerazine 128-44-9, Saccharin sodium 128-46-1, Dihydrostreptomycin 128-49-4, Docusate calcium 128-62-1, Noscapine 129-20-4, Oxyphenbutazone 129-49-7, Methysergide maleate 129-51-1, Ergonovine maleate 130-26-7, Clioquinol 130-61-0, Thioridazine hydrochloride 131-13-5 131-57-7, Oxybenzone 132-17-2 132-92-3, Methicillin sodium 133-58-4, Nitromersol 133-67-5, Trichlormethiazide 134-03-2, Sodium ascorbate 134-80-5, Diethylpropion hydrochloride 135-07-9 135-09-1, Hydroflumethiazide 136-40-3, Phenazopyridine hydrochloride 136-47-0 136-77-6, Hexylresorcinol 137-58-6, Lidocaine 141-01-5, Ferrous fumarate 143-71-5, Hydrocodone bitartrate 143-81-7, Butabarbital sodium 144-14-9, Anileridine 144-48-9, Iodoacetamide 144-55-8, Sodium bicarbonate, biological studies 144-80-9, Sulfacetamide 144-82-1, Sulfamethizole 144-83-2, Sulfapyridine 146-22-5, Nitrazepam 146-54-3, Triflupromazine 147-24-0, Diphenhydramine hydrochloride 147-52-4, Nafcillin 147-85-3, Proline, biological studies 148-79-8 148-82-3, Melphalan 151-67-7, Halothane 152-62-5, Dydrogesterone 152-97-6, Fluocortolone 154-41-6, Phenylpropanolamine hydrochloride 154-42-7, Thioguanine 156-51-4, Phenelzine sulfate 297-76-7, Ethynodiol diacetate 298-46-4, Carbamazepine 298-50-0, Propantheline 298-57-7, Cinnarizine 298-59-9, Methylphenidate hydrochloride 298-81-7, Methoxsalen 299-27-4, Potassium gluconate 299-29-6, Ferrous gluconate 299-42-3, Ephedrin 302-22-7, Chlormadinone acetate 302-79-4, Tretinoin 303-25-3, Cyclizine hydrochloride 304-20-1, Hydralazine hydrochloride 304-59-6, Potassium sodium tartrate, biological studies 305-03-3, Chlorambucil 309-43-3, Secobarbital sodium 315-30-0, Allopurinol 317-34-0, Aminophylline 318-98-9 329-65-7, 1,2-Benzenediol, 4-[1-hydroxy-2-(methylamino)ethyl]- 343-55-5, Dicloxacillin sodium

345-78-8, Pseudoephedrine hydrochloride 346-18-9, Polythiazide 356-12-7, Fluocinonide 357-07-3, Oxymorphone hydrochloride 359-83-1, Pentazocine 360-70-3, Nandrolone decanoate 364-62-5, Metoclopramide 364-98-7, Diazoxide 366-70-1, Procarbazine hydrochloride 378-44-9, Betamethasone 379-79-3, Ergotamine tartrate 382-67-2, Desoximetasone 389-08-2, Nalidixic acid 390-64-7, Prenylamine 396-01-0, Triamterene 426-13-1, Fluorometholone 434-07-1, Oxymetholone 435-97-2, Phenprocoumon 437-74-1, Xantinol nicotinate 439-14-5, Diazepam 440-17-5, Trifluoperazine hydrochloride 443-48-1, Metronidazole 446-86-6, Azathioprine 465-65-6, Naloxone 466-99-9, Hydromorphone 471-34-1, Calcium carbonate, biological studies 474-86-2, Equilin 479-18-5, Dyphylline 484-23-1, Dihydralazine 486-12-4, Triprolidine 511-12-6, Dihydroergotamine 514-36-3, Fludrocortisone acetate 514-65-8, Biperiden 518-47-8, Fluorescein sodium 519-37-9, Etofylline 520-85-4, Medroxyprogesterone 523-87-5, Dimenhydrinate 525-66-6, Propranolol 527-07-1, Sodium gluconate 532-03-6, Methocarbamol 533-45-9, Clomethiazole 536-21-0, Norfenefrine 536-33-4, Ethionamide 541-15-1, Levocarnitine 546-88-3, Acetohydroxamic acid 546-93-0, Magnesium carbonate 548-62-9, Gentian violet 548-73-2, Droperidol 549-18-8, Amitriptyline hydrochloride 550-83-4, Propoxycaine hydrochloride 551-27-9, Propicillin 552-94-3, Salsalate 554-13-2, Lithium carbonate 554-57-4, Methazolamide 554-92-7, Trimethobenzamide hydrochloride 555-30-6, Methyldopa 557-34-6, Zinc acetate 562-10-7 564-25-0, Doxycycline 577-11-7, Docusate sodium 579-56-6, Isoxsuprine hydrochloride 587-61-1, Propyliodone 590-63-6, Bethanechol chloride 595-33-5, Megestrol acetate 596-51-0, Glycopyrrolate 599-79-1, Sulfasalazine 599-88-2, Sulfaperin 603-50-9, Bisacodyl 604-75-1, Oxazepam 614-39-1, Procainamide hydrochloride 616-91-1, Acetylcysteine 620-61-1, Hyoscyamine sulfate 630-56-8, Hydroxyprogesterone caproate 637-07-0, Clofibrate 637-58-1, Pramoxine hydrochloride 638-23-3 642-78-4, Cloxacillin sodium 651-06-9, Sulfamethoxydiazine 652-67-5 672-87-7, Metyrosine 709-55-7, Etilefrine 721-50-6, Prilocaine 723-46-6, Sulfamethoxazole 738-70-5, Trimethoprim 745-65-3, Alprostadil 747-36-4, Hydroxychloroquine sulfate 768-94-5, Amantadine 777-11-7, Haloprogin 797-63-7, Levonorgestrel 826-39-1, Mecamylamine hydrochloride 846-49-1, Lorazepam 846-50-4, Temazepam 859-18-7, Lincomycin hydrochloride 865-21-4, Vinblastine 894-71-3, Nortriptyline hydrochloride 968-81-0, Acetohexamide 968-93-4, Testolacton 969-33-5, Cyproheptadine hydrochloride 985-16-0, Nafcillin sodium 1069-66-5, Sodium valproate 1070-11-7, Ethambutol hydrochloride 1077-28-7, Thioctic acid 1094-08-2, Ethopropazine hydrochloride 1095-90-5, Methadone hydrochloride 1098-97-1, Pyritinol 1104-22-9, Meclizine hydrochloride 1134-47-0, Baclofen 1143-38-0, Anthralin 1151-11-7, Ipodate calcium 1156-19-0, Tolazamide 1173-88-2, Oxacillin sodium 1197-21-3, Phentermine hydrochloride 1221-56-3, Ipodate sodium 1225-55-4, Protriptyline hydrochloride 1229-29-4, Doxepin hydrochloride 1247-42-3, Meprednisone 1263-89-4, Paromomycin sulfate 1309-48-4, Magnesium oxide, biological studies 1319-82-0, Aminocaproic acid 1321-23-9, Chloroxylenol 1343-97-1, Selenium sulfate 1393-48-2, Thiostrepton 1400-61-9, Nystatin 1403-17-4, Candicidin 1403-66-3, Gentamicin 1404-00-8, Mitomycin 1404-04-2, Neomycin 1404-88-2, Tyrothricin 1404-93-9, Vancomycin hydrochloride 1405-10-3, Neomycin sulfate 1405-20-5, Polymyxin b sulfate 1405-87-4, Bacitracin 1405-97-6, Gramicidin 1406-05-9, Penicillin 1420-55-9, Thiethylperazine 1476-53-5, Novobiocin sodium 1492-18-8, Leucovorin calcium 1508-65-2, Oxybutynin chloride 1508-75-4, Tropicamide 1508-76-5, Procyclidine hydrochloride 1524-88-5, Flurandrenolide 1597-82-6, Paramethasone acetate 1617-90-9, Vincamine 1622-61-3, Clonazepam 1622-62-4, Flunitrazepam 1639-60-7, Propoxyphene hydrochloride 1649-18-9, Azaperone 1668-19-5, Doxepin 1707-14-8, Phenmetrazine hydrochloride 1808-12-4, Bromodiphenhydramine hydrochloride 1812-30-2, Bromazepam 1897-96-7, Lonetil 1972-08-3,

Dronabinol 1977-10-2, Loxapine 1982-37-2, Methdilazine 2013-58-3, Meclocycline
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(embedding and encapsulation of controlled release particles)

IT 2022-85-7, Flucytosine 2030-63-9, Clofazimine 2062-78-4, Pimozide 2098-66-0, Cyproterone 2179-37-5, Bencyclane 2192-20-3, Hydroxyzine hydrochloride 2315-02-8, Oxymetazoline hydrochloride 2398-96-1, Tolnaftate 2438-32-6, Dexchlorpheniramine maleate 2447-57-6, Sulfadoxine 2589-47-1, Prajmalium bitartrate, biological studies 2609-46-3, Amiloride 2709-56-0, Flupentixol 2898-12-6, Medazepam 2955-38-6, Prazepam 2998-57-4, Estramustine 3313-26-6, Thiothixene 3385-03-3, Flunisolide 3485-14-1, Cyclacillin 3485-62-9, Clidinium bromide 3486-35-9, Zinc carbonate 3505-38-2, Carbinoxamine maleate 3546-41-6, Pyrvinium pamoate 3572-43-8, Bromhexine 3575-80-2, Melperone 3625-06-7, Mebeverine 3632-91-5, Magnesium gluconate 3778-73-2, Ifosfamide 3810-80-8, Diphenoxylate hydrochloride 3902-71-4, Trioxsalen 3930-20-9, Sotalol 3963-95-9, Methacycline hydrochloride 3978-86-7, Azatadine maleate 4205-90-7, Clonidine 4205-91-8, Clonidine hydrochloride 4330-99-8, Trimeprazine tartrate 4468-02-4, Zinc gluconate 4498-32-2, Dibenzepine 4499-40-5, Oxtriphylline, biological studies 4697-36-3, Carbenicillin 4759-48-2, Isotretinoin 5051-62-7, Guanabenz 5104-49-4, Flurbiprofen 5321-32-4, Hetacillin potassium 5355-48-6 5370-01-4, Mexiletine hydrochloride 5534-09-8, Beclomethasone dipropionate 5536-17-4, Vidarabine 5636-83-9, Dimetindene 5638-76-6, Betahistine 5874-97-5, Metaproterenol sulfate 5875-06-9, Proparacaine hydrochloride 5987-82-6, Benoxinate hydrochloride 6202-23-9, Cyclobenzaprine hydrochloride 6284-40-8, Meglumine 6385-02-0, Meclofenamate sodium 6452-73-9, Oxprenolol hydrochloride 6493-05-6, Pentoxifylline 6533-00-2, Norgestrel 6805-41-0, Aescin 6890-40-0, Histamine phosphate 7054-25-3, Quinidine gluconate 7195-27-9, Mefruside 7235-40-7, .beta.-Carotene 7246-21-1, Tyropanoate sodium 7280-37-7, Estropipate 7297-25-8, Erythrityl tetranitrate 7414-83-7, Etidronate disodium 7439-95-4D, Magnesium, salts, biological studies 7439-96-5, Manganese, biological studies 7439-96-5D, Manganese, salts, biological studies 7440-39-3, Barium, biological studies 7440-69-9, Bismuth, biological studies 7440-70-2, Calcium, biological studies 7447-40-7, Potassium chloride (KCl), biological studies 7491-74-9, Piracetam 7553-56-2, Iodine, biological studies 7632-00-0, Sodium nitrite 7646-85-7, Zinc chloride, biological studies 7681-11-0, Potassium iodide (KI), biological studies 7681-49-4, Sodium fluoride, biological studies 7681-82-5, Sodium iodide, biological studies 7681-93-8, Natamycin 7693-13-2, Calcium citrate 7720-78-7, Ferrous sulfate 7778-49-6, Potassium citrate 7783-00-8, Selenious acid 7786-30-3, Magnesium chloride, biological studies 8017-57-0, Trisulfapyrimidine 8024-48-4, Casanthranol 8049-47-6, Pancreatin 8050-81-5, Simethicone 8065-29-0, Liotrix 8067-24-1, Ergoloid mesylates 9001-01-8, Kallidinogenase 9001-73-4, Papain 9002-07-7, Trypsin 9002-60-2, Corticotropin, biological studies 9002-61-3, Chorionic gonadotropin 9002-86-2, Pvc 9002-89-5, Polyvinyl alcohol 9003-20-7, Polyvinyl acetate 9003-39-8, Pvp 9003-97-8, Polycarbophil 9004-07-3, Chymotrypsin 9004-10-8, Insulin, biological studies 9004-32-4, Carboxymethylcellulose 9004-34-6D, Cellulose, esters and ethers, biological studies 9004-53-9, Dextrin 9004-70-0, Pyroxylin 9005-25-8, Starch, biological studies 9005-80-5, Inulin 9008-05-3, Histoplasmin 10025-73-7, Chromic chloride 10040-45-6, Sodium picosulfate 10238-21-8, Glibenclamide 10246-75-0, Hydroxyzine pamoate 10262-69-8, Maprotiline 10347-81-6, Maprotiline hydrochloride 10379-14-3, Tetrazepam 10418-03-8, Stanozolol 10540-29-1, Tamoxifen 11000-17-2, Vasopressin 12125-02-9, Ammonium chloride, biological studies 12619-70-4, Cyclodextrin 12622-73-0, Coccidioidin 12633-72-6, Amphotericin 12650-69-0, Mupirocin

13009-99-9, Mafenide acetate 13042-18-7, Fendiline 13292-46-1, Rifampin 13311-84-7, Flutamide 13392-18-2, Fenoterol 13422-51-0, Hydroxocobalamin 13463-67-7, Titanium dioxide, biological studies 13523-86-9, Pindolol 13614-98-7, Minocycline hydrochloride 13682-92-3, Dihydroxyaluminum aminoacetate 14009-24-6, Drotaverine 14028-44-5, Amoxapine 14779-78-3, Padimate 14976-57-9, Clemastine fumarate 15078-28-1, Nitroprusside 15307-86-5, Diclofenac 15622-65-8, Molindone hydrochloride 15663-27-1, Cisplatin 15676-16-1, Sulpiride 15686-51-8, Clemastine 15686-71-2, Cephalexin 15687-27-1 15687-41-9, Oxyfedrine 16482-55-6, Dihydroxyaluminum sodium carbonate 16595-80-5, Levamisole hydrochloride 16662-47-8, Gallopamil 17140-78-2, Propoxyphene napsylate 17230-88-5, Danazol 17560-51-9, Metolazone 17617-23-1, Flurazepam 18378-89-7, Plicamycin 18559-94-9, Salbutamol 19216-56-9, Prazosin 19237-84-4, Prazosin hydrochloride 19356-17-3, Calcifediol 20830-75-5, Digoxin 21462-39-5, Clindamycin hydrochloride 21738-42-1, Oxamniquine 21829-25-4, Nifedipine 22059-60-5, Disopyramide phosphate 22071-15-4, Ketoprofen 22195-34-2, Guanadrelsulfate 22204-24-6, Pyrantel pamoate 22204-53-1, Naproxen 22232-71-9, Mazindol 22260-51-1, Bromocriptine mesylate 22316-47-8, Clobazam 22494-42-4 22916-47-8 23031-25-6, Terbutaline 23031-32-5, Terbutaline sulfate 23214-92-8, Doxorubicin 23288-49-5, Probucol 23593-75-1, Clotrimazole 23869-24-1, O-(.beta.-Hydroxyethyl)-rutoside 24219-97-4, Mianserin 24390-14-5, Doxycycline hyclate 24729-96-2, Clindamycin phosphate 25046-79-1, Glisoxepide 25086-89-9, Vinyl acetate-N-vinylpyrrolidinone copolymer 25155-18-4, Methylbenzethonium chloride 25167-80-0, Chlorophenol 25301-02-4, Tyloxapol 25322-68-3 25332-39-2, Trazodone hydrochloride 25389-94-0, Kanamycin sulfate 25614-03-3, Bromocriptine 25655-41-8, Povidone iodine 25717-80-0, Molsidomine 25812-30-0, Gemfibrozil 25953-19-9, Cefazolin 26027-38-3, Nonoxynol 9 26171-23-3, Tolmetin 26652-09-5, Ritodrine 26675-46-7, Isoflurane 26787-78-0, Amoxicillin 26807-65-8, Indapamide 26839-75-8, Timolol 26944-48-9, Glibornuride 27203-92-5, Tramadol 27823-62-7, Chlortetracycline bisulfate 28088-64-4, Aminosalicylic acid 28395-03-1, Bumetanide 28657-80-9, Cinoxacin 28797-61-7, Pirenzepine 28860-95-9, Carbidopa 28911-01-5, Triazolam 28981-97-7, Alprazolam 29122-68-7, Atenolol 29679-58-1, Fenoprofen 30578-37-1, Amezinium metilsulfate 30685-43-9, Metildigoxin 31329-57-4, Naftidrofuryl 31431-39-7, Mebendazole 31637-97-5, Etofibrate 31828-71-4, Mexiletine 32672-69-8, Mesoridazine besylate 32780-64-6, Labetalol hydrochloride 32887-01-7, Amdinocillin 33005-95-7, Tiaprofenic acid 33286-22-5, Diltiazem hydrochloride 33402-03-8, Metaraminol bitartrate 33419-42-0 33996-33-7, Oxaceprol 34031-32-8, Auranofin 34183-22-7, Propafenone hydrochloride 34552-83-5, Loperamide hydrochloride 34580-13-7, Ketotifen
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(embedding and encapsulation of controlled release particles)

IT 34787-01-4, Ticarcillin 36322-90-4, Piroxicam 36688-78-5 36791-04-5 37270-89-6, Heparin calcium 37517-28-5, Amikacin 37517-30-9, Acebutolol 38194-50-2, Sulindac 38260-01-4, Trientine hydrochloride 38304-91-5, Minoxidil 38363-40-5, Penbutolol 38396-39-3, Bupivacaine 38821-53-3, Cephradine 39562-70-4, Nitrendipine 40828-46-4, Suprofen 41859-67-0, Bezafibrate 42200-33-9, Nadolol 42399-41-7, Diltiazem 42540-40-9, Cefamandole nafate 49562-28-9, Fenofibrate 49745-95-1, Dobutamine hydrochloride 50370-12-2, Cefadroxil 50679-08-8, Terfenadine 50925-79-6, Colestipol 50972-17-3, Bacampicillin 51022-69-6, Amcinonide 51481-61-9, Cimetidine 51781-06-7, Carteolol 52468-60-7, Flunarizine 53164-05-9, Acemetacin 53179-11-6, Loperamide 53230-10-7, Mefloquine 53608-75-6, Pancrelipase 53994-73-3, Cefaclor 54063-53-5, Propafenone 54143-55-4, Flecainide 54182-58-0, Sucralfate 54965-21-8, Albendazole 54965-24-1, Tamoxifen citrate 55268-74-1, Praziquantel 55837-25-7, Buflomedil 55837-27-9, Piretanide

56392-17-7, Metoprolol tartrate 57109-90-7, Dipotassium chlorazepate
57432-61-8, Methylergonovine maleate 57435-86-6, Premazepam
58551-69-2, Carboprost tromethamine 59277-89-3, Acyclovir 59865-13-3,
Cyclosporine 60166-93-0, Iopamidol 60200-06-8, Clorsulon 60833-22-9,
Pyridoxal 5'-phosphate glutamate 61177-45-5, Clavulanate potassium
61489-71-2, Menotropin 61563-18-6, Soquinolol 62571-86-2, Captopril
62893-19-0, Cefoperazone 63527-52-6, Cefotaxime 63659-18-7, Betaxolol
64024-15-3, Pentazocine hydrochloride 64544-07-6, Cefuroxime axetil
65277-42-1, Ketoconazole 65666-07-1, Silymarin 65899-73-2, Tioconazole
66108-95-0, Iohexol 66357-35-5, Ranitidine 66711-21-5, Apraclonidine
66734-13-2, Alclometasone dipropionate 68844-77-9, Astemizole
70458-96-7, Norfloxacin 72558-82-8, Ceftazidime 74978-16-8, Magaldrate
75330-75-5, Lovastatin 76095-16-4, Enalapril maleate 76420-72-9,
Enalaprilat 76470-66-1, Loracarbef 76547-98-3, Lisinopril
76824-35-6, Famotidine 76963-41-2, Nizatidine 78110-38-0, Aztreonam
78266-06-5, Mebrofenin 79350-37-1, Cefixime 81103-11-9, Clarithromycin
83200-10-6, Anipamil 83905-01-5, Azithromycin 85721-33-1,
Ciprofloxacin 92665-29-7, Cefprozil 102188-40-9, Acromycin
150977-36-9, Bromelain
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic
use); BIOL (Biological study); PROC (Process); USES (Uses)
(embedding and encapsulation of controlled release particles)
IT 9001-92-7, Protease
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, **HIV**; embedding and encapsulation of controlled
release particles)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Carr; US 5183690 A 1993 CAPLUS
(2) Chan; US 5075058 A 1991
(3) Katzen; US 3786123 A 1974 CAPLUS
(4) Katzen; US 3962416 A 1976 CAPLUS
(5) McMahon; US 5466460 A 1995 CAPLUS

=> s l10 and l14
L23 1 L10 AND L14

=> d l23 1 all

L23 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
AN 1998:618371 CAPLUS
DN 129:255004
TI Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations, and histidine compositions therefor
IN Thomas, Peter G.
PA Cytos Pharmaceuticals LLC, USA
SO U.S., 10 pp.
CODEN: USXXAM
DT Patent
LA English
IC ICM A01N043-50
ICS C07D233-60
NCL 514399000
CC 1-12 (Pharmacology)
Section cross-reference(s): 62, 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5811446	A	19980922	US 1997-839805	19970418
	WO 9847366	A1	19981029	WO 1998-US7319	19980417

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,

DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9873583 A1 19981113 AU 1998-73583 19980417
PRAI US 1997-839805 19970418
WO 1998-US7319 19980417

AB Methods are provided for protecting the eye from degenerative eye conditions by administering prophylactic histidine compns. Also provided are for treating ocular inflammation resulting from various causative agents, by administering therapeutic histidine compns. Further provided are histidine compns. for carrying out the methods.

ST histidine pharmaceutical eye degenerative disease inflammation

IT Ulcer
(Mooren's, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(Terrein's marginal degeneration, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Granulomatous disease
(Wegener's granulomatosis, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Burn
(acid and alkali, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Glycosides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Fibronectins
Vitronectin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(and analogs; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Tear (ocular fluid)
(artificial; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Dysentery
(bacillary, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(blepharitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Acids, biological studies
Bases, biological studies
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(chem. burn, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(conjunctivitis, allergic and others, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and

inflammations)
IT Eye
(cornea, haze; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Eye
(cornea, infiltration and thinning, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Eye, disease
Eye, disease
Eye, disease
(cornea, ulcer, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Autoimmune disease
Food allergy
Leukemia
Myasthenia gravis
Psoriasis
Rheumatoid arthritis
Syphilis
(corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Excimer lasers
(corneal procedure; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Antiulcer agents
(corneal ulcer; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Amyloidosis
(corneal; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Cosmetics
(creams; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Drugs
(cytoplegics and miotics; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Eye, disease
(degeneration; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Eye, disease
(dellen, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Eye, disease
(diabetic retinopathy; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Drug delivery systems
(emulsions; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Human herpesvirus
(epithelial keratitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Edema
Infection
Lasers
(eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Cosmetics
(eye liners; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Cosmetics
(eye; histidine compns. and methods for ocular degenerative diseases

and inflammations)
IT Sexually transmitted diseases
(gonorrhea, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Human herpesvirus 3
(**herpes** zoster from, keratitis and iridocyclitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Anti-inflammatory agents
Antibacterial agents
Antibiotics
Antiglaucoma agents
Antioxidants
Antiviral agents
Eye, disease
Glaucoma (disease)
Wound healing promoters
(histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Corticosteroids, biological studies
Glycoproteins, general, biological studies
Sulfonamides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Carboxylic acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxy; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Chlamydia trachomatis
(infection with, trachoma, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Adenoviridae
Arbovirus
Bacteria (Eubacteria)
Borrelia burgdorferi
Corynebacterium diphtheriae
Cytomegalovirus
DNA viruses
Fungi
Haemophilus
Human enterovirus 70
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human poliovirus
Influenza virus
Measles virus
Moraxella
Mumps virus
Neisseria gonorrhoeae
Neisseria meningitidis
Papillomavirus
Parasite
Pseudomonas

RNA viruses
Rabies virus
Rhinovirus
Serratia marcescens
Staphylococcus
Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus
(infection, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(injections, i.v.; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(injections, intraocular; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(iridocyclitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(keratitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(keratopathy, calcific band, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Ablation
(laser-assisted photoablative surgical procedure; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(liqs.; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(macula, degeneration, age-related; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Cosmetics
(mascaras; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Angiogenesis
(neovascularization, retinal, laser-treated, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Anti-inflammatory agents
(nonsteroidal; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(ointments, creams; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(ointments, eye; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Surgery
(ophthalmic procedures, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(ophthalmic, ocular inserts; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(ophthalmic; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(oral; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Carboxylic acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oxo; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Artery, disease
(polyarteritis nodosa; corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Radicals, biological studies
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(radical-mediated eye disease; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Eye, disease
Eye, disease
Eye, disease
(retina, injury, photic or ischemia-induced; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Eye, disease
(retina, ischemia; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Eye, disease
(retina, neovascularization, laser-treated, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Ischemia
(retinal injury from; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Anti-ischemic agents
(retinal ischemia; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Eye, disease
Eye, disease
(retinitis, cytomegalovirus, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Eye, disease
(scleritis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Drug delivery systems
(solns., i.v.; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Drug delivery systems
(solns., ophthalmic; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Cataract
(surgery, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Drug delivery systems
(suspensions; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Lupus erythematosus
(systemic, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Drug delivery systems
(tablets; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Drug delivery systems
(topical; histidine compns. and methods for ocular degenerative

diseases and inflammations)
IT Injury
(trauma, eye, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Intestine, disease
(ulcerative colitis, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Eye, disease
(uveitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Infection
(viral, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Eye
(vitreous humor, age- or disease-based posterior vitreous detachment; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT 71-00-1, L-Histidine, biological studies 351-50-8, D-Histidine 4998-57-6, Histidine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations, and histidine compns. therefor)
IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-81-7, Ascorbic acid, biological studies 51-55-8, Atropine, biological studies 51-83-2, Carbachol 53-03-2, Prednisone 53-86-1, Indomethacin 54-42-2, Idoxuridine 56-75-7, Chloramphenicol **57-47-6**, Physostigmine 59-02-9, .alpha.-Tocopherol 59-42-7, Phenylephrine 59-66-5, Acetazolamide 69-53-4, Ampicillin 70-00-8, Trifluridine 70-18-8, Glutathione, biological studies 92-13-7, Pilocarpine 114-07-8, Erythromycin 127-40-2, Lutein 144-68-3, Zeaxanthin 378-44-9, Betamethasone 426-13-1, Fluorometholone 472-61-7, Astaxanthin 514-78-3, Canthaxanthin 616-91-1, Acetyl cysteine 738-70-5, Trimethoprim 768-94-5, Amantadine 1403-66-3, Gentamycin 1404-90-6, Vancomycin 1405-87-4, Bacitracin 1406-05-9, Penicillin 1406-11-7, Polymyxin 1695-77-8, Spectinomycin 4697-36-3, Carbenicillin 5104-49-4, Flurbiprofen 5536-17-4, Vidarabine 7235-40-7, .beta.-Carotene 7761-88-8, Silver nitrate, biological studies 7783-00-8, Selenious acid 9054-89-1, Superoxide dismutase 11111-12-9, Cephalosporin 13292-46-1, Rifampin 13392-28-4, Rimantadine 13410-01-0, Sodium selenate 15307-86-5, Diclofenac 18323-44-9, Clindamycin 22071-15-4, Ketoprofen 25953-19-9, Cefazolin 26787-78-0, Amoxicillin 26921-17-5, Timolol maleate 30516-87-1, Azidothymidine 32986-56-4, Tobramycin 34787-01-4, Ticarcillin 51481-65-3, Mezlocillin 56272-24-3, Histidine hydrochloride 59277-89-3, Acyclovir 68767-14-6, Loxoprofen 70458-96-7, Norfloxacin 74103-06-3, Ketorolac 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin 82768-44-3 85721-33-1, Ciprofloxacin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histidine compns. and methods for ocular degenerative diseases and inflammations)
IT 9001-03-0, Carbonic anhydrase 9001-12-1, Collagenase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; histidine compns. and methods for ocular degenerative diseases and inflammations)
RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Babizhayev; 1989 CAPLUS

(2) Babizhayev; Biochimica et Biophysica Acta 1989, V1004, P363 CAPLUS
(3) Santen; 1983 CAPLUS

=> d his

(FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003)

FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003
E STRVUDINE
L1 0 S STRVUDINE
L2 0 S D4T
E D4T
L3 5 S STAVUDINE
L4 42 S PARAOXON
L5 0 S PHYOSTIGMINE
L6 0 S PHYOSTIGMINE
L7 54 S PHYSOSTIGMINE

FILE 'CAPLUS' ENTERED AT 16:36:06 ON 27 MAY 2003
L8 1300 S L3
L9 2913 S L4
L10 4718 S L7
E HIV
L11 50075 S E3 OR E7
E HERPES
L12 21343 S E3
L13 17244 S HHV OR HSV OR HCMV OR CMV
L14 29657 S L12 OR L13
L15 7547 S PHOSPHATE ESTER
L16 2 S L8 AND L15
E ESTER
L17 518186 S E3
L18 2414368 S S
L19 54 S L17 AND L8
L20 3 S L9 AND L11
L21 0 S L9 AND L14
L22 2 S L10 AND L11
L23 1 S L10 AND L14

=> d 123

L23 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS
AN 1998:618371 CAPLUS
DN 129:255004
TI Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations, and histidine compositions therefor
IN Thomas, Peter G.
PA Cytos Pharmaceuticals LLC, USA
SO U.S., 10 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5811446	A	19980922	US 1997-839805	19970418
	WO 9847366	A1	19981029	WO 1998-US7319	19980417

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,

```
            UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
             FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
             CM, GA, GN, ML, MR, NE, SN, TD, TG
     AU 9873583        A1   19981113       AU 1998-73583    19980417
PRAI US 1997-839805         19970418
     WO 1998-US7319         19980417
RE.CNT  3     THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> e antiviral
E1            5     ANTIVIR/BI
E2            1     ANTIVIRA/BI
E3        38409 --> ANTIVIRAL/BI
E4            1     ANTIVIRALE/BI
E5            2     ANTIVIRALEN/BI
E6          100     ANTIVIRALLY/BI
E7          789     ANTIVIRALS/BI
E8            1     ANTIVIREMIC/BI
E9          111     ANTIVIRIAL/BI
E10           2     ANTIVIRIALS/BI
E11           1     ANTIVIRIL/BI
E12          15     ANTIVIRIN/BI

=> s e3-e9
          38409 ANTIVIRAL/BI
              1 ANTIVIRALE/BI
              2 ANTIVIRALEN/BI
            100 ANTIVIRALLY/BI
            789 ANTIVIRALS/BI
              1 ANTIVIREMIC/BI
            111 ANTIVIRIAL/BI
L24       38629 (ANTIVIRAL/BI OR ANTIVIRALE/BI OR ANTIVIRALEN/BI OR ANTIVIRALLY/
                BI OR ANTIVIRALS/BI OR ANTIVIREMIC/BI OR ANTIVIRIAL/BI)

=> s l24 and l9
L25           2 L24 AND L9

=> d l25 1-2

L25  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2003 ACS
AN   2002:706699  CAPLUS
DN   138:66452
TI   Influenza Infection Promotes Macrophage Traffic Into Arteries of Mice That
     Is Prevented by D-4F, an Apolipoprotein A-I Mimetic Peptide
AU   Van Lenten, Brian J.; Wagner, Alan C.; Anantharamaiah, G. M.; Garber,
     David W.; Fishbein, Michael C.; Adhikary, Lopa; Nayak, Debi P.; Hama,
     Susan; Navab, Mohamad; Fogelman, Alan M.
CS   Deo, Ned, University of California, Los Angeles, CA, USA
SO   Circulation (2002), 106(9), 1127-1132
     CODEN: CIRCAZ; ISSN: 0009-7322
PB   Lippincott Williams & Wilkins
DT   Journal
LA   English
RE.CNT  29    THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25  ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2003 ACS
AN   1996:365474  CAPLUS
DN   125:58113
TI   Preparation of arylthio and dithiobisarylamide compounds as antibacterial
```

and **antiviral** agents
IN Domagala, John Michael; Elslager, Edward Faith; Gogliotti, Rocco Dean
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 142 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9604242	A1	19960215	WO 1995-US8802	19950711
	W: AM, AU, BG, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, UA, UZ, VN				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5463122	A	19951031	US 1994-286816	19940805
	US 5734081	A	19980331	US 1995-446917	19950601
	AU 9530087	A1	19960304	AU 1995-30087	19950711
	AU 710806	B2	19990930		
	EP 775110	A1	19970528	EP 1995-926276	19950711
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
	JP 10504292	T2	19980428	JP 1995-506523	19950711
	RU 2156236	C2	20000920	RU 1997-103207	19950711
	PL 181425	B1	20010731	PL 1995-318540	19950711
	FI 9700417	A	19970131	FI 1997-417	19970131
	NO 9700495	A	19970402	NO 1997-495	19970204
	BG 63301	B1	20010928	BG 1997-101189	19970204
PRAI	US 1994-286816	A	19940805		
	US 1995-446917	A	19950601		
	WO 1995-US8802	W	19950711		

OS MARPAT 125:58113

=> s l10 and l24
L26 8 L10 AND L24

=> d l26 1-8

L26 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 2003:319255 CAPLUS
DN 138:343854
TI Buccal sprays or capsules containing drugs for treating disorders of the central nervous system
IN Dugger, Harry A.
PA USA
SO U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 537,118.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003077227	A1	20030424	US 2002-230060	20020829
	WO 9916417	A1	19990408	WO 1997-US17899	19971001
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,				

GN, ML, MR, NE, SN, TD, TG
EP 1029536 A1 20000823 EP 2000-109347 19971001
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
EP 1036561 A1 20000920 EP 2000-109357 19971001
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO
PRAI WO 1997-US17899 A2 19971001
US 2000-537118 A2 20000329
EP 1997-911621 A3 19971001

L26 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 2003:154686 CAPLUS
DN 138:198554
TI Drug interaction assay chip
IN Diamond, Scott L.; Sevrain, Christophe J.-P.
PA Morewood Molecular, Inc., USA; University of Pennsylvania-Center for Technology
SO PCT Int. Appl., 13 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003016870	A1	20030227	WO 2002-US26395	20020819

W: AE, AG, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, CZ, DE, DE, DK, DK, DM, DZ, EC, EE, EE, ES, FI, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003059846 A1 20030327 US 2002-224529. 20020819
PRAI US 2001-313366P P 20010817
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 2002:748713 CAPLUS
DN 137:268439
TI Nonaqueous fluorinated drug delivery suspensions
IN Meadows, David Louis
PA Allergan, Inc., USA
SO U.S., 12 pp., Cont.-in-part of U. S. Ser. No. 853,827, abandoned.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 6458376	B1	20021001	US 1993-179508	19931230
US 5173298	A	19921222	US 1990-588697	19900927
US 5518731	A	19960521	US 1994-260482	19940614
US 5620699	A	19970415	US 1995-556277	19951113
PRAI US 1990-588697	A2	19900927		
US 1992-853827	B2	19920319		
US 1994-260482	A3	19940614		

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 2001:136991 CAPLUS
DN 134:198075
TI Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
IN Patel, Mahesh V.; Chen, Feng-Jing
PA Lipocine, Inc., USA
SO PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012155	A1	20010222	WO 2000-US18807	20000710
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6309663	B1	20011030	US 1999-375636	19990817
	EP 1210063	A1	20020605	EP 2000-947184	20000710
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003506476	T2	20030218	JP 2001-516502	20000710
	US 2001024658	A1	20010927	US 2000-751968	20001229
	US 6458383	B2	20021001		
PRAI	US 1999-375636	A	19990817		
	WO 2000-US18807	W	20000710		

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 2000:259972 CAPLUS
DN 132:293042
TI Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
IN Van Lengerich, Bernhard H.
PA General Mills, Inc., USA
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000021504	A1	20000420	WO 1999-US20905	19991006
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,				

CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	CA 2345815	AA	20000420	CA 1999-2345815	19991006
	AU 9963872	A1	20000501	AU 1999-63872	19991006
	EP 1119345	A1	20010801	EP 1999-951433	19991006
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002527375	T2	20020827	JP 2000-575480	19991006
	NO 2000004784	A	20000925	NO 2000-4784	20000925
PRAI	US 1998-103700P	P	19981009		
	US 1998-109696P	P	19981124		
	US 1999-233443	A	19990120		
	US 1998-79060P	P	19980323		
	WO 1999-US4267	W	19990323		
	WO 1999-US20905	W	19991006		

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 1998:618371 CAPLUS
DN 129:255004
TI Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations, and histidine compositions therefor
IN Thomas, Peter G.
PA Cytos Pharmaceuticals LLC, USA
SO U.S., 10 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5811446	A	19980922	US 1997-839805	19970418
	WO 9847366	A1	19981029	WO 1998-US7319	19980417
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9873583	A1	19981113	AU 1998-73583	19980417
PRAI	US 1997-839805		19970418		
	WO 1998-US7319		19980417		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 1998:293427 CAPLUS
DN 129:8597
TI Embedding and encapsulation of controlled release particles
IN Van Lengerich, Bernhard H.
PA Van Lengerich, Bernhard H., USA
SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9818610	A1	19980507	WO 1997-US18984	19971027
	W: AU, CA, JP, NO, PL, US				

```
        RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
     AU 9749915         A1   19980522       AU 1997-49915    19971027
     AU 744156          B2   20020214
     EP 935523          A1   19990818       EP 1997-912825   19971027
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, FI
     JP 2002511777      T2   20020416       JP 1998-520558   19971027
     NO 9902036         A    19990428       NO 1999-2036     19990428
PRAI US 1996-29038P     P    19961028
     US 1997-52717P     P    19970716
     WO 1997-US18984    W    19971027
RE.CNT  5     THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26  ANSWER 8 OF 8  CAPLUS  COPYRIGHT 2003 ACS
AN   1997:440981  CAPLUS
DN   127:144786
TI   Rabies virus infection of IMR-32 human neuroblastoma cells and effect of
     neurochemical and other agents
AU   Lentz, Thomas L.; Fu, Yiguang; Lewis, Peter
CS   Dep. Cell Biol., Yale Univ. School Med., New Haven, CT, 06520-8002, USA
SO   Antiviral Research (1997), 35(1), 29-39
     CODEN: ARSRDR; ISSN: 0166-3542
PB   Elsevier
DT   Journal
LA   English


=> d l26 1 3 4 5 6 7 8 all

L26  ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2003 ACS
AN   2003:319255  CAPLUS
DN   138:343854
TI   Buccal sprays or capsules containing drugs for treating disorders of the
     central nervous system
IN   Dugger, Harry A.
PA   USA
SO   U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 537,118.
     CODEN: USXXCO
DT   Patent
LA   English
IC   ICM  A61K009-00
     ICS  A61L009-04
NCL  424043000
CC   63-6 (Pharmaceuticals)
FAN.CNT 8
     PATENT NO.         KIND  DATE           APPLICATION NO.  DATE
     ---------------    ----  --------       ---------------  --------
PI   US 2003077227      A1    20030424       US 2002-230060   20020829
     WO 9916417         A1    19990408       WO 1997-US17899  19971001
         W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
             DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ,
             LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL,
             PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US,
             UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR,
             GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA,
             GN, ML, MR, NE, SN, TD, TG
     EP 1029536         A1    20000823       EP 2000-109347   19971001
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     EP 1036561         A1    20000920       EP 2000-109357   19971001
```

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRAI WO 1997-US17899 A2 19971001
US 2000-537118 A2 20000329
EP 1997-911621 A3 19971001

AB Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biol. active compds. for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compns. of the invention comprise formulation A: aq. polar solvent, active compd., and optional flavoring agent; formulation B: aq. polar solvent, active compd., optionally flavoring agent, and propellant; formulation C: non-polar solvent, active compd., and optional flavoring agent; and formulation D: non-polar solvent, active compd., optional flavoring agent, and propellant. Thus, a lingual spray contained sumatriptan succinate 10-15, EtOH 10-20, propylene glycol 10-15, PEG 35-40, water 10-15, and flavors 2-3%.

ST buccal spray central nervous system disease; capsule central nervous system disease

IT Glycerides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C2-26; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Alcohols, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(C2-8; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Alcohols, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(C7-18; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Hydrocarbons, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C7-18; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Prostaglandins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(E; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Antihistamines
(H2; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Drug delivery systems
(aerosols; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Benzodiazepine receptors
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonists; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Mental disorder
(attention deficit disorder; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Adrenoceptor antagonists
Alzheimer's disease
Antibiotics
Anticonvulsants
Antidepressants
Antiparkinsonian agents
Antipsychotics
Antiviral agents
Anxiolytics
Cholinergic antagonists
Flavoring materials

Fungicides
Hypnotics and Sedatives
Molecular weight distribution
Neurotransmitter agonists
Neurotransmitter antagonists
Polar solvents
Propellants (sprays and foams)
Sweetening agents
Tranquilizers
(buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Esters, biological studies
Hormones, animal, biological studies
Neurotransmitters
Peptides, biological studies
Polyoxyalkylenes, biological studies
Prostaglandins
Sulfonylureas
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Drug delivery systems
(buccal; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Drug delivery systems
(capsules; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Nervous system
(central, disease; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Essential oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(citrus; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(esters, C2-24; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Echinacea
Valerian (Valeriana)
(exts.; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Flavoring materials
(fruit flavors; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Mouth
(mucosa; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Sleep
(narcolepsy; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Cytoprotective agents
(neuroprotectants; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Essential oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(peppermint; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Alcohols, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(polyhydric, C2-8; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Essential oils
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(spearmint; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Drug delivery systems
(sprays; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Brain, disease
(stroke; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Diet
(supplements; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.beta., 1A; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.beta., 1B; buccal sprays or capsule contg. drugs for treating disorders of central nervous system)

IT 50-06-6, Phenobarbital, biological studies 50-28-2, Estradiol, biological studies 50-47-5, Desipramine 50-48-6 50-49-7, Imipramine 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 50-67-9, Serotonin, biological studies 51-30-9, Isoproterenol Hydrochloride 51-41-2, Norepinephrine 51-43-4, Epinephrine 51-45-6, Histamine, biological studies 51-61-6, Dopamine, biological studies 51-64-9, Dextroamphetamine 51-71-8, Phenelzine 51-84-3, Acetylcholine, biological studies 52-86-8, Haloperidol 56-12-2, GABA, biological studies 56-40-6, Glycine, biological studies 56-65-5, ATP, biological studies 56-84-8, Aspartic acid, biological studies 56-86-0, L-Glutamic acid, biological studies 57-41-0, Phenytoin **57-47-6**, Physostigmine 57-83-0, Progesterone, biological studies 57-94-3, Tubocurarine 58-55-9, Theophylline, biological studies 58-61-7, Adenosine, biological studies 59-63-2, Isocarboxazid 59-66-5, Acetazolamide 59-92-7, Levodopa, biological studies 59-99-4, Neostigmine 60-87-7, Promethazine 64-17-5, Ethanol, biological studies 67-52-7D, 2,4,6(1H,3H,5H)-Pyrimidinetrione, derivs. 68-88-2, Hydroxyzine 72-69-5 74-98-6, Propane, biological studies 75-28-5, Isobutane 77-19-0, Dicycloverine 77-67-8, Ethosuximide 78-78-4, Isopentane 95-25-0, Chlorzoxazone 96-88-8, Mepivacaine 106-97-8, N-Butane, biological studies 109-66-0, N-Pentane, biological studies 113-45-1, Methylphenidate 114-07-8, Erythromycin 125-33-7, Primidone 127-48-0, Trimethadione 137-58-6, Lidocaine 147-24-0, Diphenhydramine hydrochloride 155-09-9, Tranylcypromine 298-46-4, Carbamazepine 300-62-9, Amphetamine 303-49-1, Clomipramine 303-53-7, Cyclobenzaprine 312-48-1, Edrophonium 321-64-2, Tacrine 322-35-0, Benserazide 357-70-0, Galantamine 363-24-6, Dinoprostone 438-60-8, Protriptyline 439-14-5, Diazepam 463-82-1, Neopentane 511-12-6, Dihydroergotamine 523-87-5, Dimenhydrinate 569-65-3, Meclizine 721-50-6, Prilocaine 768-94-5, Amantadine 1622-61-3, Clonazepam 1668-19-5, Doxepin 1744-22-5, Riluzole 2078-54-8, Propofol 2152-34-3, Pemoline 3239-45-0, Dexfenfluramine hydrochloride 3313-26-6, Thiothixene 5588-33-0, Mesoridazine 5786-21-0, Clozapine 10102-43-9, Nitric oxide, biological studies 10238-21-8, Glyburide 10262-69-8, Maprotiline 10457-90-6, Bromperidol 14028-44-5, Amoxapine 14611-51-9, Selegiline 15500-66-0, Pancuronium 15676-16-1, Sulpiride 17780-72-2, Clorgyline 19794-93-5, Trazodone 19982-08-2, Memantine 22232-71-9, Mazindol 23031-25-6, Terbutaline 23031-32-5, Terbutaline sulfate 23887-31-2, Clorazepate 25322-68-3, Polyethylene glycol 25614-03-3, Bromocriptine 27262-47-1, Levobupivacaine 27848-84-6, Nicergoline 28721-07-5, Oxcarbazepine 28860-95-9, Carbidopa 30516-87-1, Zidovudine

34911-55-2, Bupropion 36505-84-7, Buspirone 43200-80-2, Zopiclone
47931-85-1, Salmon Calcitonin 50700-72-6, Vecuronium 51022-70-9,
Albuterol sulfate 54739-18-3, Fluvoxamine 54910-89-3, Fluoxetine
59729-33-8, Citalopram 60142-96-3, Gabapentin 60205-81-4, Ipratropium
61869-08-7, Paroxetine 63798-73-2, Cyclosporine 64228-79-1, Atracurium
64840-90-0, Eperisone 66085-59-4, Nimodipine 66104-22-1, Pergolide
68291-97-4, Zonisamide 68399-58-6, Pipecuronium 68506-86-5, Vigabatrin
68693-11-8, Modafinil 70059-30-2, Cimetidine hydrochloride 71320-77-9,
Moclobemide 71675-85-9, Amisulpride 72432-10-1, Aniracetam
76584-70-8 76824-35-6, Famotidine 77191-36-7, Nefiracetam
77337-76-9, Acamprosate 78755-81-4, Flumazenil 79517-01-4, Sandostatin
79617-96-2, Sertraline 81409-90-7, Cabergoline 82626-48-0, Zolpidem
83015-26-3, Atomoxetine 83366-66-9, Nefazodone 84057-84-1, Lamotrigine
84057-95-4, Ropivacaine 85650-52-8, Mirtazapine 90293-01-9, Bifemelane
91374-21-9, Ropinirole 93107-08-5, Ciprofloxacin hydrochloride
93413-69-5, Venlafaxine 96946-41-7, Cisatracurium 97240-79-4,
Topiramate 99571-64-9, Oxitropium 99614-01-4, Ondansetron
hydrochloride 102767-28-2, Levetiracetam 103628-46-2, Sumatriptan
103628-48-4, Sumatriptan succinate 103878-84-8, Lazabemide
104632-26-0, Pramipexole 106266-06-2, Risperidone 106650-56-0,
Sibutramine 106861-44-3, Mivacurium chloride 111974-69-7, Quetiapine
113775-47-6, Dexmedetomidine 115103-54-3, Tiagabine 116539-59-4,
Duloxetine 120014-06-4, Donepezil 120444-71-5, Deramciclane
121679-13-8, Naratriptan 123441-03-2, Rivastigmine 128196-01-0,
Escitalopram 128298-28-2, Remacemide 129722-12-9, Aripiprazole
130929-57-6, Entacapone 132539-06-1, Olanzapine 133107-64-9, Insulin
lispro 133454-47-4, Iloperidone 133737-32-3, Pagoclone 133814-18-3,
Doxacurium 134308-13-7, Tolcapone 135354-02-8, Xaliproden
138729-47-2, Esopiclone 139264-17-8, Zolmitriptan 142852-51-5, TAK147
143322-58-1, Eletriptan 143558-00-3, Rocuronium 144034-80-0,
Rizatriptan 146939-27-7, Ziprasidone 148553-50-8, Pregabalin
151319-34-5, Zaleplon 154323-57-6, Almotriptan 156137-99-4,
Rapacuronium bromide 214415-55-1 325715-02-4, Indiplon 515132-12-4
516482-86-3, Sermorelin acetate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(buccal sprays or capsule contg. drugs for treating disorders of
central nervous system)

IT 9000-81-1, Acetylcholinesterase
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibitors; buccal sprays or capsule contg. drugs for treating
disorders of central nervous system)

L26 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 2002:748713 CAPLUS
DN 137:268439
TI Nonaqueous fluorinated drug delivery suspensions
IN Meadows, David Louis
PA Allergan, Inc., USA
SO U.S., 12 pp., Cont.-in-part of U. S. Ser. No. 853,827, abandoned.
CODEN: USXXAM
DT Patent
LA English
IC ICM A61K009-10
ICS A61K047-24; A61P027-02
NCL 424427000
CC 63-6 (Pharmaceuticals)
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6458376	B1	20021001	US 1993-179508	19931230
	US 5173298	A	19921222	US 1990-588697	19900927
	US 5518731	A	19960521	US 1994-260482	19940614

US 5620699 A 19970415 US 1995-556277 19951113
PRAI US 1990-588697 A2 19900927
US 1992-853827 B2 19920319
US 1994-260482 A3 19940614

AB Nonaq. pharmaceutical compns. for use in aq. physiol. systems are disclosed comprising drug delivery suspension of nonaq. perfluorocarbon or fluorinated silicone liq. carriers. The suspended drug may be water labile or water stable and therapeutic or diagnostic compds. which will remain stable and pharmaceutically effective for extended periods. The pharmaceutical compns. have improved bioavailability, are capable of low dose vol. delivery, and do not degrade the incorporated therapeutic or diagnostic compds. making them well suited for multi-dose packaging and administration. For example, 5 g of poly(Me vinyl ether/maleic anhydride) was completely dissolved in a soln. contg. 100 mg dipivefrin in 95 mL of acetonitrile. This polymer stock was then added to a roto-evaporator operating at 40.degree., and the acetonitrile was completely removed. The drug/polymer stock mixt. was roto-evapd. to dryness and the residue was first ground in a mortar and pestle and placed in a roller bottle contg. glass beads with a nonaq. diluent [preferably perfluoro(decahydronaphthalene), PFD]. The suspension was ball milled for approx. 3 days to reach the desired 2-200 .mu.m size range.

ST fluorinated silicone perfluorocarbon liq carrier ophthalmic suspension

IT Diagnosis
(agents; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Growth factors, animal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(epithelial cell growth factors; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Polysiloxanes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fluorine-contg., liq. carriers; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Perfluorocarbons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(liq. carriers; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Nervous system agents
(miotics; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Anesthetics
Anti-inflammatory agents
Antibacterial agents
Antiglaucoma agents
Antihistamines
Antiviral agents
Cholinergic antagonists
Drug delivery systems
Fungicides
Immunosuppressants
Parasiticides
Surfactants
(nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Growth factors, animal
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Peptides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oligopeptides; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Perfluoro compounds
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(perfluoroalkyl ethers; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Ethers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(perfluoroalkyl; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Fluoropolymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polysiloxane-, liq. carriers; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Drug delivery systems
(suspensions, ophthalmic; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT Eye
(targeting to; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT 9001-03-0, Carbonic anhydrase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT 9011-16-9, Poly(methyl vinyl ether/maleic anhydride)
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(matrix; nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT 92-13-7, Pilocarpine
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonaq. fluorinated drug delivery suspensions for targeting to eye)

IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 51-34-3, Scopolamine 51-43-4, Epinephrine 51-83-2, Carbachol 52-21-1, Prednisolone acetate 54-42-2, Idoxuridine 56-94-0, Demecarium bromide 57-62-5, Chlortetracycline **57-64-7**, Eserine salicylate 59-42-7, Phenylephrine 60-54-8, Tetracycline 61-33-6, biological studies 87-00-3, Homatropine 114-07-8, Erythromycin 302-79-4, Tretinoin 306-91-2, Perfluoroperhydrophenanthrene 306-92-3, Perfluoro(decahydro-1-methylnaphthalene) 306-94-5, Perfluoro(decahydronaphthalene) 311-89-7, Perfluorotributylamine 312-93-6, Dexamethasone-21-phosphate 335-27-3, Perfluoro(1,3-dimethylcyclohexane) 355-02-2, Perfluoromethylcyclohexane 374-60-7 378-44-9, Betamethasone 423-02-9, Perfluoroisopropylcyclohexane 423-03-0 426-13-1, Fluorometholone 512-15-2, Cyclopentolate 513-10-0, Echothiophate iodide 518-47-8, Sodium fluorescein 807-38-5, Fluocinolone 827-61-2, Aceclidine 1043-21-6, Pirenoxine 1404-04-2, Neomycin 1405-87-4, Bacitracin 1405-97-6, Gramicidin 1406-11-7, Polymyxin 2391-15-3 2668-66-8, Medrysone 15687-27-1, Ibuprofen 25953-19-9, Cefazolin 27912-14-7, Levo-bunolol hydrochloride 32986-56-4, Tobramycin 52365-63-6, Dipivefrin 54471-59-9, Perfluoro(decahydrodimethylnaphthalene) 60096-00-6 64221-86-9, Imipenem 67711-54-0 70458-96-7, Norfloxacin 72558-82-8, Ceftazidime 73196-05-1 75108-51-9 85721-33-1, Ciprofloxacin 118183-26-9
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonaq. fluorinated drug delivery suspensions for targeting to eye)

RE.CNT 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Anon; WO 810002 1981
(2) Anon; JP 5721312 1982
(3) Anon; EP 0089815 1983 CAPLUS
(4) Anon; EP 0091313 1983 CAPLUS
(5) Anon; WO 8400686 1984 CAPLUS
(6) Anon; EP 0288659 1988 CAPLUS
(7) Anon; EP 0322249 1988 CAPLUS
(8) Anon; WO 9118613 1991 CAPLUS

(9) Borgarello; US 4942179 A 1990 CAPLUS
(10) Chabert; US 3989843 A 1976 CAPLUS
(11) Clark; US 3911138 A 1975 CAPLUS
(12) Clark; US 4490351 A 1984 CAPLUS
(13) Haidt; US 4452818 A 1984 CAPLUS
(14) Higuchi; US 3968245 A 1976 CAPLUS
(15) Kaswan; US 4649047 A 1987 CAPLUS
(16) Kaufman; US 4865846 A 1989 CAPLUS
(17) Kaufman; US 4882150 A 1989 CAPLUS
(18) Lucas; US 4035506 A 1977 CAPLUS
(19) Moore; US 4105798 A 1978 CAPLUS
(20) Sheil; US 4115544 A 1978 CAPLUS
(21) Wheeler; US 4426374 A 1984 CAPLUS
(22) White; US 4366169 A 1982 CAPLUS
(23) Wretlind; US 4168308 A 1979 CAPLUS
(24) Yokoyama; US 3962439 A 1976 CAPLUS
(25) Yuhas; US 4889525 A 1989

L26 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 2001:136991 CAPLUS
DN 134:198075
TI Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
IN Patel, Mahesh V.; Chen, Feng-Jing
PA Lipocine, Inc., USA
SO PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DT Patent
LA English
IC ICM A61K009-00
ICS A61K009-14; A61K009-16; A61K009-20; A61K009-22; A61K009-28; A61K009-48
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012155	A1	20010222	WO 2000-US18807	20000710
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6309663	B1	20011030	US 1999-375636	19990817
	EP 1210063	A1	20020605	EP 2000-947184	20000710
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003506476	T2	20030218	JP 2001-516502	20000710
	US 2001024658	A1	20010927	US 2000-751968	20001229
	US 6458383	B2	20021001		
PRAI	US 1999-375636	A	19990817		
	WO 2000-US18807	W	20000710		

AB The present invention relates to triglyceride-free pharmaceutical compns., pharmaceutical systems, and methods for enhanced absorption of hydrophilic therapeutic agents. The compns. and systems include an absorption enhancing carrier, where the carrier is formed from a combination of at least two surfactants, at least one of which is hydrophilic. A hydrophilic therapeutic agent can be incorporated into the compn., or can

be co-administered with the compn. as part of a pharmaceutical system. The invention also provides methods of treatment with hydrophilic therapeutic agents using these compns. and systems. For example, when a compn. contg. Cremophor RH40 0.30, Arlacel 186 0.20, Na taurocholate 0.18, and propylene glycol 0.32 g, resp., was used, the relative absorption of PEG 4000 as a model macromol. drug was enhanced by 991%.

ST hydrophilic drug surfactant absorption enhancement

IT Lysophospholipids
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C18; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Diglycerides
Glycerides, biological studies
Monoglycerides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C8-10 monoglycerides and diglycerides; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Glycerides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C8-10, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Glycerides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(C8-18 and C18-unsatd. mono- and di-, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Antibodies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Fc fragment, fusion protein with TNF receptor; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Lung
Mucous membrane
(administration by; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(aerosols; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Phenols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(alkyl, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(almond, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Antiarthritics
(anti-gout agents; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(beads; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Natural products, pharmaceutical
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(belladonna; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(buccal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(capsules; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Gelatins, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(capsules; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Gonadotropins
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(chrionic; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Analgesics
Anthelmintics
Anti-inflammatory agents
Antianginal agents
Antiarrhythmics
Antiasthmatics
Antibacterial agents
Anticoagulants
Anticonvulsants
Antidepressants
Antidiabetic agents
Antifoaming agents
Antihistamines
Antihypertensives
Antimalarials
Antimigraine agents
Antiparkinsonian agents
Antipsychotics
Antitumor agents
Antitussives
Antiviral agents
Anxiolytics
Blood serum
Buffers
Chelating agents
Compression
Diuretics
Drug delivery systems
Encapsulation
Extrusion, nonbiological
Flavoring materials
Fungicides
Hypnotics and Sedatives
Immunosuppressants
Inotropics
Molding
Muscarinic antagonists
Muscle relaxants
Nervous system stimulants
Nutrients
Peptidomimetics
Plasticizers
Preservatives
Protozoacides
Solubilizers
Spheronization
Surfactants
Vaccines
(compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Acrylic polymers, biological studies
Alcohols, biological studies
Amides, biological studies
Amino acids, biological studies
Carbohydrates, biological studies
Corticosteroids, biological studies

Cytokines
Diglycerides
Elastins
Enkephalins
Esters, biological studies
Fatty acids, biological studies
Genetic element
Glycerides, biological studies
Glycosides
Interleukin 2
Interleukin 3
Lecithins
Lysophosphatidic acids
Lysophosphatidylcholines
Lysophosphatidylethanolamines
Lysophosphatidylserines
Macromolecular compounds
Nucleic acids
Nucleosides, biological studies
Nucleotides, biological studies
Oligonucleotides
Peptides, biological studies
Phosphatidic acids
Phosphatidylcholines, biological studies
Phosphatidylethanolamines, biological studies
Phosphatidylglycerols
Phosphatidylserines
Phospholipids, biological studies
Platelet-derived growth factors
Polyoxyalkylenes, biological studies
Proteins, general, biological studies
Sex hormones
Shellac
Sterols
Sulfonic acids, biological studies
Tannins
Toxoids
Tumor necrosis factors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(controlled-release; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Glycerides, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(corn, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Bath preparations
(douches; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(drops; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(elixirs; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(emulsions; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Castor oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ethoxylated, Emalex C40; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Corn oil
Ethers, biological studies
Palm kernel oil
Sterols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Tumor necrosis factor receptors
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fusion protein with antibody Fc fragment; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drugs
(gastrointestinal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(gels; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(granules; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Vaccines
(hepatitis A; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Vaccines
(hepatitis B; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Castor oil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydrogenated, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Vaccines
(influenza; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Enzymes, biological studies
Thyroid hormones
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Skin preparations (pharmaceutical)
(keratolytics; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Lipids, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(lipid regulating agents; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(lotions; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Lysophosphatides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lysophosphatidylglycerols; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Vaccines
(measles; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Polymers, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mucoadhesive; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Vaccines

(mumps; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(nasal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Surfactants
(nonionic; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(ointments, creams; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(ointments; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(oral; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(particles; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(pastes; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(pellets; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Antioxidants
(pharmaceutical; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Infection
(plague, vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Alcohols, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(polyhydric; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Phosphatidylethanolamines, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(reaction products, with PEG and PVP; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(rectal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Fatty acids, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(salts, carnitine; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(solns.; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Sterols
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soya, ethoxylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems
(sprays; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Monoglycerides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(succinylated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Drug delivery systems

(suppositories, vaginal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
IT Drug delivery systems
(suppositories; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
IT Drug delivery systems
(suspensions; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
IT Drug delivery systems
(sustained-release; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
IT Drug delivery systems
(syrups; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
IT Glycosides
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(thioglycosides, alkyl esters; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
IT Haemophilus influenzae
(type b, conjugated vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
IT Human poliovirus
(vaccine; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
IT Japanese encephalitis virus
Mycobacterium BCG
Neisseria meningitidis
Rabies
Rotavirus
Streptococcus pneumoniae
Typhoid fever
(vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
IT Drug delivery systems
(vaginal; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
IT Human herpesvirus 3
(varicella from, vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
IT Infection
(variola, vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vegetable, ethoxylated, hydrogenated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vegetable, hydrogenated; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
IT Fats and Glyceridic oils, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vegetable; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
IT Fever and Hyperthermia
(yellow, vaccines; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.alpha.; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)
IT Adrenoceptor antagonists

(.beta.-; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT Interferons
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.beta.; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT 9011-29-4, Nikkol GS 6
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Nikkol GS 460; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT 9005-25-8, Starch, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(capsules; compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT 59277-89-3, Acyclovir
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT 63585-09-1, Foscarnet sodium
RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT 50-21-5, Lactic acid, biological studies 50-21-5D, Lactic acid, acyl esters 50-56-6, Oxytocin, biological studies 50-70-4, Sorbitol, biological studies 50-81-7, Ascorbic acid, biological studies 51-15-0, Pralidoxime chloride 51-43-4, Epinephrine 51-55-8, Atropine, biological studies 51-60-5, Neostigmine methyl sulfate 52-24-4, Thiotepa 53-79-2, Puromycin 56-81-5, Glycerol, biological studies 57-10-3, Palmitic acid, biological studies 57-11-4, Stearic acid, biological studies 57-13-6, Urea, biological studies 57-22-7, Vincristine 57-55-6, Propylene glycol, biological studies 57-55-6D, Propylene glycol, ethers **57-64-7**, Physostigmine salicylate 57-88-5, Cholesterol, biological studies 57-94-3, Tubocurarine chloride 59-05-2, Methotrexate 60-00-4, EDTA, biological studies 60-00-4D, EDTA, conjugates with antipain and chitosan 60-31-1, Acetylcholine chloride 60-33-3, Linoleic acid, biological studies 62-31-7, Dopamine hydrochloride 63-91-2, Phenylalanine, biological studies 64-18-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 65-28-1, Phentolamine mesylate 65-85-0, Benzoic acid, biological studies 66-71-7, 1,10-Phenanthroline 67-42-5, EGTA 68-11-1, Thioglycolic acid, biological studies 68-19-9, Vitamin B12 69-65-8, Mannitol 69-72-7, Salicylic acid, biological studies 69-79-4D, Maltose, alkyl esters 69-93-2, Uric acid, biological studies 70-51-9, Deferoxamine 71-27-2, Suxamethonium chloride 74-89-5, Methanamine, biological studies 75-75-2, Methanesulfonic acid 77-19-0, Dicyclomine 77-92-9, Citric acid, biological studies 77-92-9D, Citric acid, glycerides 79-09-4, Propionic acid, biological studies 79-10-7, Acrylic acid, biological studies 79-10-7D, Acrylic acid, polymers 81-24-3, Taurocholic acid 81-25-4, Cholic acid 83-44-3, Deoxycholic acid 87-69-4, Tartaric acid, biological studies 87-69-4D, Tartaric acid, glycerides 89-57-6, Mesalamine 89-65-6, Isoascorbic acid 101-26-8, Pyridostigmine bromide 102-71-6, Triethanolamine, biological studies 104-15-4, p-Toluenesulfonic acid, biological studies 107-15-3, Ethylenediamine, biological studies 107-21-1, Ethylene glycol, biological studies 107-92-6, Butyric acid, biological studies 110-15-6, Succinic acid, biological studies 110-16-7, Maleic acid, biological studies 110-17-8, Fumaric acid, biological studies 110-27-0, Isopropyl myristate 111-62-6, Ethyl oleate 112-80-1, Oleic acid, biological studies 114-07-8, Erythromycin 114-80-7, Neostigmine bromide 115-77-5, Pentaerythritol, biological studies 121-44-8, Triethylamine, biological

studies 122-20-3, Triisopropanolamine 124-04-9, Adipic acid, biological studies 124-07-2, Caprylic acid, biological studies 128-13-2, Ursodeoxycholic acid 129-06-6, Warfarin sodium 131-49-7, Diatrizoate meglumine 138-36-3, p-Bromobenzenesulfonic acid 140-64-7, Pentamidine isethionate 141-22-0, Ricinoleic acid 141-43-5, Ethanolamine, biological studies 142-62-1, Caproic acid, biological studies 142-91-6, Isopropyl palmitate 143-07-7, Lauric acid, biological studies 143-07-7D, Lauric acid, Macrogol glycerides 144-55-8, Sodium hydrogen carbonate, biological studies 144-62-7, Oxalic acid, biological studies 145-42-6, Sodium taurocholate 147-94-4, Cytarabine 148-24-3, 8-Quinolinol, biological studies 151-21-3, Sodium lauryl sulfate, biological studies 151-41-7, Lauryl sulfate 154-21-2, Lincomycin 155-97-5, Pyridostigmine 299-42-3, Ephedrine 334-48-5, Capric acid 360-65-6, Glycodeoxycholic acid 434-13-9, Lithocholic acid 463-40-1, Linolenic acid 463-79-6, Carbonic acid, biological studies 471-34-1, Calcium carbonate, biological studies 474-25-9, Chenodeoxycholic acid 475-31-0, Glycocholic acid 516-35-8, Taurochenodeoxycholic acid 516-50-7, Taurodeoxycholic acid 526-95-4, Gluconic acid 541-15-1D, Carnitine, fatty acid ester salts 544-35-4, Ethyl linoleate 544-63-8, Myristic acid, biological studies 577-11-7, Sodium docusate 616-91-1, N-Acetylcysteine 640-79-9, Glycochenodeoxycholic acid 665-66-7, Amantadine hydrochloride 737-31-5, Diatrizoate sodium 863-57-0, Sodium glycocholate 865-21-4, Vinblastin 1002-62-6, Sodium caprate 1115-70-4, Metformin hydrochloride 1264-72-8, Colistin sulfate 1309-42-8, Magnesium hydroxide 1310-58-3, Potassium hydroxide, biological studies 1310-73-2, Sodium hydroxide, biological studies 1319-82-0, Aminocaproic acid 1327-43-1, Magnesium aluminum silicate 1330-80-9, Propylene glycol monooleate 1335-30-4, Aluminum silicate 1336-21-6, Ammonium hydroxide 1338-39-2, Span 20 1338-41-6, Sorbitan monostearate 1338-43-8, Span 80 1397-89-3, Amphotericin B 1403-66-3, Gentamycin 1404-90-6, Vancomycin 1405-20-5, Polymixin B sulfate 1405-37-4, Capreomycin sulfate 1405-87-4, Bacitracin 1492-18-8, Leucovorin calcium 1501-84-4, Rimantadine hydrochloride 1684-40-8, Tacrine hydrochloride 1695-77-8, Spectinomycin 1935-18-8, Palmitoyl carnitine 2016-88-8, Amiloride hydrochloride 2364-67-2, Palmitoyl carnitine 2466-77-5, Lauroyl carnitine 2646-38-0, Sodium chenodeoxycholate 2898-95-5, Sodium ursodeoxycholate 3056-17-5, Stavudine 3485-62-9, Clidinium bromide 3778-73-2, Isofosfamide 3858-83-1, P-Aminobenzamidine 4291-63-8, Cladribine 5534-95-2, Pentagastrin 6303-21-5D, Phosphinic acid, dipeptide derivs. 6493-05-6, Pentoxifylline 7087-68-5, Diisopropylethylamine 7481-89-2, Zalcitabine 7585-39-9D, .beta.-Cyclodextrin, ethers with propanediol 7647-01-0, Hydrochloric acid, biological studies 7648-98-8, Ambenonium 7664-38-2, Phosphoric acid, biological studies 7664-93-9, Sulfuric acid, biological studies 7664-93-9D, Sulfuric acid, alkyl esters, salts, biological studies 7697-37-2, Nitric acid, biological studies 8007-43-0, Sorbitan sesquioleate 8068-28-8, Colistimethate sodium 9001-28-9, Factor IX 9002-01-1, Streptokinase 9002-60-2, Corticotropin, biological studies 9002-92-0, Brij 35 9002-96-4 9003-01-4D, Polyacrylic acid, conjugates with bacitracin 9003-39-8D, Polyvinylpyrrolidone, reaction products with phosphatidylethanolamine 9004-10-8, Insulin, biological studies 9004-17-5, Insulin protamine zinc 9004-32-4D, Carboxymethyl cellulose, conjugates with pepstatin 9004-34-6, Cellulose, biological studies 9004-34-6D, Cellulose, ethers, biological studies 9004-38-0, Cellulose acetate phthalate 9004-57-3, Ethyl cellulose 9004-81-3 9004-95-9, Polyethylene glycol cetyl ether 9004-96-0, Crodet O40 9004-98-2, Polyoxyethylene oleyl ether 9004-99-3 9005-00-9, Polyoxyethylene stearyl ether 9005-02-1, Kessco PEG 300DL 9005-07-6, Kessco PEG 1540DO 9005-08-7 9005-32-7, Alginic acid 9005-63-4D, fatty acid esters 9005-64-5, Tween 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40 9005-67-8, Tween 60 9007-48-1, Plurol Oleique 9007-92-5, Glucagon,

biological studies 9011-21-6 9012-76-4, Chitosan 9012-76-4D, Chitosan, conjugates with antipain and EDTA 9015-68-3, Asparaginase 9034-40-6, Gonadotropin releasing hormone 9035-81-8, Trypsin inhibitor 9036-19-5 9039-53-6, Urokinase 9041-08-1, Enoxaparin sodium 9041-93-4, Bleomycin sulfate 9050-31-1, Hydroxypropylmethyl cellulose phthalate 9062-90-2 9063-46-1 9076-44-2, Chymostatin 9078-38-0, Soybean trypsin inhibitor 9087-70-1, Pancreatic trypsin inhibitor 10034-85-2, Hydriodic acid 10035-10-6, Hydrobromic acid, biological studies 10041-19-7D, derivs. 10043-35-3, Boric acid, biological studies 10596-23-3 11000-17-2, Vasopressin 11061-68-0, Human insulin 11140-04-8, Imwitor 988 12584-58-6, Porcine insulin 12629-01-5, Human growth hormone 13265-10-6, Methscopolamine 13284-86-1, Sodium lithocholate 13780-71-7D, Boronic acid, .alpha.-aminoalkyl derivs. 14440-80-3, Stearoyl-2-lactylate 14605-22-2, Tauroursodeoxycholic acid 15500-66-0, Pancuronium bromide 15663-27-1, Cisplatin 15686-71-2, Cephalexin 15826-37-6, Cromolyn sodium 16679-58-6, Desmopressin 16960-16-0, Cosyntropin 17438-29-8 18323-44-9, Clindamycin 18883-66-4, Streptozocin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for enhanced absorption of hydrophilic drugs using combination of surfactants)

IT 20537-88-6, Amifostine 21215-62-3, Calcitonin human 21645-51-2, Aluminum hydroxide, biological studies 21679-14-1, Fludarabine 22254-24-6, Ipratropium bromide 22882-95-7, Isopropyl linoleate 23031-32-5, Terbutaline sulfate 23214-92-8, Doxorubicin 24356-60-3, Cephapirin sodium 24938-16-7, Eudragit E 25126-32-3, Sincalide 25168-73-4, Sucrose monostearate 25212-88-8, Eudragit L100-55 25322-68-3, Polyethylene glycol 25339-99-5, Sucrose monolaurate 25496-72-4, Monoolein 25597-07-3, Myristoylcarnitine 25637-84-7, Glyceryl dioleate 25637-97-2, Sucrose dipalmitate 26264-14-2D, Propanediol, ethers with .beta.-cyclodextrin 26266-57-9, Sorbitan monopalmitate 26266-58-0, Sorbitan trioleate 26402-22-2, Glyceryl monocaprate 26402-26-6, Glyceryl monocaprylate 26446-38-8, Sucrose monopalmitate 26589-39-9, Eudragit S 26658-19-5, Sorbitan tristearate 26839-75-8, Timolol 27164-46-1, Cefazolin sodium 27195-16-0, Sucrose distearate 27214-38-6, Nikkol MGM 27215-38-9, Imwitor 312 27638-00-2, Glyceryl dilaurate 29122-68-7, Atenolol 30516-87-1, Zidovudine 31694-55-0D, C8-10-esters 33434-24-1, Eudragit RL 33515-09-2, Gonadorelin 33564-30-6, Cefoxitin sodium 34787-01-4, Ticarcillin 36354-80-0, Glyceryl dicaprylate 36791-04-5, Ribavirin 37220-82-9, Peceol 37321-62-3, Lauroglycol 37330-34-0, Bowman-Birk inhibitor 37330-34-0D, Bowman-Birk inhibitor, conjugates with polyacrylic acid 37691-11-5, Antipain 37691-11-5D, Antipain, conjugates with chitosan and EDTA 38916-34-6, Somatostatin 39324-30-6, Pepstatin 39324-30-6D, Pepstatin, conjugates with CM-cellulose 39366-43-3, Magnesium aluminum hydroxide 39438-11-4, Sorbitan monocaprate 41575-94-4, Carboplatin 42057-22-7, Mezlocillin sodium 42540-40-9, Cefamandole nafate 42766-91-6, Nikkol DHC 42907-92-6, Sodium tauro-24,25-dihydrofusidate 47931-85-1, Calcitonin salmon 50700-72-6, Vecuronium bromide 51192-09-7, Tagat O2 51384-51-1, Metoprolol 51822-44-7, Eudragit L 51938-44-4, Sorbitan sesquistearate 52504-24-2, Softigen 767 52581-71-2, Volpo 3 52907-01-4, Cellulose acetate trimellitate 53168-42-6, Myvacet 9-45 53237-50-6 53910-25-1, Pentostatin 53988-07-1, Glyceryl dicaprate 54063-53-5, Propafenone 54392-26-6, Sorbitan monoisostearate 54910-89-3, Fluoxetine 55123-66-5, Leupeptin 56180-94-0, Acarbose 57107-95-6 57171-56-9 57248-88-1, Pamidronate disodium 58561-47-0, Softigen 701 58970-76-6, Bestatin 59227-89-3, 1-Dodecylazacycloheptan-2-one 59703-84-3, Piperacillin sodium 59721-29-8, Camostat mesylate 60177-36-8, Sorbitan monocaprylate 61270-78-8, Cefonicid sodium 61489-71-2, Menotropin 61869-08-7, Paroxetine 62013-04-1, Dirithromycin 62288-83-9, Desmopressin acetate 62893-19-0, Cefoperazone 63527-52-6, Cefotaxime 64228-81-5, Atracurium besylate

64480-66-6, Glycoursodeoxycholic acid 64544-07-6, Cefuroxime axetil
66376-36-1, Alendronate 66419-50-9, Bovine growth hormone 67352-02-7
67655-94-1, Amastatin 68099-86-5, Bepridil hydrochloride 68401-81-0,
Ceftizoxime 68795-69-7, Propylene glycol monocaprate 68958-64-5
69049-74-7, Nedocromil sodium 69070-98-0 69227-93-6, Lauryl
.beta.-maltopyranoside 69655-05-6, Didanosine 70458-92-3, Pefloxacin
70458-96-7, Norfloxacin 71486-22-1, Vinorelbine 73384-59-5,
Ceftriaxone 74011-58-8, Enoxacin 74356-00-6, Cefotetan disodium
74381-53-6, Leuprolide acetate 76420-72-9, Enalaprilat 76470-66-1,
Loracarbef 78110-38-0, Aztreonam 79350-37-1, Cefixime 79517-01-4,
Octreotide acetate 79665-92-2 79665-93-3 81161-17-3, Esmolol
hydrochloride 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin
83869-56-1, Granulocyte-macrophage colony stimulating factor 83905-01-5,
Azithromycin 85721-33-1, Ciprofloxacin 87679-37-6, Trandolapril
88669-04-9, Trospectomycin 89703-10-6, FK-448 89987-06-4, Tiludronate
93790-70-6, Cholylsarcosine 93790-72-8, N-Methyltaurocholic acid
93792-59-7, Hydroxypropylmethyl cellulose succinate 94749-08-3,
Salmeterol xinafoate 98079-51-7, Lomefloxacin 100986-85-4,
Levofloxacin 104227-87-4, Famciclovir 105287-09-0, Aquateric
105462-24-6, Risedronic acid 106392-12-5, Polyoxyethylene-
polyoxypropylene block copolymer 106819-53-8, Doxacurium chloride
106861-44-3, Mivacurium chloride 107648-80-6, Cefepime hydrochloride
110871-86-8, Sparfloxacin 113189-02-9, Antihemophilic factor
113852-37-2, Cidofovir 116094-23-6, Insulin aspart 119914-60-2,
Grepafloxacin 121368-58-9, Olpadronate 121548-04-7, Gelucire 44/14
121548-05-8, Gelucire 50/13 124832-26-4, Valaciclovir 126467-48-9,
Porcine somatotropin 127759-89-1, Lobucavir 127829-97-4, Solulan C 24
133107-64-9, Insulin lispro 134678-17-4, Lamivudine 137862-53-4,
Valsartan 138636-14-3, Eudragit NE 139110-80-8, Zanamivir
139639-23-9, Tissue type plasminogen activator 141644-88-4, Hydrotalcite
142368-40-9, Imwitor 375 143003-46-7, Alglucerase 143011-72-7,
Granulocyte colony stimulating factor 146961-76-4, Alatrofloxacin
147059-72-1, Trovafloxacin 148046-81-5, Gelucire 33/01 148553-50-8,
Pregabalin 150372-93-3, Glycerox L 151126-32-8, Pramlintide
154361-50-9, Capecitabine 156259-68-6, Capmul MCM 157810-81-6,
Indinavir sulfate 160337-95-1, Insulin glargine 169148-63-4, Insulin
detemir 173146-27-5, Denileukin diftitox 191588-94-0, TNK-tPA
211365-88-7, Nikkol BPS 30
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for enhanced absorption of hydrophilic drugs using combination
of surfactants)

IT 9001-92-7, Proteinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; compns. for enhanced absorption of hydrophilic drugs using
combination of surfactants)

IT 9003-98-9, Dornase 11096-26-7, Epoetin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(.alpha.; compns. for enhanced absorption of hydrophilic drugs using
combination of surfactants)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
RE
(1) Cho; US 5858398 A 1999 CAPLUS

L26 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2003 ACS
AN 2000:259972 CAPLUS
DN 132:293042
TI Encapsulation of sensitive liquid components into a matrix to obtain
discrete shelf-stable particles
IN Van Lengerich, Bernhard H.
PA General Mills, Inc., USA
SO PCT Int. Appl., 56 pp.
CODEN: PIXXD2

DT Patent
LA English
IC ICM A61K009-10
CC 17-13 (Food and Feed Chemistry)
Section cross-reference(s): 63
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000021504	A1	20000420	WO 1999-US20905	19991006
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2345815	AA	20000420	CA 1999-2345815	19991006
	AU 9963872	A1	20000501	AU 1999-63872	19991006
	EP 1119345	A1	20010801	EP 1999-951433	19991006
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002527375	T2	20020827	JP 2000-575480	19991006
	NO 2000004784	A	20000925	NO 2000-4784	20000925
PRAI	US 1998-103700P	P	19981009		
	US 1998-109696P	P	19981124		
	US 1999-233443	A	19990120		
	US 1998-79060P	P	19980323		
	WO 1999-US4267	W	19990323		
	WO 1999-US20905	W	19991006		

AB A liq. encapsulant component which contains an active, sensitive encapsulant, such as a live microorganism or an enzyme dissolved or dispersed in a liq. plasticizer is admixed with a plasticizable matrix material. The matrix material is plasticizable by the liq. plasticizer and the encapsulation of the active encapsulant is accomplished at a low temp. and under low shear conditions. The active component is encapsulated and/or embedded in the plasticizable matrix component or material in a continuous process to produce discrete, solid particles. The liq. content of the liq. encapsulant component provides substantially all or completely all of the liq. plasticizer needed to plasticize the matrix component to obtain a formable, extrudable, cuttable, mixt. or dough. Removal of liq. plasticizer prior to extrusion is not needed to adjust the viscosity of the mixt. for formability. Release of an active component from the matrix may be delayed or controlled over time so that the active component is delivered when and where it is needed to perform its intended function. Controlled release, discrete, solid particles which contain an encapsulated and/or embedded component such as a heat sensitive or readily oxidizable pharmaceutically, biol., or nutritionally active component are continuously produced without substantial destruction of the matrix material or encapsulant.

ST encapsulation food liq component matrix preservation

IT Polymers, biological studies
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(amphiphilic; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT Nitro compounds
Nitro compounds
Nitroso compounds
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(arom.; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT Antitoxins
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(botulism; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Bakery products
(cakes; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Natural products, pharmaceutical
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(cascara sagrada; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Temperature effects, biological
(cold; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Bakery products
(cookies; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Bakery products
(crackers; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Puddings
(custard; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Natural products, pharmaceutical
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(digitalis; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Toxins
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(diphtheria, antitoxins; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Antibiotics
Antioxidants
Antitumor agents
Antivenoms
Antiviral agents
Beverages
Cholera
Detergents
Dough
Drug delivery systems
Durum wheat
Emulsifying agents
Encapsulation
Flavor
Flavoring materials
Food additives
Food functional properties
Food preservation
Food viscoelasticity
Food viscosity
Health food
Hepatitis virus
Human poliovirus
Hydrocolloids
Ice cream
Lactobacillus acidophilus
Microorganism
Pertussis
Pigments, biological
Plasticizers
Puddings

Rauvolfia serpentina
Soups
Surfactants
Thyroid gland
Vaccines
Virus
Wheat flour
(encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT Edible oils
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT Amino acids, biological studies
Castor oil
Cod liver oil
Dipeptides
Enzymes, biological studies
Estrogens
Fats and Glyceridic oils, biological studies
Glucocorticoids
Glutens
Hormones, plant
Lanolin
Mineral elements, biological studies
Paraffin waxes, biological studies
Pentosans
Peptides, biological studies
Phospholipids, biological studies
Polyolefins
Polyurethanes, biological studies
Pumice
Steroids, biological studies
Tetracyclines
Trace elements, biological studies
Tuberculin
Vitamins
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT Fatty acids, biological studies
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(essential; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT Belladonna (Atropa belladonna)
Chrysanthemum
(ext.; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT Microorganism
(food; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT Temperature effects, biological
(heat; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT Food
(infant; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT Natural products, pharmaceutical
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(ipecac; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT Carbohydrates, biological studies
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(low-mol. wt.; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Nutrients
(micronutrients; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Antibodies
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(monoclonal; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Aromatic compounds
Aromatic compounds
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(nitro; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Peptides, biological studies
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(oligopeptides; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Natural products, pharmaceutical
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(opium; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Mucopolysaccharides, biological studies
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(polysulfate; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Breakfast cereal
(ready-to-eat; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Food
(salads; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Durum wheat
(semolina; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Food
(snack; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Food
(sports bars; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Tannins
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(sulfated; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Carboxylic acids, biological studies
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(thiocarboxylic; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Fatty acids, biological studies
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(unsatd.; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Measles virus
Rabies
Rubella virus
(vaccine; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)
IT Fever and Hyperthermia
(yellow, vaccine; encapsulation of sensitive liq. components into

matrix to obtain discrete shelf-stable particles)

IT Milk preparations
(yogurt; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT 9005-25-8D, Starch, hydrolyzates
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT 50-02-2, Dexamethasone 50-04-4, Cortisone acetate 50-06-6, Phenobarbital, biological studies 50-09-9 50-12-4, Mephenytoin 50-14-6, Ergocalciferol 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-27-1, Estriol 50-28-2, Estradiol, biological studies 50-33-9, Phenylbutazone, biological studies 50-36-2, Cocaine 50-41-9, Clomiphene citrate 50-44-2, Mercaptopurine 50-47-5, Desipramine 50-48-6, Amitriptylin 50-49-7 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 50-54-4, Quinidine sulfate 50-55-5, Reserpine 50-58-8, Phendimetrazine tartrate 50-63-5, Chloroquine phosphate 50-78-2, Aspirin 50-81-7, L-Ascorbic acid, biological studies 50-96-4, Isoetharine hydrochloride 51-05-8, Procaine hydrochloride 51-15-0, Pralidoxime chloride 51-21-8, Fluorouracil 51-30-9, Isoproterenol hydrochloride 51-34-3, Scopolamine 51-43-4, Epinephrine 51-48-9, Levothyroxine, biological studies 51-52-5, Propyl thiouracil 51-55-8, Atropine, biological studies 51-57-0, Methamphetamine hydrochloride 51-64-9, Dextroamphetamine 51-74-1, Histamine phosphate 51-83-2, Carbachol 51-84-3, Acetylcholine, biological studies 51-98-9, Norethindrone acetate 52-01-7, Spironolactone 52-24-4, Thiotepa 52-49-3, Trihexyphenidyl hydrochloride 52-53-9, Verapamil 52-67-5, Penicillamine 52-68-6, Trichlorfon 52-86-8, Haloperidol 52-89-1, L-Cysteine hydrochloride 53-03-2, Prednisone 53-16-7, Estrone, biological studies 53-19-0, Mitotane 53-39-4, Oxandrolone 53-60-1, Promazine hydrochloride 53-86-1, Indomethacin 54-21-7, Sodium salicylate 54-31-9, Furosemide 54-36-4, Metyrapone 54-47-7, Pyridoxal phosphate 54-64-8, Thimerosal 54-85-3, Isoniazid 55-03-8, Levothyroxine sodium 55-06-1, Liothyronine sodium 55-63-0, Nitroglycerin 55-98-1, Busulfan 56-47-3, Deoxycorticosterone acetate 56-53-1, Diethylstilbestrol 56-54-2 56-75-7, Chloramphenicol 56-84-8, L-Aspartic acid, biological studies 56-86-0, L-Glutamic acid, biological studies 56-87-1, L-Lysine, biological studies 57-13-6, Urea, biological studies 57-22-7, Vincristine 57-33-0, Pentobarbital sodium 57-41-0, Phenytoin 57-42-1, Meperidine 57-43-2, Amobarbital **57-47-6**, Physostigmine 57-53-4, Meprobamate 57-63-6, Ethinyl estradiol 57-66-9, Probenecid 57-68-1, Sulfamethazine 57-83-0, Progesterone, biological studies 57-92-1, biological studies 57-96-5, Sulfinpyrazone 58-00-4, Apomorphine 58-08-2, Caffeine, biological studies 58-14-0, Pyrimethamine 58-18-4, Methyltestosterone 58-22-0, Testosterone 58-25-3, Chlordiazepoxide 58-27-5, Menadione 58-32-2, Dipyridamole 58-33-3, Promethazine hydrochloride 58-38-8, Prochlorperazine 58-39-9, Perphenazine 58-40-2, Promazine 58-54-8, Ethacrynic acid 58-55-9, Theophylline, biological studies 58-56-0, Pyridoxine hydrochloride 58-61-7D, Adenosine, derivs. 58-85-5 58-89-9, Lindane 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 59-33-6, Pyrilamine maleate 59-43-8, Thiamin, biological studies 59-52-9, Dimercaprol 59-63-2, Isocarboxazid 59-66-5, Acetazolamide 59-67-6, Niacin, biological studies 59-92-7, Levodopa, biological studies 60-13-9, Amphetamine sulfate 60-18-4, L-Tyrosine, biological studies 60-56-0, Methimazole 60-80-0, Antipyrine 60-87-7, Promethazine 60-99-1, Levomepromazine 61-00-7, Acepromazine 61-25-6, Papaverine hydrochloride 61-68-7, Mefenamic acid 61-76-7, Phenylephrine hydrochloride 61-90-5, L-Leucine, biological studies 62-31-7, Dopamine hydrochloride 62-44-2,

Phenacetin 62-67-9, Nalorphine 62-90-8, Nandrolone phenpropionate 63-68-3, Methionine, biological studies 63-91-2, L-Phenylalanine, biological studies 63-92-3, Phenoxybenzamine hydrochloride 63-98-9, Phenacemide 64-31-3, Morphine sulfate 64-72-2, Chlortetracycline hydrochloride 64-77-7, Tolbutamide 64-86-8, Colchicine 65-45-2, Salicylamide 66-76-2, Dicoumarol 67-03-8, Thiamine hydrochloride 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-73-2, Fluocinolone acetonide 67-96-9, Dihydrotachysterol 67-97-0, Cholecalciferol 68-19-9, Cyanocobalamin 68-22-4, Norethindrone 68-35-9, Sulfadiazine 68-41-7, Cycloserine 68-89-3, Metamizole 69-23-8, Fluphenazine 69-44-3, Amodiaquine hydrochloride 69-53-4, Ampicillin 69-72-7, Salicylic acid, biological studies 71-00-1, L-Histidine, biological studies 71-58-9, Medroxyprogesterone acetate 71-63-6, Digitoxin 71-68-1, Hydromorphone hydrochloride 71-81-8, Isopropamide iodide 72-14-0, Sulfathiazole 72-17-3 72-18-4, L-Valine, biological studies 72-19-5, L-Threonine, biological studies 72-33-3, Mestranol 72-63-9, Methandrostenolone 73-22-3, L-Tryptophan, biological studies 73-48-3, Bendroflumethiazide 76-38-0, Methoxyflurane 76-42-6, Oxycodone 76-43-7, Fluoxymesterone 76-57-3, Codeine 77-09-8 77-19-0, Dicyclomine 77-21-4, Glutethimide 77-26-9, Butalbital 77-27-0, Thiamylal 77-36-1, Chlorthalidone 77-41-8, Methsuximide 78-11-5, Pentaerythritol tetranitrate 78-44-4, Carisoprodol 79-57-2, Oxytetracycline 80-08-0 80-13-7, Halazone 80-53-5, Terpin 81-07-2, Saccharin 81-13-0, Dexpanthenol 81-23-2, Dehydrocholic acid 81-81-2, Warfarin 83-43-2 83-73-8, Iodoquinol 83-88-5, Riboflavin, biological studies 84-02-6, Prochlorperazine maleate 84-17-3, Dienestrol 84-80-0, Phytonadione 85-79-0, Dibucaine 86-35-1, Ethotoin 87-00-3, Homatropine 87-08-1, Penicillin V 87-33-2, Isosorbide dinitrate 88-04-0, Chloroxylenol 89-57-6, 5-Aminosalicylic acid 90-33-5 90-34-6, Primaquine 91-33-8, Benzthiazide 91-81-6, Tripelennamine 92-13-7, Pilocarpine 93-14-1, Guaifenesin 94-09-7, Benzocaine 94-20-2, Chlorpropamide 94-24-6, Tetracaine 95-25-0, Chlorzoxazone 97-53-0, Eugenol 97-77-8, Disulfiram 98-96-4, Pyrazinamide 99-66-1, Valproic acid 100-97-0, biological studies 101-26-8, Pyridostigmine bromide 101-31-5, Hyoscyamine 102-76-1, Triacetin 103-16-2, Monobenzone 103-86-6, Hydroxyamphetamine 103-90-2 104-28-9, Cinoxate 104-31-4, Benzonatate 106-48-9 107-43-7, Betaine 108-46-3, 1,3-Benzenediol, biological studies 110-85-0, Piperazine, biological studies 110-94-1, Pentanedioic acid 113-18-8, Ethchlorvynol 113-52-0, Imipramine hydrochloride 113-59-7, Chlorprothixene 113-92-8, Chlorpheniramine maleate 114-07-8, Erythromycin 114-80-7, Neostigmine bromide 115-38-8, Mephobarbital

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT 120-97-8, Dichlorphenamide 121-25-5, Amprolium 121-54-0, Benzethonium chloride 121-75-5, Malathion 123-31-9, Hydroquinone, biological studies 124-90-3, Oxycodone hydrochloride 124-94-7, Triamcinolone 125-28-0, Dihydrocodeine 125-33-7, Primidone 125-71-3, Dextromethorphan 125-72-4, Levorphanol tartrate 126-07-8, Griseofulvin 127-07-1, Hydroxyurea 127-33-3, Demeclocycline 127-48-0, Trimethadione 127-69-5, Sulfisoxazole 127-79-7 128-44-9, Saccharin sodium 128-46-1, Dihydrostreptomycin 128-49-4, Docusate calcium 128-62-1, Noscapine 129-20-4, Oxyphenbutazone 129-49-7, Methysergide maleate 129-51-1, Ergonovine maleate 130-26-7, Clioquinol 130-61-0, Thioridazine hydrochloride 131-13-5 131-57-7, Oxybenzone 132-17-2, Benztropine mesylate 132-92-3, Methicillin sodium 133-58-4, Nitromersol 133-67-5, Trichlormethiazide 134-03-2, Sodium ascorbate 134-80-5, Diethylpropion hydrochloride 135-07-9, Methyclothiazide 135-09-1, Hydroflumethiazide 136-40-3, Phenazopyridine hydrochloride 136-77-6, Hexyl resorcinol 137-58-6, Lidocaine 141-01-5, Ferrous fumarate 143-71-5, Hydrocodone bitartrate 143-81-7, Butabarbital

sodium 144-14-9, Anileridine 144-55-8, Sodium bicarbonate, biological studies 144-80-9, Sulfacetamide 144-82-1, Sulfamethizole 144-83-2, Sulfapyridine 146-22-5, Nitrazepam 146-54-3, Trifluprómazine 147-52-4, Nafcillin 147-85-3, L-Proline, biological studies 148-79-8 148-82-3, Melphalan 151-67-7, Halothane 152-62-5, Dydrogesterone 154-41-6, Phenylpropanolamine hydrochloride 154-42-7, Thioguanine 156-51-4, Phenelzine sulfate 297-76-7, Ethynodiol diacetate 298-46-4, Carbamazepine 298-50-0, Propantheline 298-57-7, Cinnarizine 298-59-9, Methylphenidate hydrochloride 298-81-7, Methoxsalen 299-27-4, Potassium gluconate 299-29-6, Ferrous gluconate 299-42-3, Ephedrine 302-22-7, Chlormadinone acetate 302-79-4, Tretinoin 303-25-3, Cyclizine hydrochloride 304-20-1, Hydralazine hydrochloride 304-59-6, Potassium sodium tartrate, biological studies 305-03-3, Chlorambucil 309-43-3, Secobarbital sodium 315-30-0, Allopurinol 317-34-0, Aminophylline 318-98-9 329-65-7, Racepinefrine 343-55-5, Dicloxacillin sodium 345-78-8, Pseudoephedrine hydrochloride 346-18-9, Polythiazide 356-12-7, Fluocinonide 357-07-3, Oxymorphone hydrochloride 359-83-1D, Pentazocine, salts 360-70-3, Nandrolone decanoate 364-62-5, Metoclopramide 364-98-7, Diazoxide 366-70-1, Procarbazine hydrochloride 378-44-9, Betamethasone 379-79-3, Ergotamine tartrate 382-67-2, Desoximetasone 388-51-2 389-08-2, Nalidixic acid 390-64-7, Prenylamine 396-01-0, Triamterene 426-13-1, Fluorometholone 434-07-1, Oxymetholone 435-97-2, Phenprocoumon 437-74-1, Xantinol nicotinate 439-14-5, Diazepam 440-17-5, Trifluoperazine hydrochloride 443-48-1, Metronidazole 446-86-6, Azathioprine 465-65-6, Naloxone 466-99-9, Hydromorphone 471-34-1, Calcium carbonate, biological studies 474-86-2, Equilin 479-18-5, Dyphylline 484-23-1, Dihydralazine 486-12-4, Triprolidine 511-12-6, Dihydroergotamine 514-36-3, Fludrocortisone acetate 514-65-8, Biperiden 518-47-8, Fluorescein sodium 520-85-4, Medroxyprogesterone 523-87-5, Dimenhydrinate 525-66-6 527-07-1, Sodium gluconate 532-03-6, Methocarbamol 533-45-9, Clomethiazole 536-21-0, Norfenefrine 536-33-4, Ethionamide 541-15-1, Levocarnitine 546-88-3, Acetohydroxamic acid 546-93-0, Magnesium carbonate 548-62-9, Gentian violet 548-73-2, Droperidol 549-18-8, Amitriptyline hydrochloride 550-83-4, Propoxycaine hydrochloride 551-27-9, Propicillin 552-94-3, Salsalate 554-13-2, Lithium carbonate 554-57-4, Methazolamide 554-92-7, Trimethobenzamide hydrochloride 555-30-6, Methyldopa 557-34-6, Zinc acetate 562-10-7 564-25-0 577-11-7, Docusate sodium 579-56-6, Isoxsuprine hydrochloride 587-61-1, Propyliodone 590-63-6, Bethanechol chloride 595-33-5, Megestrol acetate 596-51-0, Glycopyrrolate 599-79-1, Sulfasalazine 599-88-2, Sulfaperin 603-50-9, Bisacodyl 604-75-1, Oxazepam 614-39-1, Procainamide hydrochloride 616-91-1, Acetylcysteine 620-61-1, Hyoscyamine sulfate 630-56-8, Hydroxyprogesterone caproate 637-07-0, Clofibrate 637-58-1, Pramoxine hydrochloride 642-78-4, Cloxacillin sodium 651-06-9, Sulfamethoxydiazine 672-87-7, Metyrosine 709-55-7, Etilefrine 721-50-6, Prilocaine 723-46-6, Sulfamethoxazole 738-70-5, Trimethoprim 745-65-3, Alprostadil 747-36-4, Hydroxychloroquine sulfate 768-94-5, Amantadine 777-11-7, Haloprogin 797-63-7, Levonorgestrel 826-39-1, Mecamylamine hydrochloride 846-49-1, Lorazepam 846-50-4, Temazepam 859-18-7, Lincomycin hydrochloride 865-21-4, Vinblastine 866-83-1, Potassium citrate 894-71-3, Nortriptyline hydrochloride 968-81-0, Acetohexamide 968-93-4, Testolacton 969-33-5, Cyproheptadine hydrochloride 985-16-0, Nafcillin sodium 1069-66-5, Sodium valproate 1070-11-7, Ethambutol hydrochloride 1094-08-2, Ethopropazine hydrochloride 1095-90-5, Methadone hydrochloride 1098-97-1, Pyritinol 1104-22-9, Meclizine hydrochloride 1134-47-0, Baclofen 1143-38-0, Anthralin 1151-11-7, Ipodate calcium 1156-19-0, Tolazamide 1173-88-2, Oxacillin sodium 1197-21-3, Phentermine hydrochloride 1221-56-3, Ipodate sodium 1225-55-4, Protriptyline hydrochloride 1229-29-4, Doxepin hydrochloride 1244-76-4 1247-42-3, Meprednisone

1263-89-4, Paromomycin sulfate 1309-48-4, Magnesium oxide, biological studies 1319-82-0, Aminocaproic acid 1343-97-1, Selenium sulfate 1393-48-2, Thiostrepton 1400-61-9, Nystatin 1403-17-4, Candicidin 1403-66-3, Gentamicin 1404-00-8, Mitomycin 1404-04-2, Neomycin 1404-88-2, Tyrothricin 1404-93-9, Vancomycin hydrochloride 1405-10-3, Neomycin sulfate 1405-20-5, Polymyxin b sulfate 1405-87-4, Bacitracin 1405-97-6, Gramicidin 1406-05-9, Penicillin 1420-55-9, Thiethylperazine 1476-53-5, Novobiocin sodium 1492-18-8, Leucovorin calcium 1508-65-2, Oxybutynin chloride 1508-75-4, Tropicamide 1508-76-5, Procyclidine hydrochloride 1524-88-5, Flurandrenolide 1597-82-6, Paramethasone acetate 1617-90-9, Vincamine 1622-61-3, Clonazepam 1622-62-4, Flunitrazepam 1639-60-7, Propoxyphene hydrochloride 1649-18-9, Azaperone 1668-19-5, Doxepin 1707-14-8, Phenmetrazine hydrochloride 1808-12-4, Bromo diphenhydramine hydrochloride 1812-30-2, Bromazepam 1897-96-7, Lonetil 1972-08-3, Dronabinol 1977-10-2, Loxapine 1982-37-2, Methdilazine 2013-58-3, Meclocycline 2022-85-7, Flucytosine 2030-63-9, Clofazimine 2062-78-4, Pimozide 2098-66-0, Cyproterone 2179-37-5, Bencyclane
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT 2315-02-8, Oxymetazoline hydrochloride 2398-96-1, Tolnaftate 2438-32-6, Dexchlorpheniramine maleate 2447-57-6, Sulfadoxine 2589-47-1, Prajmalium bitartrate, biological studies 2609-46-3, Amiloride 2709-56-0, Flupentixol 2898-12-6, Medazepam 3313-26-6, Thiothixene 3385-03-3, Flunisolide 3485-14-1, Cyclacillin 3485-62-9, Clidinium bromide 3486-35-9, Zinc carbonate 3505-38-2, Carbinoxamine maleate 3546-41-6, Pyrvinium pamoate 3572-43-8, Bromhexine 3575-80-2, Melperone 3625-06-7, Mebeverine 3632-91-5, Magnesium gluconate 3778-73-2, Ifosfamide 3810-80-8, Diphenoxylate hydrochloride 3902-71-4, Trioxsalen 3930-20-9, Sotalol 3963-95-9, Methacycline hydrochloride 3978-86-7, Azatadine maleate 4205-90-7, Clonidine 4205-91-8, Clonidine hydrochloride 4330-99-8, Trimeprazine tartrate 4468-02-4, Zinc gluconate 4498-32-2, Dibenzepine 4499-40-5, Oxtriphylline, biological studies 4759-48-2, Isotretinoin 4891-15-0, Estramustine phosphate 5051-62-7, Guanabenz 5104-49-4, Flurbiprofen 5321-32-4, Hetacillin potassium 5355-48-6 5370-01-4, Mexiletine hydrochloride 5534-09-8, Beclomethasone dipropionate 5536-17-4, Vidarabine 5636-83-9, Dimetindene 5638-76-6, Betahistine 5874-97-5, Metaproterenol sulfate 5875-06-9, Proparacaine hydrochloride 5987-82-6, Benoxinate hydrochloride 6202-23-9, Cyclobenzaprine hydrochloride 6284-40-8, Meglumine 6385-02-0, Meclofenamate sodium 6452-73-9, Oxprenolol hydrochloride 6493-05-6, Pentoxifylline 6533-00-2, Norgestrel 6805-41-0, Aescin 7054-25-3, Quinidine gluconate 7195-27-9, Mefruside 7235-40-7, .beta.-Carotene 7246-21-1, Tyropanoate sodium 7280-37-7, Estropipate 7297-25-8, Erythrityl tetranitrate 7414-83-7, Etidronate disodium 7439-95-4D, Magnesium, salts 7439-96-5, Manganese, biological studies 7439-96-5D, Manganese, salts 7440-39-3D, Barium, salts 7440-69-9, Bismuth, biological studies 7440-70-2D, Calcium, salts 7447-40-7, Potassium chloride, biological studies 7491-74-9, Piracetam 7632-00-0, Sodium nitrite 7646-85-7, Zinc chloride, biological studies 7681-11-0, Potassium iodide, biological studies 7681-49-4, Sodium fluoride, biological studies 7681-82-5, Sodium iodide (NaI), biological studies 7681-93-8, Natamycin 7693-13-2, Calcium citrate 7720-78-7, Ferrous sulfate 7783-00-8, Selenious acid 7786-30-3, Magnesium chloride, biological studies 8002-55-9, Myrtol 8017-57-0, Trisulfapyrimidine 8024-48-4, Casanthranol 8029-99-0, Paregoric 8049-47-6, Pancreatin 8050-81-5, Simethicone 8065-29-0, Liotrix 8067-24-1 9000-92-4, Amylase 9001-00-7, Bromelin 9001-01-8, Kallidinogenase 9001-62-1, Lipase 9001-73-4, Papain 9001-92-7, Proteinase 9002-07-7, Trypsin 9002-60-2, Corticotropin, biological studies 9002-61-3, Chorionic

gonadotropin 9002-86-2, Polyvinyl chloride 9003-20-7, Polyvinyl acetate 9003-97-8, Polycarbophil 9004-07-3, Chymotrypsin 9004-10-8, Insulin, biological studies 9004-32-4, Carboxymethylcellulose 9004-34-6, Cellulose, biological studies 9004-70-0, Pyroxylin 9005-25-8, Starch, biological studies 9005-80-5, Inulin 9008-05-3, Histoplasmin 9012-54-8, Cellulase 9025-49-4 9025-56-3, Hemicellulase 9032-75-1, Pectinase 9068-42-2, Pentosanase 10025-73-7, Chromic chloride 10040-45-6, Sodium picosulfate 10238-21-8, Glibenclamide 10246-75-0, Hydroxyzine pamoate 10262-69-8, Maprotiline 10347-81-6, Maprotiline hydrochloride 10379-14-3, Tetrazepam 10418-03-8, Stanozolol 10540-29-1, Tamoxifen 11000-17-2, Vasopressin 12125-02-9, Ammonium chloride, biological studies 12622-73-0, Coccidioidin 12633-72-6, Amphotericin 12650-69-0, Mupirocin 13009-99-9, Mafenide acetate 13042-18-7, Fendiline 13292-46-1, Rifampin 13311-84-7, Flutamide 13392-18-2, Fenoterol 13422-51-0, Hydroxocobalamin 13463-67-7, Titanium dioxide, biological studies 13523-86-9, Pindolol 13614-98-7, Minocycline hydrochloride 13682-92-3 14009-24-6, Drotaverine 14028-44-5, Amoxapine 14402-89-2, Sodium nitroprusside 14779-78-3, Padimate 14976-57-9, Clemastine fumarate 15307-86-5, Diclofenac 15622-65-8, Molindone hydrochloride 15663-27-1, Cisplatin 15676-16-1, Sulpiride 15686-51-8, Clemastine 15686-71-2, Cephalexin 15687-27-1 15687-41-9, Oxyfedrine 16034-77-8, Iocetamic acid 16051-77-7 16482-55-6 16595-80-5, Levamisole hydrochloride 16662-47-8, Gallopamil 17140-78-2, Propoxyphene napsylate 17230-88-5, Danazol 17560-51-9, Metolazone 17617-23-1, Flurazepam 18378-89-7, Plicamycin 18559-94-9, Salbutamol 19216-56-9, Prazosin 19237-84-4, Prazosin hydrochloride 19356-17-3, Calcifediol 20830-75-5, Digoxin 21462-39-5, Clindamycin hydrochloride 21738-42-1, Oxamniquine 21829-25-4, Nifedipine 22059-60-5, Disopyramide phosphate 22071-15-4, Ketoprofen 22195-34-2, Guanadrel sulfate 22204-24-6, Pyrantel pamoate 22204-53-1, Naproxen 22232-71-9, Mazindol 22260-51-1, Bromocriptine mesylate 22316-47-8, Clobazam 22494-42-4, Diflunisal 22916-47-8, Miconazole 23031-25-6, Terbutaline 23031-32-5, Terbutaline sulfate 23214-92-8, Doxorubicin 23288-49-5, Probucol 23593-75-1, Clotrimazole 23869-24-1, O-(.beta.-Hydroxyethyl)rutoside 24219-97-4, Mianserin 24390-14-5, Doxycycline hyclate 24729-96-2, Clindamycin phosphate 25046-79-1, Glisoxepide 25155-18-4, Methylbenzethonium chloride 25301-02-4, Tyloxapol 25332-39-2, Trazodone hydrochloride 25389-94-0, Kanamycin sulfate 25614-03-3, Bromocriptine 25655-41-8, Povidone iodine 25812-30-0, Gemfibrozil 25953-19-9, Cefazolin 26027-38-3, Nonoxynol 9 26171-23-3, Tolmetin 26605-69-6, Carbenicillin indanyl sodium 26652-09-5, Ritodrine 26652-10-8 26675-46-7, Isoflurane 26787-78-0, Amoxycillin 26807-65-8, Indapamide 26839-75-8, Timolol 26944-48-9, Glibornuride 27203-92-5, Tramadol 27823-62-7, Chlortetracycline bisulfate 28088-64-4, Aminosalicylic acid 28395-03-1, Bumetanide 28657-80-9, Cinoxacin 28797-61-7, Pirenzepin 28860-95-9, Carbidopa 28911-01-5, Triazolam 28981-97-7, Alprazolam 29122-68-7, Atenolol 29679-58-1, Fenoprofen 30516-87-1 30578-37-1, Amezinium metilsulfate 30685-43-9, Metildigoxin 31329-57-4, Naftidrofuryl 31431-39-7, Mebendazole 31637-97-5, Etofibrate 31828-71-4, Mexiletine 32672-69-8, Mesoridazine besylate 32780-64-6, Labetalol hydrochloride 32887-01-7, Amdinocillin 33005-95-7, Tiaprofenic acid 33286-22-5, Diltiazem hydrochloride 33402-03-8, Metaraminol bitartrate 33419-42-0, Etoposide 33996-33-7, Oxaceprol 34031-32-8, Auranofin 34183-22-7, Propafenone hydrochloride 34552-83-5, Loperamide hydrochloride 34580-13-7, Ketotifen 34787-01-4, Ticarcillin 36322-90-4, Piroxicam 36688-78-5 36791-04-5, Ribavirin 37270-89-6, Heparin calcium
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT 37341-58-5, Phytase 37517-28-5, Amikacin 37517-30-9, Acebutolol

38194-50-2, Sulindac 38260-01-4, Trientine hydrochloride 38304-91-5, Minoxidil 38363-40-5, Penbutolol 38396-39-3, Bupivacaine 38821-53-3, Cephradine 39562-70-4, Nitrendipine 40828-46-4, Suprofen 41859-67-0 42200-33-9, Nadolol 42399-41-7 42540-40-9, Cefamandole nafate 49562-28-9 49745-95-1, Dobutamine hydrochloride 50370-12-2, Cefadroxil 50679-08-8, Terfenadine 50925-79-6, Colestipol 50972-17-3, Bacampicillin 51022-69-6, Amcinonide 51481-61-9, Cimetidine 51781-06-7, Carteolol 52468-60-7, Flunarizine 53164-05-9, Acemetacin 53179-11-6, Loperamide 53230-10-7, Mefloquine 53608-75-6, Pancrelipase 53994-73-3, Cefaclor 54063-53-5, Propafenone 54143-55-4, Flecainide 54182-58-0, Sucralfate 54504-70-0, Etofylline clofibrate 54965-21-8, Albendazole 54965-24-1, Tamoxifen citrate 55268-74-1, Praziquantel 55837-25-7, Buflomedil 55837-27-9, Piretanide 56392-17-7, Metoprolol tartrate 57109-90-7, Dipotassium chlorazepate 57432-61-8, Methylergonovine maleate 58551-69-2, Carboprost tromethamine 59277-89-3, Acyclovir 59865-13-3, Cyclosporine 60166-93-0, Iopamidol 60200-06-8, Clorsulon 61177-45-5, Clavulanate potassium 61563-18-6, Soquinolol 62571-86-2, Captopril 62893-19-0, Cefoperazone 63527-52-6, Cefotaxime 63659-18-7, Betaxolol 64544-07-6, Cefuroxime axetil 65277-42-1, Ketoconazole 65666-07-1, Silymarin 65899-73-2, Tioconazole 66108-95-0, Iohexol 66357-35-5, Ranitidine 66711-21-5, Apraclonidine 66734-13-2, Alclometasone dipropionate 68844-77-9, Astemizole 70458-96-7 72558-82-8, Ceftazidime 74978-16-8, Magaldrate 75330-75-5, Lovastatin 76095-16-4, Enalapril maleate 76420-72-9, Enalaprilat 76470-66-1, Loracarbef 76547-98-3, Lisinopril 76824-35-6, Famotidine 76963-41-2, Nizatidine 78110-38-0, Aztreonam 78266-06-5, Mebrofenin 79350-37-1, Cefixime 81103-11-9, Clarithromycin 83200-10-6, Anipamil 83905-01-5, Azithromycin 85721-33-1, Ciprofloxacin 92665-29-7, Cefprozil 102188-40-9, Acromycin 189752-49-6D, metal complexes 198080-50-1 264875-48-1, Tyrothricin-bethamethasone mixt.
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT 144114-21-6, Retropepsin
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(inhibitors; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

IT 61489-71-2, Menotropin
RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)
(menotrophin; encapsulation of sensitive liq. components into matrix to obtain discrete shelf-stable particles)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Katzen; US 3786123 A 1974 CAPLUS

L26 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 1998:618371 CAPLUS

DN 129:255004

TI Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations, and histidine compositions therefor

IN Thomas, Peter G.

PA Cytos Pharmaceuticals LLC, USA

SO U.S., 10 pp.
CODEN: USXXAM

DT Patent

LA English

IC ICM A01N043-50
ICS C07D233-60

NCL 514399000

CC 1-12 (Pharmacology)
Section cross-reference(s): 62, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5811446	A	19980922	US 1997-839805	19970418
	WO 9847366	A1	19981029	WO 1998-US7319	19980417
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9873583	A1	19981113	AU 1998-73583	19980417
PRAI	US 1997-839805		19970418		
	WO 1998-US7319		19980417		

AB Methods are provided for protecting the eye from degenerative eye conditions by administering prophylactic histidine compns. Also provided are for treating ocular inflammation resulting from various causative agents, by administering therapeutic histidine compns. Further provided are histidine compns. for carrying out the methods.

ST histidine pharmaceutical eye degenerative disease inflammation

IT Ulcer
(Mooren's, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(Terrein's marginal degeneration, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Granulomatous disease
(Wegener's granulomatosis, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Burn
(acid and alkali, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Glycosides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Fibronectins
Vitronectin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(and analogs; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Tear (ocular fluid)
(artificial; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Dysentery
(bacillary, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(blepharitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Acids, biological studies
Bases, biological studies

RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(chem. burn, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(conjunctivitis, allergic and others, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye
(cornea, haze; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye
(cornea, infiltration and thinning, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
Eye, disease
Eye, disease
(cornea, ulcer, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Autoimmune disease
Food allergy
Leukemia
Myasthenia gravis
Psoriasis
Rheumatoid arthritis
Syphilis
(corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Excimer lasers
(corneal procedure; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Antiulcer agents
(corneal ulcer; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Amyloidosis
(corneal; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Cosmetics
(creams; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drugs
(cytoplegics and miotics; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(degeneration; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(dellen, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(diabetic retinopathy; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(emulsions; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Human herpesvirus
(epithelial keratitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Edema
Infection
Lasers
(eye inflammation related to; histidine compns. and methods for ocular

degenerative diseases and inflammations)
IT Cosmetics
(eye liners; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Cosmetics
(eye; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Sexually transmitted diseases
(gonorrhea, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Human herpesvirus 3
(herpes zoster from, keratitis and iridocyclitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Anti-inflammatory agents
Antibacterial agents
Antibiotics
Antiglaucoma agents
Antioxidants
Antiviral agents
Eye, disease
Glaucoma (disease)
Wound healing promoters
(histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Corticosteroids, biological studies
Glycoproteins, general, biological studies
Sulfonamides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Carboxylic acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(hydroxy; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Chlamydia trachomatis
(infection with, trachoma, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Adenoviridae
Arbovirus
Bacteria (Eubacteria)
Borrelia burgdorferi
Corynebacterium diphtheriae
Cytomegalovirus
DNA viruses
Fungi
Haemophilus
Human enterovirus 70
Human herpesvirus 1
Human herpesvirus 2
Human herpesvirus 3
Human herpesvirus 4
Human immunodeficiency virus
Human poliovirus
Influenza virus
Measles virus
Moraxella

Mumps virus
Neisseria gonorrhoeae
Neisseria meningitidis
Papillomavirus
Parasite
Pseudomonas
RNA viruses
Rabies virus
Rhinovirus
Serratia marcescens
Staphylococcus
Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus
(infection, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(injections, i.v.; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(injections, intraocular; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(iridocyclitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(keratitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(keratopathy, calcific band, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Ablation
(laser-assisted photoablative surgical procedure; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(liqs.; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(macula, degeneration, age-related; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Cosmetics
(mascaras; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Angiogenesis
(neovascularization, retinal, laser-treated, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Anti-inflammatory agents
(nonsteroidal; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(ointments, creams; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(ointments, eye; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Surgery
(ophthalmic procedures, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(ophthalmic, ocular inserts; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(ophthalmic; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Drug delivery systems
(oral; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Carboxylic acids, biological studies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oxo; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Artery, disease
(polyarteritis nodosa; corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Radicals, biological studies
RL: ADV (Adverse effect, including toxicity); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(radical-mediated eye disease; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Eye, disease
Eye, disease
Eye, disease
(retina, injury, photic or ischemia-induced; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Eye, disease
(retina, ischemia; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Eye, disease
(retina, neovascularization, laser-treated, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Ischemia
(retinal injury from; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Anti-ischemic agents
(retinal ischemia; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Eye, disease
Eye, disease
(retinitis, cytomegalovirus, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Eye, disease
(scleritis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Drug delivery systems
(solns., i.v.; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Drug delivery systems
(solns., ophthalmic; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Cataract
(surgery, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Drug delivery systems
(suspensions; histidine compns. and methods for ocular degenerative diseases and inflammations)
IT Lupus erythematosus
(systemic, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and

inflammations)

IT Drug delivery systems
(tablets; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Drug delivery systems
(topical; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Injury
(trauma, eye, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Intestine, disease
(ulcerative colitis, corneal disorder from, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye, disease
(uveitis, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Infection
(viral, eye inflammation related to; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT Eye
(vitreous humor, age- or disease-based posterior vitreous detachment; histidine compns. and methods for ocular degenerative diseases and inflammations)

IT 71-00-1, L-Histidine, biological studies 351-50-8, D-Histidine 4998-57-6, Histidine
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations, and histidine compns. therefor)

IT 50-02-2, Dexamethasone 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-81-7, Ascorbic acid, biological studies 51-55-8, Atropine, biological studies 51-83-2, Carbachol 53-03-2, Prednisone 53-86-1, Indomethacin 54-42-2, Idoxuridine 56-75-7, Chloramphenicol **57-47-6**, Physostigmine 59-02-9, .alpha.-Tocopherol 59-42-7, Phenylephrine 59-66-5, Acetazolamide 69-53-4, Ampicillin 70-00-8, Trifluridine 70-18-8, Glutathione, biological studies 92-13-7, Pilocarpine 114-07-8, Erythromycin 127-40-2, Lutein 144-68-3, Zeaxanthin 378-44-9, Betamethasone 426-13-1, Fluorometholone 472-61-7, Astaxanthin 514-78-3, Canthaxanthin 616-91-1, Acetyl cysteine 738-70-5, Trimethoprim 768-94-5, Amantadine 1403-66-3, Gentamycin 1404-90-6, Vancomycin 1405-87-4, Bacitracin 1406-05-9, Penicillin 1406-11-7, Polymyxin 1695-77-8, Spectinomycin 4697-36-3, Carbenicillin 5104-49-4, Flurbiprofen 5536-17-4, Vidarabine 7235-40-7, .beta.-Carotene 7761-88-8, Silver nitrate, biological studies 7783-00-8, Selenious acid 9054-89-1, Superoxide dismutase 11111-12-9, Cephalosporin 13292-46-1, Rifampin 13392-28-4, Rimantadine 13410-01-0, Sodium selenate 15307-86-5, Diclofenac 18323-44-9, Clindamycin 22071-15-4, Ketoprofen 25953-19-9, Cefazolin 26787-78-0, Amoxicillin 26921-17-5, Timolol maleate 30516-87-1, Azidothymidine 32986-56-4, Tobramycin 34787-01-4, Ticarcillin 51481-65-3, Mezlocillin 56272-24-3, Histidine hydrochloride 59277-89-3, Acyclovir 68767-14-6, Loxoprofen 70458-96-7, Norfloxacin 74103-06-3, Ketorolac 82410-32-0, Ganciclovir 82419-36-1, Ofloxacin 82768-44-3 85721-33-1, Ciprofloxacin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(histidine compns. and methods for ocular degenerative diseases and inflammations)

IT 9001-03-0, Carbonic anhydrase 9001-12-1, Collagenase

RL: BSU (Biological study, unclassified); BIOL (Biological study) (inhibitors; histidine compns. and methods for ocular degenerative diseases and inflammations)

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Babizhayev; 1989 CAPLUS

(2) Babizhayev; Biochimica et Biophysica Acta 1989, V1004, P363 CAPLUS

(3) Santen; 1983 CAPLUS

L26 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 1998:293427 CAPLUS

DN 129:8597

TI Embedding and encapsulation of controlled release particles

IN Van Lengerich, Bernhard H.

PA Van Lengerich, Bernhard H., USA

SO PCT Int. Appl., 63 pp.
CODEN: PIXXD2

DT Patent

LA English

IC ICM B29C047-04
ICS B01J013-04; A01N025-26

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 5

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9818610	A1	19980507	WO 1997-US18984	19971027
	W: AU, CA, JP, NO, PL, US				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9749915	A1	19980522	AU 1997-49915	19971027
	AU 744156	B2	20020214		
	EP 935523	A1	19990818	EP 1997-912825	19971027
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002511777	T2	20020416	JP 1998-520558	19971027
	NO 9902036	A	19990428	NO 1999-2036	19990428
PRAI	US 1996-29038P	P	19961028		
	US 1997-52717P	P	19970716		
	WO 1997-US18984	W	19971027		

AB Controlled release, discrete, solid particles which contain an encapsulated and/or embedded component such as a heat sensitive or readily oxidizable pharmaceutically, biol., or nutritionally active component are continuously produced without substantial destruction of the matrix material or encapsulant. A release-rate controlling component is incorporated into the matrix to control the rate of release of the encapsulant from the particles. The addnl. component may be a hydrophobic component or a high water binding capacity component for extending the release time. The plasticizable matrix material, such as starch, is admixed with at least one plasticizer, such as water, and at least one release-rate controlling component under low shear mixing conditions to plasticize the plasticizable material without substantially destroying the at least one plasticizable material and to obtain a substantially homogeneous plasticized mass. The plasticizer content is substantially reduced and the temp. of the plasticized mass is substantially reduced prior to admixing the plasticized mass with the encapsulant to avoid substantial destruction of the encapsulant and to obtain a formable, extrudable mixt. The mixt. is extruded though a die without substantial or essentially no expansion and cut into discrete, relatively dense particles. Release properties may also be controlled by precoating the encapsulant and/or coating the extruded particles with a film-forming component. An example of encapsulation of acetylcysteine is given using starch, polyethylene, glycerol monostearate, and vegetable oil.

ST encapsulation controlled release particle

IT Drug delivery systems
(controlled-release; embedding and encapsulation of controlled release particles)

IT Antitumor agents
Antiviral agents
Encapsulation
(embedding and encapsulation of controlled release particles)

IT Estrogens
Polyoxyalkylenes, biological studies
Tuberculin
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(embedding and encapsulation of controlled release particles)

IT Antibiotics
Antioxidants
Detergents
Emulsifying agents
Extrusion, nonbiological
Fats and Glyceridic oils, biological studies
Fatty acids, biological studies
Flavor
Fungicides
Glass transition
Heat treatment
Herbicides
Hydrocolloids
Insecticides
Lipids, biological studies
Paraffin waxes, biological studies
Peptides, biological studies
Perfumes
Pesticides
Plasticizers
Polyolefins
Polyurethanes, biological studies
Proteins, general, biological studies
Rodenticides
Steroids, biological studies
Surfactants
Waxes
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(embedding and encapsulation of controlled release particles)

IT Antibodies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(monoclonal; embedding and encapsulation of controlled release particles)

IT Drug delivery systems
(particles; embedding and encapsulation of controlled release particles)

IT 50-02-2, Dexamethasone 50-04-4, Cortisone acetate 50-06-6, Phenobarbital, biological studies 50-12-4, Mephenytoin 50-14-6, Ergocalciferol 50-18-0, Cyclophosphamide 50-23-7, Hydrocortisone 50-24-8, Prednisolone 50-27-1, Estriol 50-28-2, Estradiol, biological studies 50-33-9, Phenylbutazone, biological studies 50-36-2, Cocaine 50-41-9, Clomiphene citrate 50-44-2, Mercaptopurine 50-47-5, Desipramine 50-48-6, Amitriptyline 50-49-7, Imipramine 50-52-2, Thioridazine 50-53-3, Chlorpromazine, biological studies 50-54-4, Quinidine sulfate 50-55-5, Reserpine 50-58-8, Phendimetrazine tartrate 50-63-5, Chloroquine phosphate 50-78-2, Acetylsalicylic acid 50-81-7, Ascorbic acid, biological studies 50-96-4, Isoetharine hydrochloride 51-05-8, Procaine hydrochloride 51-15-0, Pralidoxime chloride 51-21-8,

Fluorouracil 51-30-9, Isoproterenol hydrochloride 51-34-3, Scopolamine 51-43-4, Epinephrine 51-48-9, Levothyroxine, biological studies 51-52-5, Propylthiouracil 51-55-8, Atropine, biological studies 51-57-0, Methamphetamine hydrochloride 51-64-9, Dextroamphetamine 51-83-2, Carbachol 51-84-3, Acetylcholine, biological studies 51-98-9, Norethindrone acetate 52-01-7, Spironolactone 52-24-4, Thiotepa 52-49-3, Trihexyphenidyl hydrochloride 52-53-9, Verapamil 52-67-5, Penicillamine 52-68-6, Trichlorfon 52-86-8, Haloperidol 52-89-1, Cysteine hydrochloride 53-03-2, Prednisone 53-16-7, Estrone, biological studies 53-19-0, Mitotane 53-39-4, Oxandrolone 53-60-1, Promazine hydrochloride 53-86-1, Indomethacin 54-21-7, Sodium salicylate 54-31-9, Furosemide 54-36-4, Metyrapone 54-64-8, Thimerosal 54-85-3, Isoniazid 55-03-8, Levothyroxine sodium 55-06-1, Liothyronine sodium 55-63-0, Nitroglycerin 55-98-1, Busulfan 56-29-1, Hexobarbital 56-47-3, Desoxycorticosterone acetate 56-53-1, Diethylstilbestrol 56-54-2, Quinidine 56-75-7, Chloramphenicol 56-84-8, L-Aspartic acid, biological studies 56-87-1, L-Lysine, biological studies 57-13-6, Urea, biological studies 57-22-7, Vincristine 57-33-0, Pentobarbital sodium 57-41-0, Phenytoin 57-42-1, Meperidine 57-43-2, Amobarbital **57-47-6**, Physostigmine 57-53-4, Meprobamate 57-63-6, Ethinyl estradiol 57-66-9, Probenecid 57-68-1, Sulfamethazine 57-83-0, Progesterone, biological studies 57-92-1, Streptomycin, biological studies 57-96-5, Sulfinpyrazone 58-00-4, Apomorphine 58-08-2, Caffeine, biological studies 58-14-0, Pyrimethamine 58-18-4, Methyltestosterone 58-22-0 58-25-3, Chlordiazepoxide 58-27-5, Menadione 58-32-2, Dipyridamole 58-33-3, Promethazine hydrochloride 58-38-8, Prochlorperazine 58-39-9, Perphenazine 58-40-2, Promazine 58-54-8, Ethacrynic acid 58-55-9, Theophylline, biological studies 58-56-0, Pyridoxine hydrochloride 58-85-5, Biotin 58-89-9, Lindane 58-93-5, Hydrochlorothiazide 58-94-6, Chlorothiazide 59-05-2, Methotrexate 59-30-3, Folic acid, biological studies 59-33-6, Pyrilamine maleate 59-43-8, Thiamin, biological studies 59-52-9, Dimercaprol 59-63-2, Isocarboxazid 59-66-5, Acetazolamide 59-67-6, Niacin, biological studies 59-92-7, Levodopa, biological studies 60-13-9, Amphetamine sulfate 60-18-4, Tyrosine, biological studies 60-54-8, Tetracycline 60-56-0, Methimazole 60-80-0, Antipyrine 60-87-7, Promethazine 60-99-1, Levomepromazine 61-00-7, Acepromazine 61-25-6, Papaverine hydrochloride 61-68-7, Mefenamic acid 61-76-7, Phenylephrine hydrochloride 61-90-5, Leucine, biological studies 62-31-7, Dopamine hydrochloride 62-44-2, Phenacetin 62-67-9, Nalorphine 62-90-8, Nandrolone phenpropionate 63-68-3, Methionine, biological studies 63-91-2, Phenylalanine, biological studies 63-92-3, Phenoxybenzamine hydrochloride 63-98-9, Phenacemide 64-31-3, Morphine sulfate 64-72-2, Chlortetracycline hydrochloride 64-77-7, Tolbutamide 64-86-8, Colchicine 65-45-2, Salicylamide 66-76-2, Dicoumarol 67-03-8, Thiamine hydrochloride 67-20-9, Nitrofurantoin 67-45-8, Furazolidone 67-73-2, Fluocinolone acetonide 67-96-9, Dihydrotachysterol 67-97-0, Cholecalciferol 68-19-9, Cyanocobalamin 68-22-4, Norethindrone 68-35-9, Sulfadiazine 68-41-7, Cycloserine 68-89-3, Metamizole 69-23-8, Fluphenazine 69-44-3, Amodiaquine hydrochloride 69-53-4, Ampicillin 69-72-7, Salicylic acid, biological studies 71-00-1, Histidine, biological studies 71-58-9, Medroxyprogesterone acetate 71-63-6, Digitoxin 71-68-1, Hydromorphone hydrochloride 71-81-8 72-14-0, Sulfathiazole 72-17-3, Sodium lactate 72-18-4, Valine, biological studies 72-19-5, L-Threonine, biological studies 72-33-3, Mestranol 72-63-9, Methandrostenolone 73-22-3, L-Tryptophan, biological studies 73-48-3, Bendroflumethiazide 76-38-0, Methoxyflurane 76-42-6, Oxycodone 76-43-7, Fluoxymesterone 76-57-3, Codeine 77-09-8 77-19-0, Dicyclomine 77-21-4, Glutethimide 77-26-9, Butalbital 77-27-0, Thiamylal 77-36-1, Chlorthalidone 77-41-8, Methsuximide 78-44-4, Carisoprodol 79-57-2, Oxytetracycline

80-08-0, Dapsone 80-13-7, Halazone 80-53-5, Terpin 81-07-2, Saccharin 81-13-0, Dexpanthenol 81-23-2, Dehydrocholic acid 81-81-2, Warfarin 83-43-2, Methylprednisolone 83-73-8, Iodoquinol 83-88-5, Riboflavin, biological studies 84-02-6, Prochlorperazine maleate 84-17-3, Dienestrol 84-22-0, Tetrahydrozoline 84-80-0, Phytonadione 85-79-0, Dibucaine 86-35-1, Ethotoin 87-00-3, Homatropine 87-08-1, Phenoxymethylpenicillin 87-33-2, ISDN 89-57-6, 5-Aminosalicylic acid 90-33-5, Hymecromone 90-34-6, Primaquine 91-33-8, Benzthiazide 91-81-6, Tripelennamine 92-13-7, Pilocarpine 93-14-1, Guaifenesin 94-09-7, Benzocaine 94-20-2, Chlorpropamide 95-25-0, Chlorzoxazone 97-53-0, Eugenol 97-77-8, Disulfiram 98-96-4, Pyrazinamide 99-66-1, Valproic acid 100-97-0, biological studies 101-26-8, Pyridostigmine bromide 101-31-5, Hyoscyamine 102-76-1, Triacetin 103-16-2, Monobenzone 103-86-6, Hydroxyamphetamine 103-90-2, Acetaminophen 104-28-9, Cinoxate 104-31-4, Benzonatate 107-43-7, Betaine 108-46-3, 1,3-Benzenediol, biological studies 110-85-0, Piperazine, biological studies 110-94-1, Pentanedioic acid 113-18-8, Ethchlorvynol 113-52-0, Imipramine hydrochloride 113-59-7, Chlorprothixene 113-92-8, Chlorpheniramine maleate 114-07-8, Erythromycin 114-80-7, Neostigmine bromide 115-38-8, Mephobarbital 115-77-5, biological studies 120-97-8, Dichlorphenamide 121-25-5, Amprolium 121-54-0
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(embedding and encapsulation of controlled release particles)

IT 121-75-5, Malathion 123-31-9, 1,4-Benzenediol, biological studies 124-90-3, Oxycodone hydrochloride 124-94-7, Triamcinolone 125-28-0, Dihydrocodeine 125-33-7, Primidone 125-71-3, Dextromethorphan 125-72-4, Levorphanol tartrate 126-07-8, Griseofulvin 127-07-1, Hydroxyurea 127-33-3, Demeclocycline 127-48-0, Trimethadione 127-69-5, Sulfisoxazole 127-79-7, Sulfamerazine 128-44-9, Saccharin sodium 128-46-1, Dihydrostreptomycin 128-49-4, Docusate calcium 128-62-1, Noscapine 129-20-4, Oxyphenbutazone 129-49-7, Methysergide maleate 129-51-1, Ergonovine maleate 130-26-7, Clioquinol 130-61-0, Thioridazine hydrochloride 131-13-5 131-57-7, Oxybenzone 132-17-2 132-92-3, Methicillin sodium 133-58-4, Nitromersol 133-67-5, Trichlormethiazide 134-03-2, Sodium ascorbate 134-80-5, Diethylpropion hydrochloride 135-07-9 135-09-1, Hydroflumethiazide 136-40-3, Phenazopyridine hydrochloride 136-47-0 136-77-6, Hexylresorcinol 137-58-6, Lidocaine 141-01-5, Ferrous fumarate 143-71-5, Hydrocodone bitartrate 143-81-7, Butabarbital sodium 144-14-9, Anileridine 144-48-9, Iodoacetamide 144-55-8, Sodium bicarbonate, biological studies 144-80-9, Sulfacetamide 144-82-1, Sulfamethizole 144-83-2, Sulfapyridine 146-22-5, Nitrazepam 146-54-3, Triflupromazine 147-24-0, Diphenhydramine hydrochloride 147-52-4, Nafcillin 147-85-3, Proline, biological studies 148-79-8 148-82-3, Melphalan 151-67-7, Halothane 152-62-5, Dydrogesterone 152-97-6, Fluocortolone 154-41-6, Phenylpropanolamine hydrochloride 154-42-7, Thioguanine 156-51-4, Phenelzine sulfate 297-76-7, Ethynodiol diacetate 298-46-4, Carbamazepine 298-50-0, Propantheline 298-57-7, Cinnarizine 298-59-9, Methylphenidate hydrochloride 298-81-7, Methoxsalen 299-27-4, Potassium gluconate 299-29-6, Ferrous gluconate 299-42-3, Ephedrin 302-22-7, Chlormadinone acetate 302-79-4, Tretinoin 303-25-3, Cyclizine hydrochloride 304-20-1, Hydralazine hydrochloride 304-59-6, Potassium sodium tartrate, biological studies 305-03-3, Chlorambucil 309-43-3, Secobarbital sodium 315-30-0, Allopurinol 317-34-0, Aminophylline 318-98-9 329-65-7, 1,2-Benzenediol, 4-[1-hydroxy-2-(methylamino)ethyl]- 343-55-5, Dicloxacillin sodium 345-78-8, Pseudoephedrine hydrochloride 346-18-9, Polythiazide 356-12-7, Fluocinonide 357-07-3, Oxymorphone hydrochloride 359-83-1, Pentazocine 360-70-3, Nandrolone decanoate 364-62-5, Metoclopramide 364-98-7, Diazoxide 366-70-1, Procarbazine hydrochloride 378-44-9, Betamethasone 379-79-3, Ergotamine tartrate 382-67-2, Desoximetasone

389-08-2, Nalidixic acid 390-64-7, Prenylamine 396-01-0, Triamterene
426-13-1, Fluorometholone 434-07-1, Oxymetholone 435-97-2,
Phenprocoumon 437-74-1, Xantinol nicotinate 439-14-5, Diazepam
440-17-5, Trifluoperazine hydrochloride 443-48-1, Metronidazole
446-86-6, Azathioprine 465-65-6, Naloxone 466-99-9, Hydromorphone
471-34-1, Calcium carbonate, biological studies 474-86-2, Equilin
479-18-5, Dyphylline 484-23-1, Dihydralazine 486-12-4, Triprolidine
511-12-6, Dihydroergotamine 514-36-3, Fludrocortisone acetate
514-65-8, Biperiden 518-47-8, Fluorescein sodium 519-37-9, Etofylline
520-85-4, Medroxyprogesterone 523-87-5, Dimenhydrinate 525-66-6,
Propranolol 527-07-1, Sodium gluconate 532-03-6, Methocarbamol
533-45-9, Clomethiazole 536-21-0, Norfenefrine 536-33-4, Ethionamide
541-15-1, Levocarnitine 546-88-3, Acetohydroxamic acid 546-93-0,
Magnesium carbonate 548-62-9, Gentian violet 548-73-2, Droperidol
549-18-8, Amitriptyline hydrochloride 550-83-4, Propoxycaine
hydrochloride 551-27-9, Propicillin 552-94-3, Salsalate 554-13-2,
Lithium carbonate 554-57-4, Methazolamide 554-92-7, Trimethobenzamide
hydrochloride 555-30-6, Methyldopa 557-34-6, Zinc acetate 562-10-7
564-25-0, Doxycycline 577-11-7, Docusate sodium 579-56-6, Isoxsuprine
hydrochloride 587-61-1, Propyliodone 590-63-6, Bethanechol chloride
595-33-5, Megestrol acetate 596-51-0, Glycopyrrolate 599-79-1,
Sulfasalazine 599-88-2, Sulfaperin 603-50-9, Bisacodyl 604-75-1,
Oxazepam 614-39-1, Procainamide hydrochloride 616-91-1, Acetylcysteine
620-61-1, Hyoscyamine sulfate 630-56-8, Hydroxyprogesterone caproate
637-07-0, Clofibrate 637-58-1, Pramoxine hydrochloride 638-23-3
642-78-4, Cloxacillin sodium 651-06-9, Sulfamethoxydiazine 652-67-5
672-87-7, Metyrosine 709-55-7, Etilefrine 721-50-6, Prilocaine
723-46-6, Sulfamethoxazole 738-70-5, Trimethoprim 745-65-3,
Alprostadil 747-36-4, Hydroxychloroquine sulfate 768-94-5, Amantadine
777-11-7, Haloprogin 797-63-7, Levonorgestrel 826-39-1, Mecamylamine
hydrochloride 846-49-1, Lorazepam 846-50-4, Temazepam 859-18-7,
Lincomycin hydrochloride 865-21-4, Vinblastine 894-71-3, Nortriptyline
hydrochloride 968-81-0, Acetohexamide 968-93-4, Testolacton
969-33-5, Cyproheptadine hydrochloride 985-16-0, Nafcillin sodium
1069-66-5, Sodium valproate 1070-11-7, Ethambutol hydrochloride
1077-28-7, Thioctic acid 1094-08-2, Ethopropazine hydrochloride
1095-90-5, Methadone hydrochloride 1098-97-1, Pyritinol 1104-22-9,
Meclizine hydrochloride 1134-47-0, Baclofen 1143-38-0, Anthralin
1151-11-7, Ipodate calcium 1156-19-0, Tolazamide 1173-88-2, Oxacillin
sodium 1197-21-3, Phentermine hydrochloride 1221-56-3, Ipodate sodium
1225-55-4, Protriptyline hydrochloride 1229-29-4, Doxepin hydrochloride
1247-42-3, Meprednisone 1263-89-4, Paromomycin sulfate 1309-48-4,
Magnesium oxide, biological studies 1319-82-0, Aminocaproic acid
1321-23-9, Chloroxylenol 1343-97-1, Selenium sulfate 1393-48-2,
Thiostrepton 1400-61-9, Nystatin 1403-17-4, Candicidin 1403-66-3,
Gentamicin 1404-00-8, Mitomycin 1404-04-2, Neomycin 1404-88-2,
Tyrothricin 1404-93-9, Vancomycin hydrochloride 1405-10-3, Neomycin
sulfate 1405-20-5, Polymyxin b sulfate 1405-87-4, Bacitracin
1405-97-6, Gramicidin 1406-05-9, Penicillin 1420-55-9,
Thiethylperazine 1476-53-5, Novobiocin sodium 1492-18-8, Leucovorin
calcium 1508-65-2, Oxybutynin chloride 1508-75-4, Tropicamide
1508-76-5, Procyclidine hydrochloride 1524-88-5, Flurandrenolide
1597-82-6, Paramethasone acetate 1617-90-9, Vincamine 1622-61-3,
Clonazepam 1622-62-4, Flunitrazepam 1639-60-7, Propoxyphene
hydrochloride 1649-18-9, Azaperone 1668-19-5, Doxepin 1707-14-8,
Phenmetrazine hydrochloride 1808-12-4, Bromodiphenhydramine
hydrochloride 1812-30-2, Bromazepam 1897-96-7, Lonetil 1972-08-3,
Dronabinol 1977-10-2, Loxapine 1982-37-2, Methdilazine 2013-58-3,
Meclocycline
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic
use); BIOL (Biological study); PROC (Process); USES (Uses)
(embedding and encapsulation of controlled release particles)

IT 2022-85-7, Flucytosine 2030-63-9, Clofazimine 2062-78-4, Pimozide 2098-66-0, Cyproterone 2179-37-5, Bencyclane 2192-20-3, Hydroxyzine hydrochloride 2315-02-8, Oxymetazoline hydrochloride 2398-96-1, Tolnaftate 2438-32-6, Dexchlorpheniramine maleate 2447-57-6, Sulfadoxine 2589-47-1, Prajmalium bitartrate, biological studies 2609-46-3, Amiloride 2709-56-0, Flupentixol 2898-12-6, Medazepam 2955-38-6, Prazepam 2998-57-4, Estramustine 3313-26-6, Thiothixene 3385-03-3, Flunisolide 3485-14-1, Cyclacillin 3485-62-9, Clidinium bromide 3486-35-9, Zinc carbonate 3505-38-2, Carbinoxamine maleate 3546-41-6, Pyrvinium pamoate 3572-43-8, Bromhexine 3575-80-2, Melperone 3625-06-7, Mebeverine 3632-91-5, Magnesium gluconate 3778-73-2, Ifosfamide 3810-80-8, Diphenoxylate hydrochloride 3902-71-4, Trioxsalen 3930-20-9, Sotalol 3963-95-9, Methacycline hydrochloride 3978-86-7, Azatadine maleate 4205-90-7, Clonidine 4205-91-8, Clonidine hydrochloride 4330-99-8, Trimeprazine tartrate 4468-02-4, Zinc gluconate 4498-32-2, Dibenzepine 4499-40-5, Oxtriphylline, biological studies 4697-36-3, Carbenicillin 4759-48-2, Isotretinoin 5051-62-7, Guanabenz 5104-49-4, Flurbiprofen 5321-32-4, Hetacillin potassium 5355-48-6 5370-01-4, Mexiletine hydrochloride 5534-09-8, Beclomethasone dipropionate 5536-17-4, Vidarabine 5636-83-9, Dimetindene 5638-76-6, Betahistine 5874-97-5, Metaproterenol sulfate 5875-06-9, Proparacaine hydrochloride 5987-82-6, Benoxinate hydrochloride 6202-23-9, Cyclobenzaprine hydrochloride 6284-40-8, Meglumine 6385-02-0, Meclofenamate sodium 6452-73-9, Oxprenolol hydrochloride 6493-05-6, Pentoxifylline 6533-00-2, Norgestrel 6805-41-0, Aescin 6890-40-0, Histamine phosphate 7054-25-3, Quinidine gluconate 7195-27-9, Mefruside 7235-40-7, .beta.-Carotene 7246-21-1, Tyropanoate sodium 7280-37-7, Estropipate 7297-25-8, Erythrityl tetranitrate 7414-83-7, Etidronate disodium 7439-95-4D, Magnesium, salts, biological studies 7439-96-5, Manganese, biological studies 7439-96-5D, Manganese, salts, biological studies 7440-39-3, Barium, biological studies 7440-69-9, Bismuth, biological studies 7440-70-2, Calcium, biological studies 7447-40-7, Potassium chloride (KCl), biological studies 7491-74-9, Piracetam 7553-56-2, Iodine, biological studies 7632-00-0, Sodium nitrite 7646-85-7, Zinc chloride, biological studies 7681-11-0, Potassium iodide (KI), biological studies 7681-49-4, Sodium fluoride, biological studies 7681-82-5, Sodium iodide, biological studies 7681-93-8, Natamycin 7693-13-2, Calcium citrate 7720-78-7, Ferrous sulfate 7778-49-6, Potassium citrate 7783-00-8, Selenious acid 7786-30-3, Magnesium chloride, biological studies 8017-57-0, Trisulfapyrimidine 8024-48-4, Casanthranol 8049-47-6, Pancreatin 8050-81-5, Simethicone 8065-29-0, Liotrix 8067-24-1, Ergoloid mesylates 9001-01-8, Kallidinogenase 9001-73-4, Papain 9002-07-7, Trypsin 9002-60-2, Corticotropin, biological studies 9002-61-3, Chorionic gonadotropin 9002-86-2, Pvc 9002-89-5, Polyvinyl alcohol 9003-20-7, Polyvinyl acetate 9003-39-8, Pvp 9003-97-8, Polycarbophil 9004-07-3, Chymotrypsin 9004-10-8, Insulin, biological studies 9004-32-4, Carboxymethylcellulose 9004-34-6D, Cellulose, esters and ethers, biological studies 9004-53-9, Dextrin 9004-70-0, Pyroxylin 9005-25-8, Starch, biological studies 9005-80-5, Inulin 9008-05-3, Histoplasmin 10025-73-7, Chromic chloride 10040-45-6, Sodium picosulfate 10238-21-8, Glibenclamide 10246-75-0, Hydroxyzine pamoate 10262-69-8, Maprotiline 10347-81-6, Maprotiline hydrochloride 10379-14-3, Tetrazepam 10418-03-8, Stanozolol 10540-29-1, Tamoxifen 11000-17-2, Vasopressin 12125-02-9, Ammonium chloride, biological studies 12619-70-4, Cyclodextrin 12622-73-0, Coccidioidin 12633-72-6, Amphotericin 12650-69-0, Mupirocin 13009-99-9, Mafenide acetate 13042-18-7, Fendiline 13292-46-1, Rifampin 13311-84-7, Flutamide 13392-18-2, Fenoterol 13422-51-0, Hydroxocobalamin 13463-67-7, Titanium dioxide, biological studies 13523-86-9, Pindolol 13614-98-7, Minocycline hydrochloride 13682-92-3, Dihydroxyaluminum aminoacetate 14009-24-6, Drotaverine 14028-44-5,

Amoxapine 14779-78-3, Padimate 14976-57-9, Clemastine fumarate 15078-28-1, Nitroprusside 15307-86-5, Diclofenac 15622-65-8, Molindone hydrochloride 15663-27-1, Cisplatin 15676-16-1, Sulpiride 15686-51-8, Clemastine 15686-71-2, Cephalexin 15687-27-1 15687-41-9, Oxyfedrine 16482-55-6, Dihydroxyaluminum sodium carbonate 16595-80-5, Levamisole hydrochloride 16662-47-8, Gallopamil 17140-78-2, Propoxyphene napsylate 17230-88-5, Danazol 17560-51-9, Metolazone 17617-23-1, Flurazepam 18378-89-7, Plicamycin 18559-94-9, Salbutamol 19216-56-9, Prazosin 19237-84-4, Prazosin hydrochloride 19356-17-3, Calcifediol 20830-75-5, Digoxin 21462-39-5, Clindamycin hydrochloride 21738-42-1, Oxamniquine 21829-25-4, Nifedipine 22059-60-5, Disopyramide phosphate 22071-15-4, Ketoprofen 22195-34-2, Guanadrelsulfate 22204-24-6, Pyrantel pamoate 22204-53-1, Naproxen 22232-71-9, Mazindol 22260-51-1, Bromocriptine mesylate 22316-47-8, Clobazam 22494-42-4 22916-47-8 23031-25-6, Terbutaline 23031-32-5, Terbutaline sulfate 23214-92-8, Doxorubicin 23288-49-5, Probucol 23593-75-1, Clotrimazole 23869-24-1, O-(.beta.-Hydroxyethyl)-rutoside 24219-97-4, Mianserin 24390-14-5, Doxycycline hyclate 24729-96-2, Clindamycin phosphate 25046-79-1, Glisoxepide 25086-89-9, Vinyl acetate-N-vinylpyrrolidinone copolymer 25155-18-4, Methylbenzethonium chloride 25167-80-0, Chlorophenol 25301-02-4, Tyloxapol 25322-68-3 25332-39-2, Trazodone hydrochloride 25389-94-0, Kanamycin sulfate 25614-03-3, Bromocriptine 25655-41-8, Povidone iodine 25717-80-0, Molsidomine 25812-30-0, Gemfibrozil 25953-19-9, Cefazolin 26027-38-3, Nonoxynol 9 26171-23-3, Tolmetin 26652-09-5, Ritodrine 26675-46-7, Isoflurane 26787-78-0, Amoxicillin 26807-65-8, Indapamide 26839-75-8, Timolol 26944-48-9, Glibornuride 27203-92-5, Tramadol 27823-62-7, Chlortetracycline bisulfate 28088-64-4, Aminosalicylic acid 28395-03-1, Bumetanide 28657-80-9, Cinoxacin 28797-61-7, Pirenzepine 28860-95-9, Carbidopa 28911-01-5, Triazolam 28981-97-7, Alprazolam 29122-68-7, Atenolol 29679-58-1, Fenoprofen 30578-37-1, Amezinium metilsulfate 30685-43-9, Metildigoxin 31329-57-4, Naftidrofuryl 31431-39-7, Mebendazole 31637-97-5, Etofibrate 31828-71-4, Mexiletine 32672-69-8, Mesoridazine besylate 32780-64-6, Labetalol hydrochloride 32887-01-7, Amdinocillin 33005-95-7, Tiaprofenic acid 33286-22-5, Diltiazem hydrochloride 33402-03-8, Metaraminol bitartrate 33419-42-0 33996-33-7, Oxaceprol 34031-32-8, Auranofin 34183-22-7, Propafenone hydrochloride 34552-83-5, Loperamide hydrochloride 34580-13-7, Ketotifen
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(embedding and encapsulation of controlled release particles)

IT 34787-01-4, Ticarcillin 36322-90-4, Piroxicam 36688-78-5 36791-04-5 37270-89-6, Heparin calcium 37517-28-5, Amikacin 37517-30-9, Acebutolol 38194-50-2, Sulindac 38260-01-4, Trientine hydrochloride 38304-91-5, Minoxidil 38363-40-5, Penbutolol 38396-39-3, Bupivacaine 38821-53-3, Cephradine 39562-70-4, Nitrendipine 40828-46-4, Suprofen 41859-67-0, Bezafibrate 42200-33-9, Nadolol 42399-41-7, Diltiazem 42540-40-9, Cefamandole nafate 49562-28-9, Fenofibrate 49745-95-1, Dobutamine hydrochloride 50370-12-2, Cefadroxil 50679-08-8, Terfenadine 50925-79-6, Colestipol 50972-17-3, Bacampicillin 51022-69-6, Amcinonide 51481-61-9, Cimetidine 51781-06-7, Carteolol 52468-60-7, Flunarizine 53164-05-9, Acemetacin 53179-11-6, Loperamide 53230-10-7, Mefloquine 53608-75-6, Pancrelipase 53994-73-3, Cefaclor 54063-53-5, Propafenone 54143-55-4, Flecainide 54182-58-0, Sucralfate 54965-21-8, Albendazole 54965-24-1, Tamoxifen citrate 55268-74-1, Praziquantel 55837-25-7, Buflomedil 55837-27-9, Piretanide 56392-17-7, Metoprolol tartrate 57109-90-7, Dipotassium chlorazepate 57432-61-8, Methylergonovine maleate 57435-86-6, Premazepam 58551-69-2, Carboprost tromethamine 59277-89-3, Acyclovir 59865-13-3, Cyclosporine 60166-93-0, Iopamidol 60200-06-8, Clorsulon 60833-22-9, Pyridoxal 5'-phosphate glutamate 61177-45-5, Clavulanate potassium

61489-71-2, Menotropin 61563-18-6, Soquinolol 62571-86-2, Captopril
62893-19-0, Cefoperazone 63527-52-6, Cefotaxime 63659-18-7, Betaxolol
64024-15-3, Pentazocine hydrochloride 64544-07-6, Cefuroxime axetil
65277-42-1, Ketoconazole 65666-07-1, Silymarin 65899-73-2, Tioconazole
66108-95-0, Iohexol 66357-35-5, Ranitidine 66711-21-5, Apraclonidine
66734-13-2, Alclometasone dipropionate 68844-77-9, Astemizole
70458-96-7, Norfloxacin 72558-82-8, Ceftazidime 74978-16-8, Magaldrate
75330-75-5, Lovastatin 76095-16-4, Enalapril maleate 76420-72-9,
Enalaprilat 76470-66-1, Loracarbef 76547-98-3, Lisinopril
76824-35-6, Famotidine 76963-41-2, Nizatidine 78110-38-0, Aztreonam
78266-06-5, Mebrofenin 79350-37-1, Cefixime 81103-11-9, Clarithromycin
83200-10-6, Anipamil 83905-01-5, Azithromycin 85721-33-1,
Ciprofloxacin 92665-29-7, Cefprozil 102188-40-9, Acromycin
150977-36-9, Bromelain
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(embedding and encapsulation of controlled release particles)

IT 9001-92-7, Protease
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors, HIV; embedding and encapsulation of controlled release particles)

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Carr; US 5183690 A 1993 CAPLUS
(2) Chan; US 5075058 A 1991
(3) Katzen; US 3786123 A 1974 CAPLUS
(4) Katzen; US 3962416 A 1976 CAPLUS
(5) McMahon; US 5466460 A 1995 CAPLUS

L26 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2003 ACS

AN 1997:440981 CAPLUS
DN 127:144786

TI Rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochemical and other agents

AU Lentz, Thomas L.; Fu, Yiguang; Lewis, Peter
CS Dep. Cell Biol., Yale Univ. School Med., New Haven, CT, 06520-8002, USA

SO Antiviral Research (1997), 35(1), 29-39
CODEN: ARSRDR; ISSN: 0166-3542
PB Elsevier
DT Journal
LA English
CC 1-5 (Pharmacology)
Section cross-reference(s): 14, 15

AB IMR-32 human neuroblastoma cells are a continuous nerve cell line expressing neuronal nicotine acetylcholine receptors. These cells were susceptible to infection by rabies virus (CVS strain). After infection, viral antigen accumulated in the cell body in puncta and larger masses and spread out into the processes until at 3-4 days the entire cell was filled with antigen and lysed. A variety of chem. agents including cholinergic agonists and antagonists were tested for ability to inhibit infection of IMR-32 cells in a fluorescent focus assay. Agents found to inhibit infection were antibodies against the viral glycoprotein, gangliosides, a synthetic peptide of the neurotoxin-binding site of Torpedo acetylcholine receptor .alpha.1 subunit, .alpha.-bungarotoxin, and lysosomotropic agents. All other agents tested including other cholinergic ligands and synthetic peptides were not effective. Except for lysosomotropic agents, the agents which inhibited infection also inhibited attachment of virus to the cell surface. These results indicate that IMR-32 cells are a useful model in studying the interaction of a neurotropic virus with human neurons. The ability of .alpha.-bungarotoxin to inhibit infection suggests that neuronal .alpha.-bungarotoxin-binding receptors might serve as central nervous system receptors for rabies virus.

ST rabies virus infection IMR32 neuroblastoma **antiviral**; neuron
rabies virus infection **antiviral** agent; nicotinic receptor
rabies virus infection **antiviral**

IT Animal cell line
(IMR-32; rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochem. and other agents in relation to role of nicotinic receptors)

IT Venoms
(King Cobra, neurotoxin of; rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochem. and other agents in relation to role of nicotinic receptors)

IT Cholinergic receptors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Torpedo; rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochem. and other agents in relation to role of nicotinic receptors)

IT Torpedo (fish)
(acetylcholine receptor; rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochem. and other agents in relation to role of nicotinic receptors)

IT Nerve
(neuron; rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochem. and other agents in relation to role of nicotinic receptors)

IT Toxins
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(neurotoxins, of King Cobra venom; rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochem. and other agents in relation to role of nicotinic receptors)

IT Gangliosides
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(of brain; rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochem. and other agents in relation to role of nicotinic receptors)

IT Glycoproteins, general, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(of rabies virus, antibodies to; rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochem. and other agents in relation to role of nicotinic receptors)

IT **Antiviral** agents
Cholinergic agonists
Cholinergic antagonists
Disease models
Rabies virus
(rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochem. and other agents in relation to role of nicotinic receptors)

IT GABA receptors
Glycine receptors
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochem. and other agents in relation to role of nicotinic receptors)

IT Nicotinic receptors

RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochem. and other agents in relation to role of nicotinic receptors)

IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(to rabies virus glycoprotein; rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochem. and other agents in relation to role of nicotinic receptors)

IT Lysosome
(tropic agents; rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochem. and other agents in relation to role of nicotinic receptors)

IT 51-55-8, Atropine, biological studies 51-83-2, Carbamylcholine chloride 54-05-7, Chloroquine **57-47-6**, Eserine 57-94-3, d-Tubocurarine chloride 65-31-6 130-95-0 485-35-8, Cytisine 2609-46-3, Amiloride 9007-92-5, Glucagon, biological studies 11032-79-4, .alpha.-Bungarotoxin 12125-02-9, Ammonium chloride, biological studies 21019-30-7, Methyllycaconitine 64285-06-9, Anatoxin-a
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(rabies virus infection of IMR-32 human neuroblastoma cells and effect of neurochem. and other agents in relation to role of nicotinic receptors)

=> d his

(FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003)

FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003

		E	STRVUDINE
L1	0	S	STRVUDINE
L2	0	S	D4T
		E	D4T
L3	5	S	STAVUDINE
L4	42	S	PARAOXON
L5	0	S	PHYOSTIGMINE
L6	0	S	PHYOSTIGMINE
L7	54	S	PHYSOSTIGMINE

FILE 'CAPLUS' ENTERED AT 16:36:06 ON 27 MAY 2003

L8	1300	S	L3
L9	2913	S	L4
L10	4718	S	L7
		E	HIV
L11	50075	S	E3 OR E7
		E	HERPES
L12	21343	S	E3
L13	17244	S	HHV OR HSV OR HCMV OR CMV
L14	29657	S	L12 OR L13
L15	7547	S	PHOSPHATE ESTER
L16	2	S	L8 AND L15
		E	ESTER
L17	518186	S	E3
L18	2414368	S	S
L19	54	S	L17 AND L8
L20	3	S	L9 AND L11

```
L21             0 S L9 AND L14
L22             2 S L10 AND L11
L23             1 S L10 AND L14
                  E ANTIVIRAL
L24         38629 S E3-E9
L25             2 S L24 AND L9
L26             8 S L10 AND L24

=> s l8 and l9
L27           1 L8 AND L9

=>

=> d l27

L27  ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2003 ACS
AN   2001:454452  CAPLUS
DN   135:313108
TI   In vivo pharmacokinetics and metabolism of anti-human immunodeficiency
     virus agent d4T-5'-[P-bromophenyl methoxyalaninyl phosphate] (sampidine)
     in mice
AU   Chen, Chun-Lin; Venkatachalam, T. K.; Zhu, Zhao-Hai; Uckun, Fatih M.
CS   Drug Discovery Program, Department of Pharmaceutical Sciences, Parker
     Hughes Institute, St. Paul, MN, 55113, USA
SO   Drug Metabolism and Disposition (2001), 29(7), 1035-1041
     CODEN: DMDSAI; ISSN: 0090-9556
PB   American Society for Pharmacology and Experimental Therapeutics
DT   Journal
LA   English
RE.CNT  30    THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s l8 and l10
L28           5 L8 AND L10

=> d l28 1-5

L28  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2003 ACS
AN   2001:454452  CAPLUS
DN   135:313108
TI   In vivo pharmacokinetics and metabolism of anti-human immunodeficiency
     virus agent d4T-5'-[P-bromophenyl methoxyalaninyl phosphate] (sampidine)
     in mice
AU   Chen, Chun-Lin; Venkatachalam, T. K.; Zhu, Zhao-Hai; Uckun, Fatih M.
CS   Drug Discovery Program, Department of Pharmaceutical Sciences, Parker
     Hughes Institute, St. Paul, MN, 55113, USA
SO   Drug Metabolism and Disposition (2001), 29(7), 1035-1041
     CODEN: DMDSAI; ISSN: 0090-9556
PB   American Society for Pharmacology and Experimental Therapeutics
DT   Journal
LA   English
RE.CNT  30    THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28  ANSWER 2 OF 5  CAPLUS  COPYRIGHT 2003 ACS
AN   2001:396644  CAPLUS
DN   135:24671
TI   Solid carriers for improved delivery of active ingredients in
     pharmaceutical compositions
IN   Patel, Manesh V.; Chen, Feng-jing
PA   Lipocine, Inc., USA
```

SO PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 7

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001037808	A1	20010531	WO 2000-US32255	20001122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6248363	B1	20010619	US 1999-447690	19991123
EP 1233756	A1	20020828	EP 2000-980761	20001122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRAI US 1999-447690 A 19991123
WO 2000-US32255 W 20001122
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 2001:300514 CAPLUS
DN 134:331617
TI Oil-in-water emulsion compositions for polyfunctional active ingredients
IN Chen, Feng-jing; Patel, Mahesh V.
PA Lipocine, Inc., USA
SO PCT Int. Appl., 82 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001028555	A1	20010426	WO 2000-US28835	20001018
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002107265	A1	20020808	US 1999-420159	19991018

PRAI US 1999-420159 A 19991018
RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 2001:136991 CAPLUS
DN 134:198075
TI Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
IN Patel, Mahesh V.; Chen, Feng-Jing
PA Lipocine, Inc., USA
SO PCT Int. Appl., 113 pp.

CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 7

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001012155	A1	20010222	WO 2000-US18807	20000710
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6309663	B1	20011030	US 1999-375636	19990817
	EP 1210063	A1	20020605	EP 2000-947184	20000710
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003506476	T2	20030218	JP 2001-516502	20000710
	US 2001024658	A1	20010927	US 2000-751968	20001229
	US 6458383	B2	20021001		
PRAI	US 1999-375636	A	19990817		
	WO 2000-US18807	W	20000710		

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L28 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS
AN 2000:725436 CAPLUS
DN 133:301171
TI Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
IN Chen, Feng-jing; Patel, Manesh V.
PA Lipocine, Inc., USA
SO PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000059475	A1	20001012	WO 2000-US7342	20000316
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6383471	B1	20020507	US 1999-287043	19990406
	EP 1165048	A1	20020102	EP 2000-916547	20000316
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1999-287043	A	19990406		
	WO 2000-US7342	W	20000316		

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s l9 and l10
L29 152 L9 AND L10

=> d l29 100-152

L29 ANSWER 100 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1975:597775 CAPLUS
DN 83:197775
TI Germ content of some pharmaceuticals for eye medication preparation
AU Mengert, Ch.; Weiss, H.
CS Gesundheitswes. Gotha, Staatl. Tenneberg-Apotheke, Waltershausen, Ger. Dem. Rep.
SO Pharmazeutische Praxis (1975), (8), 177-80
CODEN: PHPXAK; ISSN: 0048-3656
DT Journal
LA German

L29 ANSWER 101 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1975:543468 CAPLUS
DN 83:143468
TI Significance of multiple molecular forms of acetylcholinesterase in the sensitivity of houseflies to organophosphorus poisoning
AU Tripathi, R. K.; O'Brien, R. D.
CS Sect. Neurobiol. Behav., Cornell Univ., Ithaca, NY, USA
SO Isozymes, Int. Conf., 3rd (1975), Meeting Date 1974, Volume 2, 395-407. Editor(s): Markert, Clement. Publisher: Academic, New York, N. Y.
CODEN: 30VGAW
DT Conference
LA English

L29 ANSWER 102 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1975:491112 CAPLUS
DN 83:91112
TI Action of drugs on the repetitively stimulated superior cervical ganglion of the rat
AU Iwasaki, Mitsuyoshi
CS Res. Inst. Chemobiodyn., Chiba Univ., Chiba, Japan
SO Chiba Igaku Zasshi (1975), 51(2), 73-80
CODEN: CIZAAZ; ISSN: 0303-5476
DT Journal
LA Japanese

L29 ANSWER 103 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1975:438457 CAPLUS
DN 83:38457
TI Toxicity of DFP [diisopropylphosphorofluoridate] and related compounds to squids in relation to cholinesterase inhibition and detoxifying enzyme levels
AU Dettbarn, W. D.; Hoskin, Francis C. G.
CS Pharmacol. Dep., Vanderbilt Univ., Nashville, TN, USA
SO Bulletin of Environmental Contamination and Toxicology (1975), 13(2), 133-40
CODEN: BECTA6; ISSN: 0007-4861
DT Journal
LA English

L29 ANSWER 104 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1975:401482 CAPLUS
DN 83:1482
TI Influence of esterase inhibitors on platelet aggregation and release induced by phorbol myristate acetate
AU Rao, Gundu H. R.; White, James G.

CS Sch. Med., Univ. Minnesota, Minneapolis, MN, USA
SO Biochemical Pharmacology (1975), 24(2), 293-5
CODEN: BCPCA6; ISSN: 0006-2952
DT Journal
LA English

L29 ANSWER 105 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1975:51668 CAPLUS
DN 82:51668
TI Effect of paraoxon on the hypnotic action of chloral hydrate
AU Koepke, Uwe Ch.; Coon, J. M.; Triolo, Anthony J.
CS Jefferson Med. Coll., Thomas Jefferson Univ., Philadelphia, PA, USA
SO Toxicology and Applied Pharmacology (1974), 30(1), 36-51
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

L29 ANSWER 106 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1974:515001 CAPLUS
DN 81:115001
TI Reaction of the somatic musculature of the nematode Ascaridia galli to cholinergic substances
AU Shishov, B. A.; Malyutina, T. A.
CS USSR
SO Trudy Gel'mintologicheskoi Laboratorii, Akademiya Nauk SSSR (1974), 24, 258-62
CODEN: TGMLA6; ISSN: 0568-5524
DT Journal
LA Russian

L29 ANSWER 107 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1974:434164 CAPLUS
DN 81:34164
TI Interaction of dichlorvos and anticholinesterases on the in vitro inhibition of human blood cholinesterases
AU Carter, M. Kathleen; Maddux, Betty
CS Sch. Med., Tulane Univ., New Orleans, LA, USA
SO Toxicology and Applied Pharmacology (1974), 27(2), 456-63
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

L29 ANSWER 108 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1974:422020 CAPLUS
DN 81:22020
TI Toxicological tolerance of antidotes during alkyl phosphate poisoning
AU Kermes, U.; Wiezorek, W. D.
CS Inst. Pharmakol. Toxikol., Karl-Marx-Univ., Leipzig, Ger. Dem. Rep.
SO Zeitschrift fuer Militaermedizin (1973), 14(6), 320-3
CODEN: ZEMIAF; ISSN: 0514-8782
DT Journal
LA German

L29 ANSWER 109 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1973:439281 CAPLUS
DN 79:39281
TI Mechanism of action of some organophosphorus insecticides on esterase activity of Musca domestica larvae classified by ultramicroelectrophoresis on polyacrylamide gel
AU Kharsun, A. I.; Liptuga, N. I.
CS Inst. Org. Khim., Kiev, USSR
SO Fiziologicheski Aktivnye Veshchestva (1966-1992) (1972), No. 4, 35-41

CODEN: FAVUAI; ISSN: 0533-1153
DT Journal
LA Russian

L29 ANSWER 110 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1973:106098 CAPLUS
DN 78:106098
TI Influence of atropine and cholinesterase inhibitors on brain potentials evoked by tooth pulp stimulation
AU Schmidt, J.; Wolf, H.
CS Inst. Pharmakol. Toxikol., Med. Akad. Magdeburg, Magdeburg, Ger. Dem. Rep.
SO Acta Biologica et Medica Germanica (1972), 29(4-5), 723-8
CODEN: ABMGAJ; ISSN: 0001-5318
DT Journal
LA German

L29 ANSWER 111 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1973:80563 CAPLUS
DN 78:80563
TI Effect of diisopropyl phosphorofluoridate and paraoxon in vivo and in vitro on the sodium and potassium contents of mouse liver tissue
AU Ramachandran, B. V.; Patil, B. G.
CS Natl. Chem. Lab., Poona, India
SO Indian Journal of Experimental Biology (1972), 10(5), 371-4
CODEN: IJEBA6; ISSN: 0019-5189
DT Journal
LA English

L29 ANSWER 112 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1973:23913 CAPLUS
DN 78:23913
TI Relation of the acylation of membrane esterases and proteins to the teratogenic action of organophosphorus insecticides and eserine in developing hen eggs
AU Flockhart, Ian R.; Casida, John E.
CS Div. Entomol., Univ. California, Berkeley, CA, USA
SO Biochemical Pharmacology (1972), 21(19), 2591-603
CODEN: BCPCA6; ISSN: 0006-2952
DT Journal
LA English

L29 ANSWER 113 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1973:13185 CAPLUS
DN 78:13185
TI Effect of pH on the activity of nerve cholinesterases of the rat towards different biochemical and histochemical substrates and inhibitors
AU Eranko, Liisa
CS Dep. Anat., Univ. Helsinki, Helsinki, Finland
SO Histochemie (1973), 33(1), 1-14
CODEN: HICHAU; ISSN: 0018-2222
DT Journal
LA English

L29 ANSWER 114 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1972:483469 CAPLUS
DN 77:83469
TI Renal tubular transport of acetylcholine and atropine. Enhancement and inhibition
AU Acara, Margaret; Rennick, Barbara
CS Sch. Med., State Univ. New York, Buffalo, NY, USA
SO Journal of Pharmacology and Experimental Therapeutics (1972), 182(1), 14-26

CODEN: JPETAB; ISSN: 0022-3565
DT Journal
LA English

L29 ANSWER 115 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1972:457115 CAPLUS
DN 77:57115
TI Effect of cholinergic substances on the contractile activity of the reproductive tube of female Ascaris suum
AU Terenina, N. B.
CS USSR
SO Trudy Vsesoyuznogo Instituta Gel'mintologii imeni K. I. Skryabina (1971), 17, 169-70
CODEN: TVIGA8; ISSN: 0372-2759
DT Journal
LA Russian

L29 ANSWER 116 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1972:414945 CAPLUS
DN 77:14945
TI Effect of drugs on the contractile activity of the genital tube of a female ascarid
AU Terenina, N. B.
CS USSR
SO Trudy Gel'mintologicheskoi Laboratorii, Akademiya Nauk SSSR (1971), 22, 203-7
CODEN: TGMLA6; ISSN: 0568-5524
DT Journal
LA Russian

L29 ANSWER 117 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1972:414346 CAPLUS
DN 77:14346
TI Cataracts following the use of long-acting cholinesterase inhibitors in glaucoma patients
AU Axelsson, Uno
CS Dep. Ophthalmol., Sabbatsberg Hosp., Stockholm, Swed.
SO Proceedings of the European Society for the Study of Drug Toxicity (1971), 12, 199-203
CODEN: PSDTAP; ISSN: 0071-3090
DT Journal
LA English

L29 ANSWER 118 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1972:149707 CAPLUS
DN 76:149707
TI Effect of tri-o-tolyl phosphate pretreatment on the toxicity and metabolism of parathion and paraoxon in mice
AU Lynch, W. T.; Coon, J. M.
CS Jefferson Med. Coll., Thomas Jefferson Univ., Philadelphia, PA, USA
SO Toxicology and Applied Pharmacology (1972), 21(2), 153-65
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

L29 ANSWER 119 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1972:149092 CAPLUS
DN 76:149092
TI Potentiation of barbital narcosis in mice by cholinomimetics and cholinesterase blockers
AU Oelszner, W.; Ebert, W.; Westermann, K. H.
CS Inst. Pharmakol. Toxikol., Med. Akad. "Carl Gustav Carus", Dresden, Fed.

Rep. Ger.
SO Acta Biologica et Medica Germanica (1971), 27(5-6), 983-92
CODEN: ABMGAJ; ISSN: 0001-5318
DT Journal
LA German

L29 ANSWER 120 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1972:122541 CAPLUS
DN 76:122541
TI Influence of the route of exposure on the acute toxicity of cholinesterase inhibitors
AU Natoff, I. L.
CS Tunstall Lab., Shell Res. Ltd., Sittingbourne/Kent, UK
SO Arhiv za Higijenu Rada i Toksikologiju (1970), 21(4), 347-52
CODEN: AHRTAN; ISSN: 0004-1254
DT Journal
LA English

L29 ANSWER 121 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1972:10275 CAPLUS
DN 76:10275
TI Participation of the cholinergic system in temperature regulation in the mouse
AU Staib, A. H.; Schroeder
CS Inst. Pharmakol. Toxikol., Med. Akad. "Carl Gustav Carus", Dresden, Ger. Dem. Rep.
SO Archives Internationales de Pharmacodynamie et de Therapie (1971), 192(1), 88-95
CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA German

L29 ANSWER 122 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1971:539261 CAPLUS
DN 75:139261
TI Effect of phenelzine on the toxicity of cholinergic drugs modified by reserpine
AU Liebmann, H.; Matthies, H.; Kumbier, E.
CS Inst. Pharmakol. Toxikol., Med. Akad. Magdeburg, Magdeburg, Fed. Rep. Ger.
SO Acta Biologica et Medica Germanica (1971), 26(3), 551-8
CODEN: ABMGAJ; ISSN: 0001-5318
DT Journal
LA German

L29 ANSWER 123 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1971:440395 CAPLUS
DN 75:40395
TI Vibratory comminution [of active substances] for the preparation of eye ointments
AU Quellmalz, K.; Schmidt, R.; Kastens, W.
CS Pharm. Zentrum Kreises Schmoelln, Schmoelln, Fed. Rep. Ger.
SO Pharmazeutische Praxis (1971), (5), 113-15
CODEN: PHPXAK; ISSN: 0048-3656
DT Journal
LA German

L29 ANSWER 124 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1971:416706 CAPLUS
DN 75:16706
TI Protein synthesis in lobster walking leg nerves
AU Welsch, Federico; Dettbarn, Wolf D.
CS Sch. Med., Vanderbilt Univ., Nashville, TN, USA

SO Comparative Biochemistry and Physiology, Part B: Biochemistry & Molecular Biology (1971), 38(2), 393-403
CODEN: CBPBB8; ISSN: 1096-4959
DT Journal
LA English

L29 ANSWER 125 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1971:140083 CAPLUS
DN 74:140083
TI Influence of the route of exposure on the acute toxicity of cholinesterase inhibitors
AU Natoff, Ian L.
CS Tunstall Lab., Shell Res. Ltd., Sittingbourne/Kent, UK
SO Journal Europeen de Toxicologie (1970), 3(6), 363-7
CODEN: JETOAS; ISSN: 0021-8219
DT Journal
LA English

L29 ANSWER 126 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1971:138807 CAPLUS
DN 74:138807
TI Protection of animals against soman (1,2,2-trimethylpropyl methylphosphonofluoridate) by pretreatment with some other organophosphorus compounds, followed by oxime and atropine
AU Berry, William K.; Davies, David Reginald; Gordon, J. J.
CS Chem. Def. Establ., Porton Down/Wiltshire, UK
SO Biochemical Pharmacology (1971), 20(1), 125-34
CODEN: BCPCA6; ISSN: 0006-2952
DT Journal
LA English

L29 ANSWER 127 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1971:137090 CAPLUS
DN 74:137090
TI Histochemical specificity of cholinesterases to phenylthio-acetate in differentiated neural tissues of insects and teleosts
AU Booth, Gary M.; Whitt, Gregory S.
CS Dep. Entomol., Univ. Illinois, Urbana, IL, USA
SO Tissue & Cell (1970), 2(4), 521-8
CODEN: TICEBI; ISSN: 0040-8166
DT Journal
LA English

L29 ANSWER 128 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1971:108765 CAPLUS
DN 74:108765
TI Mechanism of the action of phenol on the central nervous system of fish in connection with a change in the external symptom complex of phenol poisoning under the affect of anticholine esterase preparations
AU Luk'yanenko, V. I.
CS Tsent. Nauchno-Issled. Inst. Osetrovogo Khoz., Astrakhan, USSR
SO Vop. Vod. Toksikol. (1970), 154-62. Editor(s): Topachevskii, A. V. Publisher: "Nauka", Moscow, USSR.
CODEN: 22TYA9
DT Conference
LA Russian

L29 ANSWER 129 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1971:97753 CAPLUS
DN 74:97753
TI Reaction of an isolated rat intestine to choline-potentiating agents
AU Prozorovskii, V. B.; Khromova, O. N.; Gladysheva, N. I.

CS Leningr. Pediatr. Med. Inst., Leningrad, USSR
SO Farmakologiya i Toksikologiya (Moscow) (1971), 34(1), 54-7
CODEN: FATOAO; ISSN: 0014-8318
DT Journal
LA Russian

L29 ANSWER 130 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1970:518943 CAPLUS
DN 73:118943
TI Comparative antiparamyonic activity of cholinopotentiating agents
AU Prozorovskii, V. B.; Vladeeva, N. V.; Khromova, O. N.; Dubovitskaya, S. I.
CS Leningrad. Pediat. Med. Inst., Leningrad, USSR
SO Farmakol. Tsent. Kholinolitikov Drugikh Neirotropnykh Sredstv (1969), 225-6. Editor(s): Denisenko, P. P. Publisher: Leningrad. Sanit.-Gig. Med. Inst., Leningrad, USSR.
CODEN: 17FBAU
DT Conference
LA Russian

L29 ANSWER 131 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1970:475458 CAPLUS
DN 73:75458
TI Significance of the content of nucleic acids and proteins in the retina for evaluation of side-effects of miotics on the eye
AU Artem'ev, N. I.; Romashenkov, F. A.
CS Astrakhan. Med. Inst., Astrakhan, USSR
SO Oftal'mologicheskii Zhurnal (1969), 24(8), 573-7
CODEN: OFZHAV; ISSN: 0030-0675
DT Journal
LA Russian

L29 ANSWER 132 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1970:475429 CAPLUS
DN 73:75429
TI Alteration of the work of the myocardium and phase structure of the cardiac cycle under the influence of sympatho- and vagomimetics
AU Savitskii, N. N.; Blinova, T. A.
CS USSR
SO Kardiologiya (1969), 10(3), 66-74
CODEN: KARDA2; ISSN: 0022-9040
DT Journal
LA Russian

L29 ANSWER 133 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1970:475348 CAPLUS
DN 73:75348
TI Antimyorelaxant effect of cholinopotentiating agents
AU Prozorovskii, V. B.; Vladeeva, N. V.; Khromova, O. N.; Dubovitskaya, S. I.
CS Cent. Sci.-Res. Lab., Leningrad Pediat. Med. Inst., Leningrad, USSR
SO Byulleten Eksperimental'noi Biologii i Meditsiny (1970), 69(6), 51-4
CODEN: BEBMAE; ISSN: 0365-9615
DT Journal
LA Russian

L29 ANSWER 134 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1970:63004 CAPLUS
DN 72:63004
TI Acetylcholinesterases of organophosphate-susceptible and -resistant spider mites
AU Smissaert, H. R.; Voerman, Simon; Oostenbrugge, Lies; Renooy, Nel
CS Lab. Res. Insect., Wageningen, Neth.
SO Journal of Agricultural and Food Chemistry (1970), 18(1), 66-75

CODEN: JAFCAU; ISSN: 0021-8561
DT Journal
LA English

L29 ANSWER 135 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1969:489852 CAPLUS
DN 71:89852
TI Experimental therapy of poisoning with anticholinesterase medicinal agents
AU Prozorovskii, V. B.; Khromova, O. N.
CS Leningrad. Pediat. Med. Inst., Leningrad, USSR
SO Farmakologiya i Toksikologiya (Moscow) (1969), 32(4), 475-9
CODEN: FATOAO; ISSN: 0014-8318
DT Journal
LA Russian

L29 ANSWER 136 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1969:479642 CAPLUS
DN 71:79642
TI Glaucoma miotic therapy and cataract studies on echothiophate (phospholine iodide) and paraoxon (mintacol) with regard to cataractogenic effect
AU Axelsson, Uno
CS Sabbatsberg Hosp., Stockholm, Swed.
SO Acta Ophthalmologica, Supplementum (1969), 102, 37 pp.
CODEN: AOPSAP; ISSN: 0065-1451
DT Journal
LA English

L29 ANSWER 137 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1969:467554 CAPLUS
DN 71:67554
TI Binding sites of cholinesterases. Alkylation by an aziridinium derivative
AU O'Brien, Richard D.
CS Cornell Univ., Ithaca, NY, USA
SO Biochemical Journal (1969), 113(4), 713-19
CODEN: BIJOAK; ISSN: 0264-6021
DT Journal
LA English

L29 ANSWER 138 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1969:437337 CAPLUS
DN 71:37337
TI Sensitization of striated muscle choline receptors to acetylcholine
AU Prozorovskii, V. B.
CS Leningrad Pediat. Med. Inst., Leningrad, USSR
SO Byulleten Eksperimental'noi Biologii i Meditsiny (1969), 67(4), 56-9
CODEN: BEBMAE; ISSN: 0365-9615
DT Journal
LA Russian

L29 ANSWER 139 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1969:429118 CAPLUS
DN 71:29118
TI Inversion of physostigmine hypertension by Para-oxon and diisopropylfluorophosphate
AU Varagic, Vladislav; Kazic, T.; Rosic, N.
CS Med. Fac., Beograd, Yugoslavia
SO Iugoslavica Physiologica et Pharmacologica Acta, Supplementum (1968), (1), 113-20
CODEN: IPPSBJ
DT Journal
LA English

L29 ANSWER 140 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1969:420696 CAPLUS
DN 71:20696
TI Inhibition of pain reactions of the mouse by cholinomimetics and the influence of antagonists
AU Oelssner, W.; Andreas, K.
CS Med. Akad. "Carl Gustav Carus" Dresden, Dresden, Fed. Rep. Ger.
SO Acta Biologica et Medica Germanica (1969), 22(2), 369-85
CODEN: ABMGAJ; ISSN: 0001-5318
DT Journal
LA German

L29 ANSWER 141 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1969:45050 CAPLUS
DN 70:45050
TI Direct measurement of acetylesterase in living protist cells
AU Medzon, Edward L.; Brady, Marilyn L.
CS Univ. Western Ontario, London, ON, Can.
SO Journal of Bacteriology (1969), 97(1), 402-15
CODEN: JOBAAY; ISSN: 0021-9193
DT Journal
LA English

L29 ANSWER 142 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1969:10039 CAPLUS
DN 70:10039
TI Effectiveness of cholinolytics as antidotes in poisoning of mice and rats with anticholinesterase agents
AU Prozorovskii, V. B.
CS Leningrad. Pediat. Med. Inst., Leningrad, USSR
SO Farmakologiya i Toksikologiya (Moscow) (1968), 31(5), 553-6
CODEN: FATOAO; ISSN: 0014-8318
DT Journal
LA Russian

L29 ANSWER 143 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1969:1615 CAPLUS
DN 70:1615
TI The action of ATP and cholinesterase inhibitors on mechanical properties of glycerinated muscle fibers
AU Kalamkarova, M. B.
CS Inst. Biol. Fiz., Moscow, USSR
SO Biofiz. Myshechnogo Sokrashcheniya, Simp., Moscow (1966), Meeting Date 1964, 175-80. Editor(s): Frank, G. M. Publisher: Izd. "Nauka", Moscow, USSR.
CODEN: 19YSAK
DT Conference
LA Russian

L29 ANSWER 144 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1968:93108 CAPLUS
DN 68:93108
TI Properties of an acetylcholinesterase from the face fly, Musca autumnalis
AU Bratkowski, Thomas A.; Knowles, Charles O.
CS Univ. of Missouri, Columbia, MO, USA
SO Annals of the Entomological Society of America (1968), 61, 397-402
CODEN: AESAAI; ISSN: 0013-8746
DT Journal
LA English

L29 ANSWER 145 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1967:506983 CAPLUS

DN 67:106983
TI Influence of the route of administration on the toxicity of some cholinesterase inhibitors
AU Natoff, I. L.
CS "Shell" Res. Ltd., Settingbourne, UK
SO Journal of Pharmacy and Pharmacology (1967), 19(9), 612-16
CODEN: JPPMAB; ISSN: 0022-3573
DT Journal
LA English

L29 ANSWER 146 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1967:420336 CAPLUS
DN 67:20336
TI Poly(vinyl alcohol) as vehicle for eye drops
AU Trautmann, I.
CS Univ.-Augenklin., Leipzig, Fed. Rep. Ger.
SO Deutsche Gesundheitswesen (1967), 22(7), 317-20
CODEN: DEGEA3; ISSN: 0012-0219
DT Journal
LA German

L29 ANSWER 147 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1967:410012 CAPLUS
DN 67:10012
TI Cholinesterase inhibitors: eserine and myoticol
AU Grijalbo Lizondo, Pilar
CS Inst. Farmacol. Exptl., Madrid, Spain
SO Archivos del Instituto de Farmacologia Experimental, Madrid (1966), 18(1), 27-48
CODEN: AIFEAR; ISSN: 0081-3303
DT Journal
LA Spanish

L29 ANSWER 148 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1967:84447 CAPLUS
DN 66:84447
TI Relation between cholinesterase activity and brain permeability to barbitone
AU Rosic, N.; Milosevic, Milenko P.
CS Dep. Pharmacol. Toxicol., Univ. Belgrade, Belgrade, Yugoslavia
SO Archives Internationales de Pharmacodynamie et de Therapie (1967), 165(2), 302-7
CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA English

L29 ANSWER 149 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1967:52702 CAPLUS
DN 66:52702
TI Effect of oximes on the hypertensive action of para-oxon and physostigmine in nonanesthetized rats
AU Milosevic, Milenko P.
CS Dept. Pharmacol., Med. Fac., Univ. Belgrade, Belgrade, Yugoslavia
SO Medicina et Pharmacologia Experimentalis (1967), 16(1), 6-10
CODEN: MPHEAE; ISSN: 0543-3002
DT Journal
LA English

L29 ANSWER 150 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1967:17758 CAPLUS
DN 66:17758
TI Protective effect of aldrin against the toxicity of organophosphate

anticholinesterases
AU Triolo, Anthony J.; Coon, Julius M.
CS Jefferson Med. Coll., Philadelphia, PA, USA
SO Journal of Pharmacology and Experimental Therapeutics (1966), 154(3), 613-23
CODEN: JPETAB; ISSN: 0022-3565
DT Journal
LA German/French

L29 ANSWER 151 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1967:10202 CAPLUS
DN 66:10202
TI Mode of action of organophosphate anthelmintics. Cholinesterase inhibition in Ascaris lumbricoides
AU Knowles, Charles O.; Casida, John E.
CS Univ. of Wisconsin, Madison, WI, USA
SO Journal of Agricultural and Food Chemistry (1966), 14(6), 566-72
CODEN: JAFCAU; ISSN: 0021-8561
DT Journal
LA English

L29 ANSWER 152 OF 152 CAPLUS COPYRIGHT 2003 ACS
AN 1967:10152 CAPLUS
DN 66:10152
TI Toxicologic interactions of chlorinated hydrocarbon and organophosphate insecticides
AU Triolo, Anthony J.; Coon, Julius M.
CS Jefferson Med. Coll., Philadelphia, PA, USA
SO Journal of Agricultural and Food Chemistry (1966), 14(6), 549-55
CODEN: JAFCAU; ISSN: 0021-8561
DT Journal
LA English

=> d his

(FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003)

FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003
E STRVUDINE
L1 0 S STRVUDINE
L2 0 S D4T
E D4T
L3 5 S STAVUDINE
L4 42 S PARAOXON
L5 0 S PHYOSTIGMINE
L6 0 S PHYOSTIGMINE
L7 54 S PHYSOSTIGMINE

FILE 'CAPLUS' ENTERED AT 16:36:06 ON 27 MAY 2003
L8 1300 S L3
L9 2913 S L4
L10 4718 S L7
E HIV
L11 50075 S E3 OR E7
E HERPES
L12 21343 S E3
L13 17244 S HHV OR HSV OR HCMV OR CMV
L14 29657 S L12 OR L13
L15 7547 S PHOSPHATE ESTER
L16 2 S L8 AND L15
E ESTER

```
L17      518186 S E3
L18     2414368 S  S
L19          54 S L17 AND L8
L20           3 S L9 AND L11
L21           0 S L9 AND L14
L22           2 S L10 AND L11
L23           1 S L10 AND L14
                E ANTIVIRAL
L24       38629 S E3-E9
L25           2 S L24 AND L9
L26           8 S L10 AND L24
L27           1 S L8 AND L9
L28           5 S L8 AND L10
L29         152 S L9 AND L10

=> e detoxification
E1            1     DETOXIFICATI/BI
E2            2     DETOXIFICATING/BI
E3        14393 --> DETOXIFICATION/BI
E4            1     DETOXIFICATIONAL/BI
E5           23     DETOXIFICATIONS/BI
E6            4     DETOXIFICATIVE/BI
E7            4     DETOXIFICATORY/BI
E8            1     DETOXIFICING/BI
E9         2395     DETOXIFIED/BI
E10          52     DETOXIFIER/BI
E11          31     DETOXIFIERS/BI
E12         294     DETOXIFIES/BI

=> s e3-e12
          14393 DETOXIFICATION/BI
              1 DETOXIFICATIONAL/BI
             23 DETOXIFICATIONS/BI
              4 DETOXIFICATIVE/BI
              4 DETOXIFICATORY/BI
              1 DETOXIFICING/BI
           2395 DETOXIFIED/BI
             52 DETOXIFIER/BI
             31 DETOXIFIERS/BI
            294 DETOXIFIES/BI
L30       16332 (DETOXIFICATION/BI OR DETOXIFICATIONAL/BI OR DETOXIFICATIONS/BI
                OR DETOXIFICATIVE/BI OR DETOXIFICATORY/BI OR DETOXIFICING/BI OR
                DETOXIFIED/BI OR DETOXIFIER/BI OR DETOXIFIERS/BI OR DETOXIFIES/B
                I)

=> s l30 and l8
L31           0 L30 AND L8

=> e excrete
E1            4     EXCRETATORY/BI
E2            1     EXCRETD/BI
E3         3220 --> EXCRETE/BI
E4            1     EXCRETEA/BI
E5        41174     EXCRETED/BI
E6            1     EXCRETEDAND/BI
E7            1     EXCRETEDGLUTAMIC/BI
E8            1     EXCRETEDIN/BI
E9            1     EXCRETEDWITH/BI
E10           1     EXCRETEED/BI
E11           2     EXCRETEION/BI
E12           1     EXCRETEN/BI
```

```
=> s e3-e5
          3220 EXCRETE/BI
             1 EXCRETEA/BI
         41174 EXCRETED/BI
L32      43680 (EXCRETE/BI OR EXCRETEA/BI OR EXCRETED/BI)

=> s l30 and l9
L33        126 L30 AND L9

=> d l33 100-126

L33  ANSWER 100 OF 126  CAPLUS  COPYRIGHT 2003 ACS
AN   1986:124479  CAPLUS
DN   104:124479
TI   Mechanism of enhanced parathion/paraoxon toxicity during pregnancy in the
     mouse
AU   Weitman, Steven D.; Vodicnik, Mary Jo; Lech, John J.
CS   Dep. Pharmacol. Toxicol., Med. Coll. Wisconsin, Milwaukee, WI, 53226, USA
SO   Fundamental and Applied Toxicology (1986), 6(1), 155-61
     CODEN: FAATDF; ISSN: 0272-0590
DT   Journal
LA   English

L33  ANSWER 101 OF 126  CAPLUS  COPYRIGHT 2003 ACS
AN   1985:466085  CAPLUS
DN   103:66085
TI   Interethnic differences of human serum paraoxonase activity-relevance for
     the detoxification of organophosphorous compounds
AU   Geldmacher-Von Mallinckrodt, M.; Diepgen, T. L.; Enders, P. W.
CS   Inst. Rechtsmed., Univ. Erlangen-Nuernberg, Erlangen, D-8520, Fed. Rep.
     Ger.
SO   Archives Belges de Medecine Sociale, Hygiene, Medecine du Travail et
     Medecine Legale (1984), Suppl.(Proc.-World Congr. "New Compd. Biol. Chem.
     Warf.: Toxicol. Eval., 1st, 1984), 243-51
     CODEN: ABMHAM; ISSN: 0003-9578
DT   Journal; General Review
LA   English

L33  ANSWER 102 OF 126  CAPLUS  COPYRIGHT 2003 ACS
AN   1985:449626  CAPLUS
DN   103:49626
TI   A fruit fly bioassay with phosphotriesterase for detection of certain
     organophosphorus insecticide residues
AU   Chiang, Tom; Dean, Mary C.; McDaniel, C. Steven
CS   Agric. Anal. Serv. Dep., Texas A and M Univ., College Station, TX, 77843,
     USA
SO   Bulletin of Environmental Contamination and Toxicology (1985), 34(6),
     809-14
     CODEN: BECTA6; ISSN: 0007-4861
DT   Journal
LA   English

L33  ANSWER 103 OF 126  CAPLUS  COPYRIGHT 2003 ACS
AN   1985:161862  CAPLUS
DN   102:161862
TI   Metabolic activation of phosphorothioate pesticides:  role of the liver
AU   Sultatos, Lester G.; Minor, Lerna D.; Murphy, Sheldon D.
CS   Med. Cent., Louisiana State Univ., New Orleans, LA, USA
SO   Journal of Pharmacology and Experimental Therapeutics (1985), 232(3),
     624-8
     CODEN: JPETAB; ISSN: 0022-3565
DT   Journal
```

LA English

L33 ANSWER 104 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1984:565142 CAPLUS
DN 101:165142
TI Paraoxonase and paraoxon **detoxification**
AU Butler, Edward Grant
CS Univ. Michigan, Ann Arbor, MI, USA
SO (1984) 111 pp. Avail.: Univ. Microfilms Int., Order No. DA8412112
From: Diss. Abstr. Int. B 1984, 45(2), 522-3
DT Dissertation
LA English

L33 ANSWER 105 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1983:417760 CAPLUS
DN 99:17760
TI Hepatic microsomal **detoxification** of the organophosphates paraoxon and chlorpyrifos oxon in the mouse
AU Sultatos, L. G.; Murphy, S. D.
CS Med. Sch., Univ. Texas, Houston, TX, 77025, USA
SO Drug Metabolism and Disposition (1983), 11(3), 232-8
CODEN: DMDSAI; ISSN: 0090-9556
DT Journal
LA English

L33 ANSWER 106 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1983:66771 CAPLUS
DN 98:66771
TI Enzymic detoxication of organophosphorus insecticides and nerve gases in primates
AU Losch, H.; Losch, K.; Haselmeyer, K. H.; Chemnitius, J. M.; Zech, R.
CS Zent. Biochem., Georg-August-Univ., Goettingen, 3400, Fed. Rep. Ger.
SO Arzneimittel-Forschung (1982), 32(12), 1523-9
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA German

L33 ANSWER 107 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1983:29641 CAPLUS
DN 98:29641
TI The biochemical basis of resistance to organophosphorus insecticides in the sheep blowfly, Lucilia cuprina
AU Hughes, P. B.; Devonshire, A. L.
CS Biol. Chem. Res. Inst., New South Wales Dep. Agric., Rydalmere, 2116, Australia
SO Pesticide Biochemistry and Physiology (1982), 18(3), 289-97
CODEN: PCBPBS; ISSN: 0048-3575
DT Journal
LA English

L33 ANSWER 108 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1981:615979 CAPLUS
DN 95:215979
TI Biological effect of organophosphorus pesticides at low concentration. I. The detoxication of fenitrooxon at low concentration by mouse liver preparation
AU Kawamura, Youko; Takeda, Mitsuharu; Uchiyama, Mitsuru
CS Natl. Inst. Hyg. Sci., Tokyo, Japan
SO Eisei Kagaku (1981), 27(4), 252-6
CODEN: ESKGA2; ISSN: 0013-273X
DT Journal
LA Japanese

L33 ANSWER 109 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1981:456297 CAPLUS
DN 95:56297
TI In vitro degradation of organophosphorus acaricides by the mites Sancassania berlesei (Tyroglyphidae) and Tetranychus urticae (Tetranychidae)
AU Blank, R. H.
CS Lincoln Coll., Canterbury, N. Z.
SO New Zealand Journal of Agricultural Research (1980), 23(4), 589-93
CODEN: NEZFA7; ISSN: 0028-8233
DT Journal
LA English

L33 ANSWER 110 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1980:20699 CAPLUS
DN 92:20699
TI Criteria for toxicological and epidemiological evaluation for an updating of the standards of primary food protection
AU Orecchio, Fausto; Ghezzo, Floriano; Ficarra, Maria Giovanna; Villa, Piergiuseppe
CS Fac. Med. Chir., Univ. Cattol. Sacro Cuore, Rome, Italy
SO Dif. Antiparassit. Ind. Aliment. Prot. Alimenti, Atti Simp., 2nd (1979), Meeting Date 1977, 465-78. Editor(s): Domenichini, Giorgio. Publisher: Camera Commer. Ind. Artigianato Agric. Piacenza, Piacenza, Italy.
CODEN: 41PTAN
DT Conference
LA Italian

L33 ANSWER 111 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1979:484616 CAPLUS
DN 91:84616
TI Biological effects of dithiocarbamates: effect of zinc ethylenebisdithiocarbamate (zineb) on the acute toxicity of parathion and paraoxon in mice
AU Orecchio, F.; Togna, G.; Di Battista, L.; Villa, P.; Ficarra, M. G.
CS Ist. Ig., Univ. Cattol. Sacro Cuore, Rome, Italy
SO Igiene Moderna (1979), 72(3), 305-10
CODEN: IGMPAX; ISSN: 0019-1655
DT Journal
LA Italian

L33 ANSWER 112 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1978:610014 CAPLUS
DN 89:210014
TI Effects of naturally occurring food plant components on insecticide degradation in rats
AU Fuhremann, Tom W.; Lichtenstein, E. Paul; Stratman, Fredrick W.
CS Inst. Enzyme Res., Univ. Wisconsin, Madison, WI, USA
SO Journal of Agricultural and Food Chemistry (1978), 26(5), 1068-75
CODEN: JAFCAU; ISSN: 0021-8561
DT Journal
LA English

L33 ANSWER 113 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1978:184105 CAPLUS
DN 88:184105
TI **Detoxification** of nitrophenyl phosphate and nitrophenyl phosphonates in tissue homogenates of white rats
AU Galebskaya, L. V.
CS I Leningr. Med. Inst., Leningrad, USSR
SO Neirogumoral'n. Endokr. Regul. Funkts. (1975), 28-9. Editor(s): Denisova,

G. A.; Maslennikov, I. V.; Smirnova, N. N. Publisher: Pervyi Leningr. Med. Inst. im. I. P. Pavlova, Leningrad, USSR.
CODEN: 37TFAW
DT Conference
LA Russian

L33 ANSWER 114 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1978:46005 CAPLUS
DN 88:46005
TI DDVP (dichlorvos) **detoxification** by binding and interactions with DDT, dieldrin, and malaoxon
AU Ehrich, Marion; Cohen, Steven D.
CS Sch. Pharm., Univ. Connecticut, Storrs, CT, USA
SO Journal of Toxicology and Environmental Health (1977), 3(3), 491-500
CODEN: JTEHD6; ISSN: 0098-4108
DT Journal
LA English

L33 ANSWER 115 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1977:497026 CAPLUS
DN 87:97026
TI Effect of piperonyl butoxide on the metabolism of dimethyl and diethyl phosphorothionate insecticides
AU Levine, Barry S.; Murphy, Sheldon D.
CS Sch. Public Health, Harvard Univ., Boston, MA, USA
SO Toxicology and Applied Pharmacology (1977), 40(3), 393-406
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

L33 ANSWER 116 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1977:463744 CAPLUS
DN 87:63744
TI Parathion and methyl parathion toxicity and metabolism in piperonyl butoxide and diethyl maleate pretreated mice
AU Mirer, Franklin E.; Levine, Barry S.; Murphy, Sheldon D.
CS Kresge Cent. Environ. Health, Harvard Sch. Public Health, Boston, MA, USA
SO Chemico-Biological Interactions (1977), 17(1), 99-112
CODEN: CBINA8; ISSN: 0009-2797
DT Journal
LA English

L33 ANSWER 117 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1977:133557 CAPLUS
DN 86:133557
TI Pharmacologic-toxicologic consequences of circadian rhythm
AU Von Mayersbach, H.; Mueller, O.; Philippens, K.; Scheving, L. E.
CS Anat. Inst., Med. Hochsch. Hannover, Hannover, Fed. Rep. Ger.
SO Acta Histochemica, Supplementband (1976), 16, 123-7
CODEN: AHSUAV; ISSN: 0567-7556
DT Journal
LA German

L33 ANSWER 118 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1976:131127 CAPLUS
DN 84:131127
TI Development of microbial systems for the disposal of concentrated pesticide suspensions
AU Munnecke, Douglas M.; Hsieh, D. P. H.
CS Inst. Bodenbiol., Forschungsanst. Landwirtsch., Braunschweig, Fed. Rep. Ger.
SO Mededelingen van de Faculteit Landbouwwetenschappen, Universiteit Gent

(1975), 40(2, Pt. 2), 1237-47
CODEN: MFLRA3; ISSN: 0368-9697
DT Journal
LA English

L33 ANSWER 119 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1974:486536 CAPLUS
DN 81:86536
TI Simplified bioassay for organophosphate **detoxification** and interactions
AU Cohen, Steven D.; Murphy, Sheldon D.
CS Kresge Cent. Environ. Health, Harvard Sch. Public Health, Boston, MA, USA
SO Toxicology and Applied Pharmacology (1974), 27(3), 537-50
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

L33 ANSWER 120 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1974:422010 CAPLUS
DN 81:22010
TI Comparative toxicity, anticholinesterase action, and metabolism of methyl parathion and parathion in sunfish and mice
AU Benke, G. M.; Cheever, K. L.; Mirer, F. E.; Murphy, S. D.
CS Sch. Public Health, Harvard Univ., Boston, MA, USA
SO Toxicology and Applied Pharmacology (1974), 28(1), 97-109
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

L33 ANSWER 121 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1973:449643 CAPLUS
DN 79:49643
TI Comparison of the metabolism of parathion by lobsters and rats
AU Carlson, Gary P.
CS Coll. Pharm., Univ. Rhode Island, Kingston, RI, USA
SO Bulletin of Environmental Contamination and Toxicology (1973), 9(5), 296-300
CODEN: BECTA6; ISSN: 0007-4861
DT Journal
LA English

L33 ANSWER 122 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1973:428129 CAPLUS
DN 79:28129
TI Metabolism of carbon-14-labeled parathion and carbon-14-labeled paraoxon with fractions and subfractions of rat liver cells
AU Lichtenstein, E. Paul; Fuhremann, Tom W.; Hochberg, Abraham A.; Zahlten, Rainer N.; Stratman, Fred W.
CS Dep. Entomol., Univ. Wisconsin, Madison, WI, USA
SO Journal of Agricultural and Food Chemistry (1973), 21(3), 416-24
CODEN: JAFCAU; ISSN: 0021-8561
DT Journal
LA English

L33 ANSWER 123 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1972:522985 CAPLUS
DN 77:122985
TI Increase in the toxicity of organophosphorus insecticides to house flies due to polychlorinated biphenyl compounds
AU Fuhremann, T. W.; Lichtenstein, E. P.
CS Dep. Entolmol., Univ. Wisconsin, Madison, WI, USA
SO Toxicology and Applied Pharmacology (1972), 22(4), 628-40

CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

L33 ANSWER 124 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1970:519612 CAPLUS
DN 73:119612
TI Resistance to organophosphorus insecticides in tobacco budworms
AU Whitten, C. J.; Bull, Don L.
CS Entomol. Res. Div., Agr. Res. Serv., College Station, TX, USA
SO Journal of Economic Entomology (1970), 63(5), 1492-5
CODEN: JEENAI; ISSN: 0022-0493
DT Journal
LA English

L33 ANSWER 125 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1969:27255 CAPLUS
DN 70:27255
TI Effect of Melleril on the detoxication of insecticidal phosphates
AU Klotzsche, Claus
CS Med.-Biol. Forsch., Sandoz A.-G., Basel, Switz.
SO Pflanzenschutzberichte (1968), 38(10-11), 125-34
CODEN: PSBEA4; ISSN: 0031-675X
DT Journal
LA German

L33 ANSWER 126 OF 126 CAPLUS COPYRIGHT 2003 ACS
AN 1967:17758 CAPLUS
DN 66:17758
TI Protective effect of aldrin against the toxicity of organophosphate anticholinesterases
AU Triolo, Anthony J.; Coon, Julius M.
CS Jefferson Med. Coll., Philadelphia, PA, USA
SO Journal of Pharmacology and Experimental Therapeutics (1966), 154(3), 613-23
CODEN: JPETAB; ISSN: 0022-3565
DT Journal
LA German/French

=> d his

(FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003)

FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003
E STRVUDINE
L1 0 S STRVUDINE
L2 0 S D4T
E D4T
L3 5 S STAVUDINE
L4 42 S PARAOXON
L5 0 S PHYOSTIGMINE
L6 0 S PHYOSTIGMINE
L7 54 S PHYSOSTIGMINE

FILE 'CAPLUS' ENTERED AT 16:36:06 ON 27 MAY 2003
L8 1300 S L3
L9 2913 S L4
L10 4718 S L7
E HIV
L11 50075 S E3 OR E7
E HERPES

```
L12        21343 S E3
L13        17244 S HHV OR HSV OR HCMV OR CMV
L14        29657 S L12 OR L13
L15         7547 S PHOSPHATE ESTER
L16            2 S L8 AND L15
                 E ESTER
L17       518186 S E3
L18      2414368 S  S
L19           54 S L17 AND L8
L20            3 S L9 AND L11
L21            0 S L9 AND L14
L22            2 S L10 AND L11
L23            1 S L10 AND L14
                 E ANTIVIRAL
L24        38629 S E3-E9
L25            2 S L24 AND L9
L26            8 S L10 AND L24
L27            1 S L8 AND L9
L28            5 S L8 AND L10
L29          152 S L9 AND L10
                 E DETOXIFICATION
L30        16332 S E3-E12
L31            0 S L30 AND L8
                 E EXCRETE
L32        43680 S E3-E5
L33          126 S L30 AND L9

=> s l30 and l10
L34           10 L30 AND L10

=> d 134 1-10

L34  ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2003 ACS
AN   2002:363815  CAPLUS
DN   136:351556
TI   Alkaloid tolerance in Manduca sexta and phylogenetically related sphingids
     (Lepidoptera: Sphingidae)
AU   Wink, Michael; Theile, Vera
CS   Institut fur Pharmazeutische Biologie, Universitat Heidelberg, Heidelberg,
     D-69120, Germany
SO   Chemoecology (2002), 12(1), 29-46
     CODEN: CHMOE9; ISSN: 0937-7409
PB   Birkhaeuser Verlag
DT   Journal
LA   English
RE.CNT  57    THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34  ANSWER 2 OF 10  CAPLUS  COPYRIGHT 2003 ACS
AN   2001:676210  CAPLUS
DN   135:222701
TI   Detoxification of humans affected by feed toxins passing through
     the food chain
IN   Kiefer, Heinz
PA   Germany
SO   Ger. Offen., 6 pp.
     CODEN: GWXXBX
DT   Patent
LA   German
FAN.CNT 1
     PATENT NO.         KIND  DATE          APPLICATION NO.  DATE
     ---------------    ----  --------      ---------------  --------
```

PI DE 10106530 A1 20010913 DE 2001-10106530 20010213
DE 10106530 C2 20020627
PRAI DE 2001-10106530 20010213

L34 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 2000:573354 CAPLUS
DN 134:52581
TI Mechanisms associated with methiocarb resistance in Frankliniella occidentalis (Thysanoptera: Thripidae)
AU Jensen, Sten E.
CS Department of Crop Protection, Research Centre Flakkebjerg, Danish Institute of Agricultural Sciences, Slagelse, DK-4200, Den.
SO Journal of Economic Entomology (2000), 93(2), 464-471
CODEN: JEENAI; ISSN: 0022-0493
PB Entomological Society of America
DT Journal
LA English
RE.CNT 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 1998:276403 CAPLUS
DN 129:23341
TI Subchronic physostigmine pretreatment in guinea pigs: effective against soman and without side effects
AU Philippens, Ingrid H. C. H. M.; Busker, Ruud W.; Wolthuis, Otto L.; Olivier, Berend; Bruijnzeel, Piet L. B.; Melchers, Bert P. C.
CS Research Group Pharmacology, TNO Prins Maurits Lab (TNO-PML), Rijswijk, 2280 AA, Neth.
SO Pharmacology, Biochemistry and Behavior (1998), 59(4), 1061-1067
CODEN: PBBHAU; ISSN: 0091-3057
PB Elsevier Science Inc.
DT Journal
LA English
RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L34 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 1995:779743 CAPLUS
DN 123:191172
TI Imidacloprid binding site in Musca nicotinic acetylcholine receptor: interactions with physostigmine and a variety of nicotinic agonists with chloropyridyl and chlorothiazolyl substituents
AU Liu, Ming-Yie; Latli, Bachir; Casida, John E.
CS Environmental Chemistry and Toxicology Laboratory, Univ. California, Berkeley, CA, 94720-3112, USA
SO Pesticide Biochemistry and Physiology (1995), 52(3), 170-81
CODEN: PCBPBS; ISSN: 0048-3575
PB Academic
DT Journal
LA English

L34 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 1988:585141 CAPLUS
DN 109:185141
TI Effect of carboxylesterase inhibition on carbamate protection against soman toxicity
AU Maxwell, Donald M.; Brecht, Karen M.; Lenz, David E.; O'Neill, Barbara L.
CS U. S. Army Med. Res. Inst. Chem. Def., Aberdeen Proving Ground, MD, 21010-5425, USA
SO Journal of Pharmacology and Experimental Therapeutics (1988), 246(3), 986-91

CODEN: JPETAB; ISSN: 0022-3565
DT Journal
LA English

L34 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 1988:524378 CAPLUS
DN 109:124378
TI Reaction of Rhabditis oxycerca after long-term exposure to aldicarb and oxamyl. II: Enzyme changes in nematicide resistance
AU Below, S.; Kaempfe, L.; Mueller, A.
CS Dep. Zool., Ernst-Moritz-Arndt-Univ., Greifswald, DDR-2200, Ger. Dem. Rep.
SO Nematologica (1987), 33(3), 298-309
CODEN: NEMAAT; ISSN: 0028-2596
DT Journal
LA English

L34 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 1975:164856 CAPLUS
DN 82:164856
TI Effect upon drug toxicity of surgical interference with hepatic or renal function
AU Selye, H.; Mecs, I.
CS Inst. Medecine Chir. Exp., Univ. Montreal, Montreal, QC, Can.
SO Acta Hepato-Gastroenterologica (1974), 21(3), 191-202; (4), 266-73
CODEN: AHGSBY; ISSN: 0300-970X
DT Journal
LA English

L34 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 1968:103714 CAPLUS
DN 68:103714
TI Effect of impaired acetylcholine tolerance on traumatic shock in the rat
AU Ninomiya, Harutada; Michaelis, Moritz
CS Univ. of Maryland Sch. of Med., Baltimore, MD, USA
SO Enzymologia (1968), 34(3), 165-70
CODEN: ENZYAS; ISSN: 0013-9424
DT Journal
LA English

L34 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2003 ACS
AN 1967:17758 CAPLUS
DN 66:17758
TI Protective effect of aldrin against the toxicity of organophosphate anticholinesterases
AU Triolo, Anthony J.; Coon, Julius M.
CS Jefferson Med. Coll., Philadelphia, PA, USA
SO Journal of Pharmacology and Experimental Therapeutics (1966), 154(3), 613-23
CODEN: JPETAB; ISSN: 0022-3565
DT Journal
LA German/French

=> d his

(FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003)

FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003
E STRVUDINE
L1 0 S STRVUDINE
L2 0 S D4T
E D4T

```
L3            5 S STAVUDINE
L4           42 S PARAOXON
L5            0 S PHYOSTIGMINE
L6            0 S PHYOSTIGMINE
L7           54 S PHYSOSTIGMINE

     FILE 'CAPLUS' ENTERED AT 16:36:06 ON 27 MAY 2003
L8         1300 S L3
L9         2913 S L4
L10        4718 S L7
                E HIV
L11       50075 S E3 OR E7
                E HERPES
L12       21343 S E3
L13       17244 S HHV OR HSV OR HCMV OR CMV
L14       29657 S L12 OR L13
L15        7547 S PHOSPHATE ESTER
L16           2 S L8 AND L15
                E ESTER
L17      518186 S E3
L18     2414368 S  S
L19          54 S L17 AND L8
L20           3 S L9 AND L11
L21           0 S L9 AND L14
L22           2 S L10 AND L11
L23           1 S L10 AND L14
                E ANTIVIRAL
L24       38629 S E3-E9
L25           2 S L24 AND L9
L26           8 S L10 AND L24
L27           1 S L8 AND L9
L28           5 S L8 AND L10
L29         152 S L9 AND L10
                E DETOXIFICATION
L30       16332 S E3-E12
L31           0 S L30 AND L8
                E EXCRETE
L32       43680 S E3-E5
L33         126 S L30 AND L9
L34          10 S L30 AND L10

=> e synergist
E1          315     SYNERGISMS/BI
E2            4     SYNERGISN/BI
E3         3219 --> SYNERGIST/BI
E4            1     SYNERGISTAICALLY/BI
E5            2     SYNERGISTC/BI
E6            1     SYNERGISTE/BI
E7            1     SYNERGISTED/BI
E8            1     SYNERGISTEIC/BI
E9           35     SYNERGISTES/BI
E10           1     SYNERGISTGIC/BI
E11           2     SYNERGISTI/BI
E12       54122     SYNERGISTIC/BI

=> s e1-e12
           315 SYNERGISMS/BI
             4 SYNERGISN/BI
          3219 SYNERGIST/BI
             1 SYNERGISTAICALLY/BI
             2 SYNERGISTC/BI
             1 SYNERGISTE/BI
```

```
             1 SYNERGISTED/BI
             1 SYNERGISTEIC/BI
            35 SYNERGISTES/BI
             1 SYNERGISTGIC/BI
             2 SYNERGISTI/BI
         54122 SYNERGISTIC/BI
L35      56539 (SYNERGISMS/BI OR SYNERGISN/BI OR SYNERGIST/BI OR SYNERGISTAICAL
               LY/BI OR SYNERGISTC/BI OR SYNERGISTE/BI OR SYNERGISTED/BI OR
               SYNERGISTEIC/BI OR SYNERGISTES/BI OR SYNERGISTGIC/BI OR SYNERGIS
               TI/BI OR SYNERGISTIC/BI)

=> s l35 and l8
L36          55 L35 AND L8

=> s l35 and l9
L37          31 L35 AND L9

=> d l37 10-31

L37  ANSWER 10 OF 31  CAPLUS  COPYRIGHT 2003 ACS
AN   1992:146120  CAPLUS
DN   116:146120
TI   Mechanisms in the selective sensitivity to insecticides of the larvae and
     imago of beet webworm (Margaretia sticticalis)
AU   Leonova, I. N.; Slyn'ko, N. M.; Knor, I. B.
CS   Inst. Tsitol. Genet., Novosibirsk, USSR
SO   Agrokhimiya (1991), (3), 114-20
     CODEN: AGKYAU; ISSN: 0002-1881
DT   Journal
LA   Russian

L37  ANSWER 11 OF 31  CAPLUS  COPYRIGHT 2003 ACS
AN   1989:473038  CAPLUS
DN   111:73038
TI   A mutant esterase degrading organophosphates in a resistant strain of the
     predacious mite Amblyseius potentillae (Garman)
AU   Anber, H. A. I.; Oppenoorth, F. J.
CS   Lab. Exp. Entomol., Univ. Amsterdam, Amsterdam, 1098, Neth.
SO   Pesticide Biochemistry and Physiology (1989), 33(3), 283-97
     CODEN: PCBPBS; ISSN: 0048-3575
DT   Journal
LA   English

L37  ANSWER 12 OF 31  CAPLUS  COPYRIGHT 2003 ACS
AN   1988:217727  CAPLUS
DN   108:217727
TI   Effect of organophosphorus synergists on fenitrothion resistance in rice
     stem borer, Chilo suppressalis (Walker)
AU   Konno, Yashukio; Shishido, Takashi; Tanaka, Fukusaburo
CS   Div. Pestic., Natl. Inst. Agro-Environ. Sci., Tsukuba, 305, Japan
SO   Applied Entomology and Zoology (1988), 23(1), 99-102
     CODEN: APEZAW; ISSN: 0003-6862
DT   Journal
LA   English

L37  ANSWER 13 OF 31  CAPLUS  COPYRIGHT 2003 ACS
AN   1987:629142  CAPLUS
DN   107:229142
TI   Stimulation of defenses of biological systems using toxic substances
IN   Berdal, Pascal
PA   Fr.
SO   Fr. Demande, 25 pp.
```

CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2584294	A1	19870109	FR 1985-10403	19850708
	FR 2584294	B1	19920221		
PRAI	FR 1985-10403		19850708		

L37 ANSWER 14 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1987:419456 CAPLUS
DN 107:19456
TI Inhibition of trans-permethrin hydrolysis in Pseudoplusia includens (Walker) and use of inhibitors as pyrethroid synergists
AU Dowd, Patrick F.; Sparks, Thomas C.
CS Agric. Cent., Louisiana State Univ., Baton Rouge, LA, 70803, USA
SO Pesticide Biochemistry and Physiology (1987), 27(2), 237-45
CODEN: PCBPBS; ISSN: 0048-3575
DT Journal
LA English

L37 ANSWER 15 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1986:566856 CAPLUS
DN 105:166856
TI Mode of action of N-ethylmaleimide as a parathion **synergist** in Triatoma infestans
AU Wood, E. J.; De Villar, M. I. P.; Melgar, F. J.; Zerba, E. N.
CS CIPEIN, Buenos Aires, Argent.
SO Pesticide Biochemistry and Physiology (1986), 26(2), 170-82
CODEN: PCBPBS; ISSN: 0048-3575
DT Journal
LA English

L37 ANSWER 16 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1985:608864 CAPLUS
DN 103:208864
TI Relationships between **synergistic** and biochemical analyses of paraoxon tolerance in pea aphids
AU Al-Rajhi, Deifalla H.; Brindley, William A.
CS Dep. Biol., Utah State Univ., Logan, UT, 84322, USA
SO Alexandria Science Exchange (1985), 6(2), 142-59
CODEN: ALSEEF; ISSN: 1110-0176
DT Journal
LA English

L37 ANSWER 17 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1985:418357 CAPLUS
DN 103:18357
TI Synergism of organophosphorus insecticides by diethyl maleate and related compounds in houseflies
AU Welling, W.; De Vries, J. W.
CS Inst. Pestic. Res., Wageningen, 6709 PG, Neth.
SO Pesticide Biochemistry and Physiology (1985), 23(3), 358-69
CODEN: PCBPBS; ISSN: 0048-3575
DT Journal
LA English

L37 ANSWER 18 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1984:46971 CAPLUS
DN 100:46971
TI Synthesis and biological activity studies of selected organophosphorus

esters
AU McElroy, Roger D.; Chambers, Howard W.
CS Dep. Entomol., Mississippi State Univ., Mississippi State, MS, 39762, USA
SO Journal of Agricultural and Food Chemistry (1984), 32(1), 119-23
CODEN: JAFCAU; ISSN: 0021-8561
DT Journal
LA English

L37 ANSWER 19 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1983:193024 CAPLUS
DN 98:193024
TI Mutagenicity of some organophosphorus compounds at the ade6 locus of Schizosaccharomyces pombe
AU Gilot-Delhalle, J.; Colizzi, A.; Moutschen, J.; Moutschen-Dahmen, M.
CS Lab. Genet., Univ. Liege, Liege, B-4000, Belg.
SO Mutation Research (1983), 117(1-2), 139-48
CODEN: MUREAV; ISSN: 0027-5107
DT Journal
LA English

L37 ANSWER 20 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1983:102653 CAPLUS
DN 98:102653
TI Organophosphorus resistance in the sheep blowfly, Lucilia cuprina (Wiedemann) (Diptera: Calliphoridae): a genetic study incorporating synergists
AU Hughes, P. B.
CS Biol. Chem. Res. Inst., Dep. Agric., Rydalmere, 2116, Australia
SO Bulletin of Entomological Research (1982), 72(4), 573-82
CODEN: BEREA2; ISSN: 0007-4853
DT Journal
LA English

L37 ANSWER 21 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1980:463526 CAPLUS
DN 93:63526
TI Phthalate-organophosphate interactions: toxicity, penetration, and metabolism studies with house flies
AU Al-Badry, Mahdiy S.; Knowles, Charles O.
CS Dep. Entomol., Univ. Missouri, Columbia, MO, 65211, USA
SO Archives of Environmental Contamination and Toxicology (1980), 9(2), 147-61
CODEN: AECTCV; ISSN: 0090-4341
DT Journal
LA English

L37 ANSWER 22 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1980:53312 CAPLUS
DN 92:53312
TI Biologically active components of anise: toxicity and interactions with insecticides in insects
AU Marcus, Craig; Lichtenstein, E. Paul
CS Dep. Entomol., Univ. Wisconsin, Madison, WI, 53706, USA
SO Journal of Agricultural and Food Chemistry (1979), 27(6), 1217-23
CODEN: JAFCAU; ISSN: 0021-8561
DT Journal
LA English

L37 ANSWER 23 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1979:17607 CAPLUS
DN 90:17607
TI Synergism of anticholinesterase insecticides by non-insecticidal

phosphorus esters in the boll weevil Anthonomus grandis Boheman
AU Urrelo, Rafael; Chambers, Howard
CS Univ. Nac. Agrar. Selva, Tingo Maria, Peru
SO Turrialba (1978), 28(1), 71-6
CODEN: TURRAB; ISSN: 0041-4360
DT Journal
LA English

L37 ANSWER 24 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1977:400070 CAPLUS
DN 87:70
TI NADH synergism of microsomal aniline metabolism in the presence of enhancing agents
AU Powis, Garth; Lyon, Linda; McKillop, David
CS Dep. Pharmacol., Glasgow Univ., Glasgow, UK
SO Biochemical Pharmacology (1977), 26(2), 137-41
CODEN: BCPCA6; ISSN: 0006-2952
DT Journal
LA English

L37 ANSWER 25 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1977:166109 CAPLUS
DN 86:166109
TI DDE increases the toxicity of parathion to Coturnix quail
AU Ludke, J. Larry
CS Patuxent Wildl. Res. Cent., U. S. Fish. Wildl. Serv., Laurel, MD, USA
SO Pesticide Biochemistry and Physiology (1977), 7(1), 28-33
CODEN: PCBPBS; ISSN: 0048-3575
DT Journal
LA English

L37 ANSWER 26 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1974:564303 CAPLUS
DN 81:164303
TI Effect of TOTP[triorthotolyl phosphate] pretreatment on paraoxon and methylparaoxon detoxication in rats
AU Benke, Gary M.; Murphy, Sheldon D.
CS Kresge Cent. Environ. Health, Harvard Sch. Public Health, Boston, MA, USA
SO Research Communications in Chemical Pathology and Pharmacology (1974), 8(4), 665-72
CODEN: RCOCB8; ISSN: 0034-5164
DT Journal
LA English

L37 ANSWER 27 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1974:546826 CAPLUS
DN 81:146826
TI Genetics of resistance of a dimethoate-selected strain of houseflies(Musca domestica) to several insecticides and methylenedioxyphenyl synergists
AU Sawicki, Roman M.
CS Dep. Insectic. Fungic., Rothamsted Exp. Stn., Harpenden/Herts, UK
SO Journal of Agricultural and Food Chemistry (1974), 22(3), 344-9
CODEN: JAFCAU; ISSN: 0021-8561
DT Journal
LA English

L37 ANSWER 28 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1972:122870 CAPLUS
DN 76:122870
TI Selection for resistance to carbamate and organophosphorus insecticides in Anopheles albimanus
AU Ariaratnam, V.; Georghiou, G. P.

CS Dep. Entomol., Univ. California, Riverside, CA, USA
SO Nature (London, United Kingdom) (1971), 232(5313), 642-4
CODEN: NATUAS; ISSN: 0028-0836
DT Journal
LA English

L37 ANSWER 29 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1971:404397 CAPLUS
DN 75:4397
TI Effect of chlorocholine chloride on the toxicity of cholinesterase inhibitors
AU Ackermann, Heinz; Kretzschmann, Fritz
CS Inst. Ernaehr. Potsdam-Rehbruecke, Dtsch. Akad. Wiss. Berlin, Potsdam-Rehbruecke, Fed. Rep. Ger.
SO Archiv fuer Experimentelle Veterinaermedizin (1970), 24(4), 1045-7
CODEN: AXVMAW; ISSN: 0003-9055
DT Journal
LA German

L37 ANSWER 30 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1969:500248 CAPLUS
DN 71:100248
TI Effect of acetylcholine, anticholinesterases and cholinolytic agents on the vessels of an isolated rabbit heart
AU Nikitin, A. I.
CS USSR
SO Probl. Klin. Eksp. Med. (1967), 354-5. Editor(s): Neimark, I. I. Publisher: Altai. Knizhnoe Izd., Barnaul, USSR.
CODEN: 21FSAG
DT Conference
LA Russian

L37 ANSWER 31 OF 31 CAPLUS COPYRIGHT 2003 ACS
AN 1969:46376 CAPLUS
DN 70:46376
TI Effect of time on the co-toxicity coefficients of insecticides with sesamex
AU Rai, Bhupendra K.
CS Div. Entomol., Indian Agr. Res. Inst., New Delhi, India
SO Indian Journal of Entomology (1967), 29(Pt. 3), 311-12
CODEN: IJENA8; ISSN: 0367-8288
DT Journal
LA English

=> d his

(FILE 'HOME' ENTERED AT 16:27:38 ON 27 MAY 2003)

FILE 'REGISTRY' ENTERED AT 16:27:58 ON 27 MAY 2003
E STRVUDINE
L1 0 S STRVUDINE
L2 0 S D4T
E D4T
L3 5 S STAVUDINE
L4 42 S PARAOXON
L5 0 S PHYOSTIGMINE
L6 0 S PHYOSTIGMINE
L7 54 S PHYSOSTIGMINE

FILE 'CAPLUS' ENTERED AT 16:36:06 ON 27 MAY 2003
L8 1300 S L3

```
L9          2913 S L4
L10         4718 S L7
                 E HIV
L11        50075 S E3 OR E7
                 E HERPES
L12        21343 S E3
L13        17244 S HHV OR HSV OR HCMV OR CMV
L14        29657 S L12 OR L13
L15         7547 S PHOSPHATE ESTER
L16            2 S L8 AND L15
                 E ESTER
L17       518186 S E3
L18      2414368 S  S
L19           54 S L17 AND L8
L20            3 S L9 AND L11
L21            0 S L9 AND L14
L22            2 S L10 AND L11
L23            1 S L10 AND L14
                 E ANTIVIRAL
L24        38629 S E3-E9
L25            2 S L24 AND L9
L26            8 S L10 AND L24
L27            1 S L8 AND L9
L28            5 S L8 AND L10
L29          152 S L9 AND L10
                 E DETOXIFICATION
L30        16332 S E3-E12
L31            0 S L30 AND L8
                 E EXCRETE
L32        43680 S E3-E5
L33          126 S L30 AND L9
L34           10 S L30 AND L10
                 E SYNERGIST
L35        56539 S E1-E12
L36           55 S L35 AND L8
L37           31 S L35 AND L9

=> s l35 and l10
L38           40 L35 AND L10

=> d 138 10-40

L38  ANSWER 10 OF 40  CAPLUS  COPYRIGHT 2003 ACS
AN   1995:927588  CAPLUS
DN   123:308647
TI   Purification and characterization of a resistance-associated esterase from
     the Colorado potato beetle, Leptinotarsa decemlineata (Say)
AU   Anspaugh, Douglas D.; Kennedy, George G.; Roe, R. Michael
CS   Dep. Entomol., North Carolina State Univ., Raleigh, NC, 27695-7613, USA
SO   Pesticide Biochemistry and Physiology (1995), 53(2), 84-96
     CODEN: PCBPBS; ISSN: 0048-3575
PB   Academic
DT   Journal
LA   English

L38  ANSWER 11 OF 40  CAPLUS  COPYRIGHT 2003 ACS
AN   1995:865572  CAPLUS
DN   123:329289
TI   Intrathecal acetyl cholinesterase inhibitors produce analgesia that is
     synergistic with morphine and clonidine in rats
AU   Abram, Stephen E.; Winne, Richard P.
CS   Department Anesthesia, Medical College Wisconsin, Milwaukee, WI, 53226,
```

USA
SO Anesthesia & Analgesia (Baltimore) (1995), 81(3), 501-7
CODEN: AACRAT; ISSN: 0003-2999
PB Williams & Wilkins
DT Journal
LA English

L38 ANSWER 12 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1995:779743 CAPLUS
DN 123:191172
TI Imidacloprid binding site in Musca nicotinic acetylcholine receptor: interactions with physostigmine and a variety of nicotinic agonists with chloropyridyl and chlorothiazolyl substituents
AU Liu, Ming-Yie; Latli, Bachir; Casida, John E.
CS Environmental Chemistry and Toxicology Laboratory, Univ. California, Berkeley, CA, 94720-3112, USA
SO Pesticide Biochemistry and Physiology (1995), 52(3), 170-81
CODEN: PCBPBS; ISSN: 0048-3575
PB Academic
DT Journal
LA English

L38 ANSWER 13 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1995:621797 CAPLUS
DN 123:17911
TI Combination of lithium compound and acetylcholinesterase inhibitor for treatment of Alzheimer's disease
IN Lehmann, Karla
PA Germany
SO Ger., 4 pp.
CODEN: GWXXAW
DT Patent
LA German
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4340272	C1	19950511	DE 1993-4340272	19931126
	WO 9514481	A1	19950601	WO 1994-EP3921	19941126
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ				
	RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9510677	A1	19950613	AU 1995-10677	19941126
	EP 730463	A1	19960911	EP 1995-901442	19941126
	EP 730463	B1	20000202		
	R: AT, CH, DE, FR, GB, IT, LI				
	AT 189391	E	20000215	AT 1995-901442	19941126
PRAI	DE 1993-4340272		19931126		
	DE 1993-4340273		19931126		
	WO 1994-EP3921		19941126		

L38 ANSWER 14 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1991:400641 CAPLUS
DN 115:641
TI Thermic response of selective muscarinic agonists and antagonists in rat
AU Sen, A. P.; Bhattacharya, S. K.
CS Inst. Med. Sci., Banaras Hindu Univ., Varanasi, 221 005, India
SO Indian Journal of Experimental Biology (1991), 29(2), 131-5
CODEN: IJEBA6; ISSN: 0019-5189

DT Journal
LA English

L38 ANSWER 15 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1990:493280 CAPLUS
DN 113:93280
TI Resistance to trichlorfon in Musca domestica and the effect of synergists
AU Otto, D.; Weber, B.
CS Inst. Plant Prot. Res., Acad. Agric. Sci. GDR, Kleinmachnow, DDR-1532, Ger. Dem. Rep.
SO Tagungsbericht - Akademie der Landwirtschaftswissenschaften der Deutschen Demokratischen Republik (1989), 274(Insectic.-Mech. Action Resist.), 253-67
CODEN: TALDA3; ISSN: 0138-2659
DT Journal
LA English

L38 ANSWER 16 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1988:506494 CAPLUS
DN 109:106494
TI Model studies of carbamate tolerance and resistance in Rhabditis oxycerca (de Man, 1985) (Nematoda)
AU Below, Silvia; Kampfe, Lothar
CS Sekt. Biol., Ernst-Moritz-Arndt-Univ. Greifswald, Greifswald, DDR-2200, Ger. Dem. Rep.
SO Archiv fuer Phytopathologie und Pflanzenschutz (1988), 24(1), 45-53
CODEN: APPZAJ; ISSN: 0323-5408
DT Journal
LA German

L38 ANSWER 17 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1987:419456 CAPLUS
DN 107:19456
TI Inhibition of trans-permethrin hydrolysis in Pseudoplusia includens (Walker) and use of inhibitors as pyrethroid synergists
AU Dowd, Patrick F.; Sparks, Thomas C.
CS Agric. Cent., Louisiana State Univ., Baton Rouge, LA, 70803, USA
SO Pesticide Biochemistry and Physiology (1987), 27(2), 237-45
CODEN: PCBPBS; ISSN: 0048-3575
DT Journal
LA English

L38 ANSWER 18 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1984:603897 CAPLUS
DN 101:203897
TI Observations on the interaction between ketamine and other drugs in animal experiments
AU Zhao, Dehua; Sheng, Baoheng; Shi, Yuwu
CS Dep. Pharmacol., 4th Mil. Med. Univ., Peop. Rep. China
SO Zhonghua Mazuixue Zazhi (1984), 4(2), 79-81
CODEN: ZMZADD; ISSN: 0254-1416
DT Journal
LA Chinese

L38 ANSWER 19 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1983:447741 CAPLUS
DN 99:47741
TI Antianoxic effect of 4-(o-benzylphenoxy)-N-methylbutylamine hydrochloride (MCI 2016)
AU Tobe, Akihiro; Egawa, Mitsuo; Hashimoto, Noriko
CS Res. Cent., Mitsubishi Chem. Ind., Ltd., Yokohama, 227, Japan
SO Nippon Yakurigaku Zasshi (1983), 81(5), 421-9

CODEN: NYKZAU; ISSN: 0015-5691
DT Journal
LA Japanese

L38 ANSWER 20 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1982:538549 CAPLUS
DN 97:138549
TI Choline and physostigmine enhance haloperidol-induced HVA and DOPAC accumulation
AU Millington, William R.; Wurtman, Richard J.
CS Dep. Nutr. Food Sci., Massachusetts Inst. Technol., Cambridge, MA, 02139, USA
SO European Journal of Pharmacology (1982), 80(4), 431-4
CODEN: EJPHAZ; ISSN: 0014-2999
DT Journal
LA English

L38 ANSWER 21 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1976:554251 CAPLUS
DN 85:154251
TI Pharmacological studies on the stimulation of the phospholipase A2-acylation system of synaptic membranes of brain, by neurotransmitters and other agonists
AU Gullis, R. J.; Rowe, C. E.
CS Dep. Biochem., Univ. Birmingham, Birmingham, UK
SO Journal of Neurochemistry (1976), 26(6), 1217-30
CODEN: JONRA9; ISSN: 0022-3042
DT Journal
LA English

L38 ANSWER 22 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1973:119177 CAPLUS
DN 78:119177
TI Quillaiate of choline iodide, a new monoquaternary neuromuscular blocking agent
AU Hamed, Mohamed Ismail; El-Gholmy, Zeinab
CS Fac. Pharm., Univ. Khartoum, Khartoum, Sudan
SO Arzneimittel-Forschung (1972), 22(12), 2133-6
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA English

L38 ANSWER 23 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1972:95387 CAPLUS
DN 76:95387
TI **Synergistic** action of 2-(o-cresyl)-4H-1:3:2-benzodioxaphosphorine 2-oxide with soman and physostigmine
AU McKay, D. H.; Jardine, R. V.; Adie, P. A.
CS Biomed. Sect., Def. Res. Establ. Suffield, Ralston, AB, Can.
SO Toxicology and Applied Pharmacology (1971), 20(4), 474-9
CODEN: TXAPA9; ISSN: 0041-008X
DT Journal
LA English

L38 ANSWER 24 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1972:263 CAPLUS
DN 76:263
TI Physostigmine and pentobarbital. Biphasic interaction in mice
AU Davis, W. Marvin; King, William T.; Babbini, M.
CS Sch. Pharm., Univ. Mississippi, University, MS, USA
SO Archives Internationales de Pharmacodynamie et de Therapie (1971), 192(1), 152-9

CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA English

L38 ANSWER 25 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1969:27381 CAPLUS
DN 70:27381
TI Relation between the activating action of ATP and chemical mediation in the lingual receptors
AU Rapuzzi, Giovanni; Violante, A.
CS Univ. Pavia, Pavia, Italy
SO Bollettino - Societa Italiana di Biologia Sperimentale (1968), 44(13), 1113-16
CODEN: BSIBAC; ISSN: 0037-8771
DT Journal
LA Italian

L38 ANSWER 26 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1965:466092 CAPLUS
DN 63:66092
OREF 63:12180h,12181a
TI Effects of cholinergics on antispasmodic activity of phenacone
AU Artemenko, G. N.
CS Inst. Pharmacol. and Chemotherapy, Moscow
SO Farmakologiya i Toksikologiya (Moscow) (1965), 28(3), 290-1
CODEN: FATOAO; ISSN: 0014-8318
DT Journal
LA Unavailable

L38 ANSWER 27 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1965:85393 CAPLUS
DN 62:85393
OREF 62:15259c-d
TI Effect of parasympathomimetic and sympathomimetic drugs on secretion in vitro by ciliary processes of the rabbit eye
AU Berggren, Lennart
CS Univ. Uppsala, Swed.
SO Investigative Ophthalmology (1965), 4(1), 91-7
CODEN: INOPAO; ISSN: 0020-9988
DT Journal
LA English

L38 ANSWER 28 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1963:476352 CAPLUS
DN 59:76352
OREF 59:14239b-c
TI Electrophoretic properties of esterases from susceptible and resistant strains of the housefly (Musca domestica)
AU Menzel, Daniel B.; Craig, Roderick; Hoskins, W. M.
CS Univ. of Cali-fornia, Berkeley
SO Journal of Insect Physiology (1963), 9(4), 479-93
CODEN: JIPHAF; ISSN: 0022-1910
DT Journal
LA Unavailable

L38 ANSWER 29 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1962:479141 CAPLUS
DN 57:79141
OREF 57:15750e-i
TI Apomorphine synergism (compulsive gnawing by mice) as a test for differentiating psychotropic substances
AU Ther, L.; Schramm, H.

CS Farbwerke, Hoechst, Germany
SO Archives Internationales de Pharmacodynamie et de Therapie (1962), 138, 302-10
CODEN: AIPTAK; ISSN: 0003-9780
DT Journal
LA Unavailable

L38 ANSWER 30 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1961:101137 CAPLUS
DN 55:101137
OREF 55:19046e-f
TI Effects of combinations of active compounds on Daphnia
AU Seume, F. W.; Fuchs, W. H.
CS Univ. Gottingen, Germany
SO Arzneimittel-Forschung (1961), 11, 307-14
CODEN: ARZNAD; ISSN: 0004-4172
DT Journal
LA Unavailable

L38 ANSWER 31 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1958:22175 CAPLUS
DN 52:22175
OREF 52:4017h-i,4018a-c
TI Pharmacological and toxicological properties of thiophosphorus compounds
AU Reut, N. A.
CS State Med. Inst., Minsk
SO Khim. i Primenenie Fosfororg. Soedineni, Akad. Nauk S.S.S.R., Trudy 1-oi Konferents. (1957), Volume Date 1955 313-17
DT Journal
LA Unavailable

L38 ANSWER 32 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1958:7990 CAPLUS
DN 52:7990
OREF 52:1467a-i,1468a-b
TI The influence of analgesics and antonomic drugs on the blood sugar of rabbits
AU Ishikawa, Masaaki
CS Kyoto Univ.
SO Nippon Yakurigaku Zasshi (1956), 52(Breviaria 32(in English)), 646-61
DT Journal
LA Unavailable

L38 ANSWER 33 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1957:91714 CAPLUS
DN 51:91714
OREF 51:16674h-i,16675a
TI In vitro studies of the **synergistic** and antagonistic effects of physostigmine salicylate on the bacterial growth-inhibitory activity of some antibiotics
AU Green, V. A.; Steber, M.; McKenna, G. F.; Davis, J. E.; Taylor, Alfred
CS Univ. of Texas, Austin
SO Texas J. Sci. (1957), 9, 89-98
DT Journal
LA Unavailable

L38 ANSWER 34 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1956:29183 CAPLUS
DN 50:29183
OREF 50:5909h-i
TI Demonstration of a toxic synergy between the potassium ion and eserine and neostigmine

AU Hazard, Rene; Delga, Jean
CS Fac. med., Paris
SO Compt. rend. soc. biol. (1955), 149, 1106-7
DT Journal
LA Unavailable

L38 ANSWER 35 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1955:5733 CAPLUS
DN 49:5733
OREF 49:1220f-g
TI Factors that influence the analgesic action of morphine and its derivatives. I. The action of parasympathicolytic compounds
AU Lecannelier, R. S.; Bardisa, U. L.; Tamayo, R. L.; Abarca, B. F.
SO Bol. soc. biol. Concepcion (1953), 28, 73-82
DT Journal
LA Unavailable

L38 ANSWER 36 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1953:74315 CAPLUS
DN 47:74315
OREF 47:12647d-f
TI Role of the protein complex in the synergism of analgetics and parasympathomimetics
AU Knoll, J.; Komlos, E.; Tardos, L.
CS Univ. Budapest, Hung.
SO Acta Physiol. Acad. Sci. Hung. (1953), 4, 131-40
DT Journal
LA German

L38 ANSWER 37 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1953:63183 CAPLUS
DN 47:63183
OREF 47:10735h-i
TI Effect of parasympathetic substances in analgesia
AU Porszasz, J.; Knoll, J.; Komlos, E.
CS Univ. Budapest
SO Acta Physiol. Acad. Sci. Hung. (1951), 2, 469-77
DT Journal
LA German

L38 ANSWER 38 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1951:24789 CAPLUS
DN 45:24789
OREF 45:4342h-i
TI Drug protection against the lethal action of parathion
AU Salerno, Paul R.; Coon, J. M.
CS Univ. of Chicago
SO Arch. intern. pharmacodynamie (1950), 84, 227-36
DT Journal
LA Unavailable

L38 ANSWER 39 OF 40 CAPLUS COPYRIGHT 2003 ACS
AN 1947:26072 CAPLUS
DN 41:26072
OREF 41:5216i,5217a-e
TI Mechanism of the strengthening action of parasympathomimetic drugs on the effect of acetylcholine
AU Koiwaya, Osamu
SO Folia Pharm. Japon. (1943), 39, 116-33
DT Journal
LA Unavailable

```
                E SYNERGIST
L35         56539 S E1-E12
L36            55 S L35 AND L8
L37            31 S L35 AND L9
L38            40 S L35 AND L10

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   333.47     402.42

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -9.77      -9.77

STN INTERNATIONAL LOGOFF AT 16:57:36 ON 27 MAY 2003
```